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Abstract
Human Immunodeficiency Virus (HIV) remains the main cause of premature death
globally. In 2013, Kenya was the fourth largest endemic HIV country in the world
having over 1.6 million people living with the virus. The fact that there is an increase
in the rate of new-HIV infections in Africa and especially in Kenya underscores the
need for adequate strategies to cope with this deadly disease and to achieve vision
2020. Where the government envision that, by 2020, 90% of all people living with
HIV will know their HIV status, 90% of all people with diagnosed HIV infection will
receive sustained antiretroviral therapy and 90% of all people receiving antiretroviral
therapy will have viral suppression. Currently, there is no known cure for HIV, hence
the most optimal way is the management of HIV infected people to prevent virus pro-
gression and HIV transmission. Although there has been progress in management of
HIV by the use of antiretroviral drugs (ARTs), long-term use of these ARTs leads
to overwhelming challenges. These challenges are: toxicity of the medication, non-
adherence problems as a result of inaccessibility of comprehensive care centres, drug
resistance-mutations and significant financial burdens. This study aimed at formulat-
ing and analysing mathematical in-vivo models for the interaction between HIV viri-
ons, CD4+ T-cells, CD8+ T-cells and the optimal control for effective therapy, whose
numerical simulations would assist in giving more insight about the challenges afore-
mentioned.
Various mathematical methods including ordinary differential equations, Runge-Kutta
forth order scheme and optimal control theory have been applied in the development
and the analysis of the model. Analysis of the formulated model indicates existence of
multiple equilibria whose stability and bifurcation analysis have been presented. From
the simulated results, we have noted that early initiation of HIV treatment reduce viral
replication in HIV infected people. In particular, highly active antiretroviral therapy
(HAART) which include the combination therapy of Fusion inhibitor (FI), Reverse
Transcriptase inhibitor (RTI) and Protease inhibitor (PI) in different proportions have
been found to be more effective in treating HIV than a single drug therapy. The model
iii
simulations show how to best choose the proportions of FI, RTI and PI in order to
maintain an acceptable level of CD4+ T-cells and, at the same time, reduce the side
effects associated with their long term use. In addition, the most optimal way of ad-
ministering ART drugs that lead to maximum benefit has been predicted from optimal
control simulation.
The findings give a significant explanation of why late initiation of ARTs might not
be helpful to an HIV infected person and suggest that the controls ought to be opti-
mal at the acute phase of infection where the viral replication is extremely high. If
the controls are well implemented, many potential infections would be averted by low-
ering the viral load and increasing the number of the T-helper cells. This, in turn,
will also lead to reduction in HIV transmission. Therefore, there is need for increased
awareness campaigns to encourage people to know their HIV status and adhere to the
prescribed treatment. The research outcomes in this study emphasizes the importance
of “Anza Sasa”campaign that was launched on 15th July 2016 by the Government of
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1.1 Background to the Study
Human Immunodeficiency Virus (HIV) is a retrovirus that has been associated with
Acquired Immunodeficiency Syndrome (AIDS). Since the identification of the first
case of HIV/AIDS, in 1983 in the United States, HIV has emerged as one of the
main challenges for global public health. According to UNAIDS, UNICEF and World
Health Organization (2011), more than 36.7 million people worldwide are living with
HIV/AIDS, of which 22.9 million live in Sub-Sahara Africa. By the end of 2015,
Kenya in particular, had over 1.6 million people living with the virus (Kimanga et al.,
2014; Joint United Nations Programme on HIV/AIDS,(UNAIDS), 2015). Nonethe-
less, by March 2015, 15 million people representing 41% of all the cases in the world
had access to antiretroviral drugs (ARTs). The drugs were aimed at reducing viral pro-
gression and improving the patients health conditions. Use of ARTs, is one of the main
achievements so far in the control of HIV progression and HIV transmission (Musicco
et al., 1994; Castilla et al., 2005).
Unfortunately, even with the many studies (Wodarz and Nowak, 2002; Miron and
Smith, 2010; Hattaf and Yousfi, 2012b) conducted on HIV, there is no effective strat-
egy so far that prevents the virus progression or elimination altogether. That, however,
does not mean that the intervention has not made any difference as far as treatment
is concerned. Even though there are challenges in the use of ARTs, it is one of the
most successful intervention measures so far in the control of HIV progression and
HIV prevention (Musicco et al., 1994; Castilla et al., 2005). However, eradication of
the virus to zero level remains an immense challenge. In spite of the huge scientific
strides made in understanding many complex biological phenomena underlying HIV
dynamics, HIV remains a major challenge to the scientific world and to the public
health practitioners.
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Consequently, management, control and prevention of HIV requires an integrated ap-
proach, which include, awareness/education and treatment with the best ARTs combi-
nations. Lack of awareness/education, access to early diagnosis and effective treatment
has delayed the success of the global HIV programme in reducing new infections and
HIV/AIDS related deaths. Therefore, there is need for new and more advanced inter-
ventions for HIV prevention, management and care.
It is in this regard that researchers hope that, in future, a solution to this pandemic
will be obtained and that timely diagnosis, timely introduction of ARTs and use of
mathematical modelling may be the lead to this solution.
Figure 1.1 shows a summary of people living with HIV globally by 2014.
Figure 1.1: People living with HIV per region, as a percent of global total
1.1.1 HIV replication mechanism
HIV is highly concentrated in human blood, semen, vaginal fluid and breast milk. If
a non-infected person is exposed to the aforementioned fluids of an infected person,
one is at a risk of being infected. There are three major ways in which HIV could be
2
transmitted, that is, through sexual intercourse, through blood transfusion and mother-
to-child transmission. However, HIV transmission through sexual intercourse accounts
for the largest percentage of the HIV cases reported in the world. It is evident from past
studies that the likelihood of one to be infected is directly proportional to the number
of sex partners one has (Bulterys and Lepage, 1998; Pope and Haase, 2003).
Like most viruses, HIV, a retrovirus, lacks the ability to replicate on its own. HIV,
therefore, relies on a host for replication and carries the copies of its own RNA (Mbogo
et al., 2013). When the virus gets in the body, it mainly targets the CD4+ T-cells. Af-
ter the infection of the cells by the virus, it is important to note that the symptoms do
not show immediately until the CD4+ T-cells level reduces to about 200 cells/ mm3
and the viral load increases to 500,000 copies /mL (Wodarz and Nowak, 2002). The
process of HIV reproduction is outlined in the following steps: For HIV to replicate,
it joins the membrane of the CD4+ T-cell. The virus then fuses with the host cell and
releases an enzyme called reverse transcriptase. Reverse transcriptase changes the ge-
netic material of the virus from a single-stranded HIV RNA to a double-stranded HIV
DNA, so that it can be integrated into the host DNA. The genetic material of the virus
enters the host cell’s nucleus and uses an enzyme called integrase to integrate itself
into the CD4+ T-cell genetic material. Once HIV is integrated in the cell’s DNA, it
starts using their CD4+ T-cell’s DNA to make long chains of HIV protein (Laskey and
Siliciano, 2014). The HIV proteins are the building blocks for more HIV. These long
chains of HIV proteins (immature and non-infectious) then assemble near the mem-
brane of the CD4+ T-cells and bud out.
The immature virions then release an enzyme called the protease, which cut the long
HIV proteins/RNA into smaller individual proteins. As the smaller HIV proteins come
together with copies of HIV’s RNA genetic material, a new mature virion is formed.
The new copies of HIV can now move on to infect other cells. This clearly shows that
a single virion produces many potential threats to other cells (Yuan et al., 2016). A
schematic diagram of HIV life cycle is presented in Figure 1.2.
3
Figure 1.2: HIV life cycle.
1.1.2 Stages of HIV progression
The pattern of HIV progression in the body is divided into three stages (Kirschner,
1996).
Acute Infection
During the first few weeks of infection, patients experience a period of increasing viral
load and a decline in CD4+ T-cells numbers. During this period the infected person
may experience the following symptoms: fever (raised temperature), body rash, sore
throat, swollen glands, headache, upset stomach, joint aches and pains and muscle
pains. In addition, the body immune system, in response, tries to attack the virus by
producing HIV antibodies and the activation of the CD8+ T-cells (Hollingsworth et al.,
2008). This process is referred to as seroconversion.
It is worth noting that due to the high number of HIV virions in the blood during
this stage, exposure to the blood or sexual fluid of someone in the acute phase of infec-
tion is more likely to result in an infection than exposure to someone with long-term
infection. It has been estimated that the risk of infection is approximately 20 times
4
higher during acute HIV infection (Pinkerton, 2008).
The asymptomatic stage
This is the stage when the infected person does not experience any symptoms. In
fact, the HIV virus may not reveal any other symptoms for up to 10 or even 15 years
(depending on age, background and overall health). However, the virus will still be
active, infecting new cells and making copies of itself. Over time this will cause a lot
of damage in the infected persons immune system. In fact, during this stage, increased
viral loads cause an impairment of CD4+ T-cells. This compromises the longetivity of
CD8+ memory cells, however, there is a stimulation of the CD8+ T-cells by the high
antigen levels. This response help in reducing the viral load (Fiebig et al., 2003).
Symptomatic HIV infection
By the third stage of HIV infection, the immune system is completely damaged. At
this point, the infected person is likely to get serious infections; bacterial and fun-
gal diseases due to the compromised immune response. The infected person experi-
ences symptoms such as: weight loss, chronic diarrhoea, night sweats, fever, persistent
cough, mouth and skin problems, regular infections and other serious illnesses or dis-
eases. This is the stage that leads to AIDS where the CD4+ T-cells falls below 200
cells per cubic millimeter and the body is prone to many opportunistic infections. This
phase also coincides with a shift in the virus population and the emergence of virus
strains that are able to use CXCR4 co-receptors (instead of CCR5 co-receptors) and
thus a wider range of immune cells become susceptible to the virus (Bonhoeffer et al.,
2005; Regoes and Bonhoeffer, 2005). Due to the fragility of their immune system
(low T-cell counts), patients suffer from a variety of opportunistic infections during
the AIDS phase. Consequently, the diseases from these infections eventually lead to
death of the infected person. It is worth noting that at this level the CD8+ T-cells are
overwhelmed by the many infections and hence not able to control any infection. A
summary of the HIV stages is given in Figure 1.3.
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Figure 1.3: Stages of HIV progression (Pantaleo et al., 1993)
1.1.3 Relationship between CD4+ T-cell count and viral load in
HIV patients
According to Hogg et al. (2001), CD4+ T-cell count is a blood test that health provider
uses to check the level of CD4+ T-cells in the body. The core role of the CD4+ T-
cells as far as HIV is concerned is to alert the CD8+ T-cells. However, certain recep-
tors on the CD4+ T-cells make them prime targets for HIV. A normal CD4+ T-cell
count ranges from 500 to 1, 600 cells per cubic millimeter. In addition, if the CD4+
T-cell count is below 200 cells per cubic millimeter for HIV patients the immune sys-
tem becomes so compromised leading to the body being prone to many opportunistic
diseases. At this stage, the body′s immune system is weak due to the low number
of CD4+ T-cells available to alert the CD8+ T-cells that fight the infections and hence
the deterioration of the immune system lead to Acquired Immunodeficiency Syndrome
(AIDS). On the other hand, the viral load is a test used to assess the level of HIV viri-
ons in the body. It measures the number of HIV virions in a millilitre of the blood. A
low viral load is a sign of the virus copying itself in low amounts in the body and it is
undetectable for levels below 40 − 75 copies/mL. A viral load test helps in providing
information on one’s health status and how well antiretroviral therapy (ART treatment
with HIV medicines) is controlling the HIV virions. Figure 1.4 shows the relationship
between the viral load and the CD4+ T-cell count at different stages of HIV infection.
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Figure 1.4: CD4+ T-cell count and viral load without ART (Marcelo and Sonia, 2014)
Figure1.4 shows that after infection, the viral load level increases within the first three
months. Then the immune system fights back and the viral load level drops to much
lower levels. Over time though, usually after several years, viral load increases again.
As the viral load increases the CD4+ T-cell count decreases. Consequently, when the
CD4+ T-cell count is very low, the immune system is no longer strong enough to fight
off infections, this lead to the body being attacked by many opportunistic diseases,
where the patient finally dies.
1.1.4 The role of the CD8+ T-cells in HIV infection
CD8+ T-cells play a very vital role in controlling HIV replication during the early
phase of infection. HIV-specific CD8+T-cells are targeted at the dominant viral variant
and their emergence is associated with a rapid fall in viral load before the development
of an antibody response. After the HIV virions enter the body there is a period of
rapid viral replication, leading to an abundance of virus in the peripheral blood. This
results to a high drop in the number of circulating CD4+ T-cells. This acute viremia
is associated with the activation of CD8+ T-cells, which kill HIV-infected cells, and
subsequently with antibody production, or seroconversion. The CD8+ T-cell response
is important in controlling virions levels, which peak and then decline, as the CD4+
T-cells counts rebound (Klatt et al., 2013). Clinicians have associated a high CD8+
T-cell response with slower disease progression and a better prognosis, though it does
not eliminate the virus completely. However, majority of the CD8+ T-cells generated
during primary infection die within a few weeks, leaving a reservoir of HIV-specific
CD8+ memory T-cells that will persist, regardless of the presence of antigen or CD4
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helper T-cells.
Researchers have found that viral load is better controlled in people whose HIV-specific
CD8+ T-cells mature fully into ’effector memory’ T-cells (Croft et al., 1994). With-
out helper T-cells, which slowly disappear during HIV disease, the CD8+ T-cells are
unable to keep up with the increasingly diverse population of HIV inside the body
(Benito et al., 2004). As HIV mutates in the body, due to several factors including
pressure from antiretroviral medications, these CD8+ T-cells become increasingly ir-
relevant. In addition, CD8+ T-cells have been shown to express CD4+ T-cells receptors
on their surface following activation through the T-cell receptor, permitting infection
by HIV. It has been suggested that this is a mechanism through which CD8+ T-cells
become depleted late in infection (Varela-Rohena et al., 2008).
Wodarz et al. (1998) in their study observed that the ability of HIV to infect the CD4+
T-cells and a fast replication rate are the main factors that contribute to the depletion
of the CD8+ T-cells. This can be explained by the fact that CD4+ T-cells play a vital
role in the initiation of CD8+ T-cells response, maturation and maintenance of CD8+
T-cells memory.
1.1.5 Antiretroviral therapy
Many management options exist for control of HIV progression including use of an-
tiretroviral therapies (ARTs), healthy diet, quitting drug abuse (alcohol, cigarettes, etc)
and use pre exposure prophylaxis. However, the use of ARTs is the most effective as
far as reducing viral progression and HIV prevention is concerned. Use of ARTs for the
treatment of HIV has improved steadily since the introduction of potent combination
therapy in 1996. ARTs have greatly reduced HIV-associated morbidity and mortal-
ity and has transformed HIV infection into a manageable chronic condition (Murphy
et al., 2001). They are also highly effective at preventing HIV transmission. How-
ever, the most appropriate drug combinations are still under constant development and
the best treatment for an HIV-infected person remains a subject of rigorous discussion
(Culshaw et al., 2004; Nampala et al., 2014).
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To date, the US Food and Drug Administration (FDA) has approved twenty-six ARTs
and six fixed dose combinations for the treatment of HIV. These ARTs include Re-
verse Transcriptase Inhibitors (RTIs) also called nucleoside or nucleotide analogues,
viral entry Inhibitors such as Fusion Therapy Inhibitors and Protease Inhibitors (PIs).
The aim of ARTs is to reduce the replication of the HIV and prevent virus transmis-
sion. In particular, the RTIs inhibits the reverse transcription process (Joly and Pinto,
2006). This is because HIV is a retrovirus and it carries a copy of its own RNA.
Consequently, HIV must be reverse transcribed into DNA using an enzyme it also car-
ries called reverse transcriptase. Therefore, if RTIs are introduced in the human body
they will block the reverse transcription process of the HIV RNA to HIV DNA, thus
reducing cellular infection and the viral spread. Similarly, the PIs interfere with the vi-
ral protease enzyme necessary to produce mature virions upon budding from the host
membrane. Consequently, the virions produced by the infected cells after the intro-
duction of PIs are defective and non-infectious (Hattaf and Yousfi, 2012b). A process
in which the virus become non-infectious though it is in the bloodstream plays a very
important role in in-vivo dynamics. Inclusion of non-infectious virus in the optimal
HIV therapy and management models would allow researchers to examine the efficacy
of protease inhibitors.
The combination of RTIs and PIs has proved successful in many cases (Sullivan et al.,
2009). For example, RTIs may prevent the reverse transcription process while the PIs
may prevent the cells in which reverse transcription has taken place from releasing
infectious HIV virions. Viral entry inhibitors such as Fusion inhibitors are a new fam-
ily of ARTs whose use is not very common. Clinicians are still doing more research
on the HIV entry process (Tilton and Doms, 2010). This is because the process of
HIV entry into the CD4+ T-cells represents a very important aspect in the search for
new drug combinations to treat HIV infection. Nonetheless, researchers have identi-
fied three main steps that represent the mechanism of the virus entry process, that is,
attachment of the virus to the CD4+ T-cell receptor, binding of the virus to CCR5 or
CXCR4 co-receptors and fusion of the viral and cellular membranes. Consequently,
fusion inhibitors prevent the fusion of the virus and the CD4+ T-cells. Unfortunately,
up to now no drug combinations studied is known to completely shut down viral repli-
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cation. HIV life-cycle with therapy is described in Figure 1.5.
Figure 1.5: HIV life cycle with therapy (Simon, 2012)
Effects of ARTs on CD4+ T-cell count and Viral load
The role played by ARTs as far as controlling the HIV is well represented in Figure
1.6.
Figure 1.6: CD4+ T-cell count and viral load with ART (Pantaleo et al., 1993)
Figure 1.6 shows how ARTS play a very vital role in ensuring that the level of the
CD4+ T-cells counts does not fall below 300 cells per cubic millimeter. It is evident
from Figure 1.6 that the patient might live many years even after infection. It is there-
fore paramount for any HIV infected persons to adhere to the drugs. Government of
Kenya through the Ministry of Health has started a campaign dubbed “Anza Sasa”
where any person who test positive irrespective of their CD4+ T-cells counts is put
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on ARTs. This is a very noble idea since it will increase the life expectancy of HIV
infected people. Many researchers (Musicco et al., 1994; Castilla et al., 2005), have
pointed out that ARTs help in the reduction of HIV transmission by 80%. The results
from the work done by Sullivan et al. (2009) in Zambia indicate that the infected peo-
ple taking ARTs were less likely to transmit the virus to their sex partners than those
who remained untreated. During acute infection there is high risk for transmission and
researches have established that if patients are treated during this period there might be
a reduction of latently infected cells (Chomont et al., 2009). Hence, the need for more
research on the optimal use of ARTs.
1.1.6 Problems encountered during therapy
Despite the effectiveness of ARTs in suppressing the virus and reducing viral progres-
sion, it is evident that they cannot completely get rid of the virus and the patients have
to rely on them for life. Use of the current combinations of ARTs for a long period is
difficult to maintain and they cannot be considered as ideal drugs due to the many chal-
lenges that are associated with their use. To start with, the cost of the drugs is beyond
reach for many infected patients, bearing in mind that they must continue taking ARTs
for life. Most African governments have allocated a lot of financial resources to ARTs
at the expense of other development projects. For instance, the National Government
of Kenya allocated Ksh. 2.9 billion in the 2015/2016 national budget for HIV expense.
African governments also face difficult choices in striking the right balance between
prevention, treatment, and care, all of which are necessary to deal comprehensively
with the epidemic (Creese et al., 2002).
The use of ARTs also leads to severe side effects such as fatigue, pain and nerve prob-
lems, anaemia, vivid dreams, and diarrhoea (Adams et al., 2005). These side effects
are the main cause of therapy discontinuation and medication non-adherence in many
HIV-infected people. Non-adherence to ARTs increases the level of the viral load
(Ammassari et al., 2001) and could also lead to emergence of drug-resistant mutations
(Miron and Smith, 2010). Drug resistance is one of the major reasons for therapeutic
failure in people with HIV. It hinders complete eradication of the virus. Similar to
drug resistant, it is evident that the drug may also fail to reach the target cells and this
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explains why 100% viral eradication has not been achieved. Other challenges include
lipid abnormalities, body habitual change, and toxicities.
In spite of these disadvantages, use of ARTs has led to prolonged life of HIV-infected
persons, made them socially and economically active, less infectious to their sex part-
ners, and has led to reduced rates of mother-to-child transmission (Kirschner, 1996).
Nonetheless, many questions including who should be treated, when they should be
treated, and what treatment scheme should be used are still a challenge to many health
practitioners. Consequently, the optimal treatment and management scheme for HIV-
positive patients that is able to address all the shortcomings associated with the use of
ARTs remains the subject of intense research.
1.2 Statement of the Problem
HIV remains one of the main causes of premature deaths especially in developing
countries. Even though so much research has been done on the management of HIV,
most deaths in Sub-Saharan Africa are still due to HIV related opportunistic diseases
that attack the body due to weak immune system. To suppress HIV, different combi-
nations of ARTs have been recommended. Currently, HIV has no cure and long-term
use of ARTs come with many challenges that require to be addressed. For instance, the
cost of treatment is beyond reach of many Kenyans. Therefore, a lot of government
money and donor money is used in acquiring these ARTs for infected people at the
expense of other development projects. Secondly, most of these ARTs are associated
with severe side effects, such as, fatigue, anaemia, pain, and nerve problems. Hence,
a balance between the benefits of treatment in reducing the viral load and minimiz-
ing the side effects need to be drawn. In addition, non-adherence caused by toxicity
and non-accessibility of the comprehensive care centers is a big challenge that leads
to drug resistance mutations. Lastly, the optimal time to start ARTs remains a ques-
tion of discussion. For all the reasons mentioned and more, it is essential that more
and deeper research efforts be committed to the process until HIV is eradicated or is
no longer such a debilitating global and local public health dilemma. Therefore, to
address the problems aforementioned, there is a need to develop HIV optimal therapy
and management models that endeavors to maximize treatment while minimizing the




The main objective of this work is to develop and analyze mathematical models for the
in-vivo interaction between HIV virions, CD4+ T-cells and CD8+ T-cells and optimal
control for effective therapy.
1.3.2 Specific objectives
The specific objectives are:
1. To formulate an in-vivo interaction model of HIV, the CD4+ T-cells and the
CD8+ T-cells that would predict virus progression prior to intiation of therapy.
2. To formulate an in-vivo HIV model to investigate the effectiveness of the various
HIV therapy combinations in reducing viral production.
3. To develop an optimal control model for HIV therapy.
1.4 Justification
Although strategies using ARTs for management of the infectious virus has been rec-
ommended, for HIV positive persons few studies have been carried out to examine
how to manage and reduce drug non-adherence, drug toxicity, the optimal time to start
ARTs for the infected people, and most importantly to establish optimal control therapy
for HIV management. The benefits of ARTs can be fully realized by establishing the
optimal way to manage HIV infected people. In this study the best ARTs combination
that would minimize the toxicity and cost of treatment while maximizing therapeutic
effects has been established. Implementation of the findings from this study will, hope-
fully, assist the Ministry of Health on the formulation of the guidelines and frameworks
for clinical testing and monitoring of HIV/AIDS. Moreover, health practitioners could
use this model in establishing the best combinations of ARTs that will lead to mini-
mum side effects. They could also rely on the model in making informed decisions on
the optimal time to start ARTs; this is in relation to the CD4+ T-cell count. Similarly,
the model might help the government and donors in making informed decisions on
allocations of resources for HIV management. Most importantly, this research is in
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line with Kenya's long-term vision for HIV control, that is, a Kenya free of new HIV
infections, stigma and AIDS related deaths by 2030 and also the HIV global target of
90-90-90.
1.5 Thesis outline
This thesis is organized as follows: In Chapter 1, the study has described the biologi-
cal background information on HIV/AIDS, as well as research aims and objectives. In
Chapter 2, literature review based on mathematical models of HIV in-vivo dynamics
both with and without therapy has been presented.
In Chapter 3, a deterministic in-vivo HIV model without therapy is formulated. Here
the study focuses on the stability and bifurcation analysis to establish the existence of
the equilibria and to understand the behaviour of the model, formulated in the study.
The numerical simulations have been carried out and deductions made from the results
obtained are presented. The model has been extended to include treatment in Chapter
4. Here, the effects of the three types of drugs (FIs, RTIs and PIs) combination on
the HIV dynamics is explored and the numerical simulations for the extended model
presented and discussions given.
In Chapter 5, optimal control theory has been applied to carry out economic evalu-
ation and deriving the most optimal drug for HIV treatment. The optimality system
is solved numerically using the Runge-Kutta forth order scheme. Finally, the conclu-





According to UNAIDS, JUNPOHA (2010) HIV is one of the major causes of death
worldwide. While in developed countries notable success has been obtained in terms
of treatment and management of the infected persons, the situation in developing coun-
tries is pathetic. This therefore, makes HIV an important and an active field for research
especially for the developing countries. Since the first HIV cases were reported in the
early 1980’s, there has been enormous effort made in the field of mathematical mod-
elling of HIV/AIDS. To date, mathematical modelling is an integral part of the ongoing
research on HIV dynamics. Numerous mathematical models of HIV epidemic at dif-
ferent levels in either population or in-host have been formulated and applied to the
estimation of HIV/AIDS epidemics in a variety of settings over many years of active
HIV research (Silva and Torres, 2015; Ghosh et al., 2016). The models have been
known to synthesize existing knowledge and provide a framework for understanding
the complex mechanisms on HIV dynamics. These models rely on almost all compo-
nents of analysis and probability theory, deterministic and stochastic.
It is evident from past studies that the type of modelling methodology to be em-
ployed clearly depends on the process to be modelled and the point of view of the
researchers. Many mathematical models on HIV in-host interaction use determinis-
tic approach and are set in continuous time (use differential equations); that is not to
suggest that stochastic approach has not been employed. For instance, Mbogo et al.
(2013) used stochastic approach in modelling in-vivo HIV and CD4+ T- cells dynam-
ics and were able to obtain a probability generating function, the moment structures
of the healthy CD4+ T-cells and the virus particles at any time, and the probability of
HIV clearance. Contrary to Mbogo et al. (2013) who used the stochastic approach, this
study adopted the deterministic approach due to its non-complexity when dealing with
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HIV dynamics.
2.2 Mathematical modelling of in-vivo HIV dynamics
HIV is a virus that causes AIDS and has led to high percentage of deaths especially
in Africa. When the HIV gets in the body, it targets the CD4+ T-cells, although the
symptoms do not show immediately until the level of CD4+ T-cells reduces and the
viral load increases (Wodarz and Nowak, 2002). It should be noted that, many of the
host-pathogen interaction mechanisms during HIV infection and progression to AIDS
are still unknown hence, mathematical modelling of HIV infection is of interest to the
medical community. This is due to the fact that no adequate animal models exist to test
efficacy of drug regimes. These models test different assumptions and provide new
insights into questions that are difficult to answer by clinical or experimental studies.
To date, a number of mathematical models have been formulated to describe vari-
ous aspects of the interaction of HIV with healthy cells. It is evident that viral load
measurements and CD4+T-cell counts are important factors used in monitoring virus
progression and treatment decisions. For instance, CD4+ T-cell counts reflect immuno-
logical status and very low CD4+T-cell counts are associated with higher mortality and
increased risk of virus progression (Egger et al., 2002). Due to this fact, the earliest
mathematical models were based on the interaction between the CD4+ T-cells and
the HIV virus. These basic non-linear models were developed and used to study the
dynamics of the HIV virus and in measuring crucial parameters that led to new under-
standing of the disease process (Rivadeneira et al., 2014).
With the aim of providing the most fundamental information on controlling the vi-
ral progression, the most basic of these models typically include two or three of the
three key/state variables. The key variables include: the susceptible CD4+ T-cells, T,
the already infected CD4+ T-cells, IT and the free virus, V . System (2.1) represents
such models as used by: Shirazian and Farahi (2010); Hattaf and Yousfi (2012b).
dT
dt
= s− βT − κV T,
dIT
dt
= κV T − αIT ,
dV
dt
= ηαIT − cV.
(2.1)
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Here s is the rate at which the CD4+ T-cells are produced from the thymus and β is the
decay rate of the CD4+ T-cells. In addition, κ represents the rate at which the CD4+ T-
cells get infected by the virus. Once they are infected, the model assumes that they die
at constant rate α. The free virus is generated by the infected cells at the rate η and they
die at the rate c. In this simple model, it was assumed that after infection, the CD4+
T-cells become actively infected and they produce the infectious- free virus. This basic
model gives some insight on HIV infection dynamics. For instance, the model pre-
dicts adequately the disease progression from the initial infection stage, asymptomatic
stage, to full Blown-AIDs and the viral load at the asymptomatic stage. However, as
much as this simple model described by system (2.1) gives valuable information, a lot
of improvement has been done and many other advanced models developed.
For instance, Duffin and Tullis (2002) formulated a mathematical model to represent
complete dynamics of HIV infection:
dT
dt














= πTTi+ πMMi− cV ∗,
(2.2)
where T, T i,M,Mi and V ∗ represent the uninfected CD4+ T-cells, the infected CD4+
T-cells, macrophage cells, infected macrophage cells and the infectious virus from both
the macrophage cells and the CD4+ T-cells respectively. According to this model, λT
is the rate at which the CD4+ T-cells are produced from the thymus and dT is the de-
cay rate of the CD4+ T-cells. In addition, kT represents the rate at which the CD4+
T-cells are infected by the virus. The infected CD4+ T-cells die at the rate δT . The
free virus is generated by the infected CD4+ T-cells at the rate πT and they die at the
rate c. In addition, πM is the production rate of macrophages, dM the death rate of
health macrophages, δM the death rate of infected macrophages, kM represents the in-
fection rate of macrophages and the production of virus by infected macrophages. The
model aimed at showing the relationship between the CD4+ T-cells, macrophage cells,
and the viral load. The study suggested that infected macrophages cells are capable
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of producing the large amount of virus seen late in infection period. The study pro-
vided insight on the relationship and interaction between the viral load, macrophages
cells and the CD4+ T-cells at early stages of infection but not after consistent infection.
This study was in agreement with other studies that have concluded on the importance
of the macrophages cells in early stages of HIV infection (Orenstein et al., 1997).
Although this simple model focused on the CD4+ T-cells which represent the most
important aspect of the HIV/ host relationship, the study did not assess the quantitative
importance of the model on the dynamics on HIV infections. The inclusion of CD8+
T-cells in the model would have given information valuable in the treatment of an HIV
infected person. This is because when the CD4+ T-cells sense there is danger they
signal the CD8+ T-cells to eliminate the virus by killing the infected CD4+ T-cells.
However, Culshaw et al. (2004) acknowledged the importance of the immune system
in HIV infection dynamics by incorporating the CD8+ T-cells in HIV dynamic model.
The study considered a system of three-dimensional ordinary differential equations
of the untreated model. The model showed the interaction between the non-infected
CD4+ T-cells, infected CD4+ T-cells, and the immune response as shown by system
(2.3). From the model, the production of the immune CD8+ T-cells depended on the
infected CD4+ T-cells and the non-infected CD4+ T-cells. However, it is clear that the
production of the CD8+ T-cells do not depend precisely on the CD4+ T-cell as some
are produced directly from the thymus hence such an assumption is misleading.
dx
dt
= λ− δx− βxy,
dy
dt
= β′xy − ay − ρyz,
dz
dt
= cxyz − hz,
(2.3)
where x(t), y(t) and z(t) are the variables representing the population of uninfected
cells, infected CD4+ T-cells and the population of immune response cells at any given
time, t respectively. While the parameter λ is the source term for healthy CD4+ T-
cells, δ is their death rate and β is the rate at which they are infected by the HIV virus.
The study considered the viral source to be directly from the infected cells. a is the
death rate of the infected cells (natural death), ρ is the rate at which they are killed
by the CD8+ T-cells whereas c is the generation constant of the CD8+ T-cells and h
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is their death rate. Although this model incorporated the immune response, it made
some very expensive assumptions, such as, the interaction between the infected and
the non-infected CD4+ T-cells; the only possible interaction is between non-infected
CD4+ T-cells and the virus to give infected CD4+ T-cells. Moreover, the CD8+ T-cells
are activated by the interaction of the virus, the infected CD4+ T-cells and the CD8+
T-cells but not with the uninfected CD4+ T-cells. The shortcomings of the model in
system (2.3) need to be addressed.
Zhuang and Zhu (2013) analyzed a three dimensional in-host HIV model which in-
clude the susceptible CD4+ T-cells, infected CD4+ T-cells and the HIV virions. As
much as this model was so basic since it had only three compartments it brought out
important insight as far as HIV dynamics is concerned. The time lag from infection of
the CD4+ T-cells to the cells becoming actively infected was included in the model.
The consideration of such a parameter is very important in HIV research. The study
established the global existence of bifurcating periodic solutions with the assistance
of global Hopf bifurcation theory. The numerical results in the study indicated that
the latent period plays an important role in the disease spread and the disease may be
controlled by shortening it.
Pankavich and Shutt (2015) analyzed an in-host model of HIV incorporating latent in-
fection and viral mutation. The study was mainly interested in the analysis of the local
behaviour of the system over time. The results indicated that the long term behaviour
of the HIV model depends crucially upon parameter values, and even in the presence
of viral mutation, the virus may be completely cleared from the body. Additionally, it
was evident that HIV possesses a strong propensity to mutate, due to common errors in
reverse transcription process. The effects of viral mutation contribute significantly to
the dynamics of the disease. This is a very important insight since it allows researchers
to work on the introduction of different combinations of ARTs in the body which will
reduce the mutation and consequently the drug resistance. Nonetheless, the model
failed to consider the body immune response which is a key variable in determining
the disease dynamics and its progression.
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Alshorman et al. (2017) formulated and analyzed a HIV model with time delay repre-
senting the time between initial cell infection and the establishment of latent infection,
and the time between viral entry into cell and viral production in productively infected
cells. The results indicated that the time delay between viral infection and viral pro-
duction causes a very small change in the steady states of infected cells and viral load,
but postpones the time to reach the viral peak. Inclusion of such a parameter in the
model is of great importance since it will give a clear representation of the in-vivo
dynamics of HIV. For instance, the intrinsic stability of latently infected CD4+ T-cells
explains the reason why the current HIV treatment consisting of several antiretroviral
drugs cannot eradicate the latent reservoir of the infected cells. In addition, inclusion
of the latently infected cells in the model gives room for the analysis of the homoeo-
static proliferation of latently infected cells, latent reservoir and low-level viral load
persistence during effective antiretroviral therapy.
Overall, the aforementioned modelling quests to capture the in-host dynamics of an
HIV infection has improved our understanding of the progression to AIDS, but more
generally, have also led to the insight that use of ARTs is very important if we want
to reduce the rate of viral replication. Modelling drug treatment had a huge success in
determining strategies to reduce the risk of evolution of drug resistant strains and lead
to the combination therapy which is widely used in HIV treatment. These models with
drug treatment are discussed in the next section.
2.3 HIV Dynamics with Therapy
To date, HIV has no cure and hence the most optimal way is to consider virus eradica-
tion up to non-detectable levels (Baryarama et al., 2006). This means that the second
major components to consider in the HIV in-host model is treatment. For HIV treat-
ment, drugs such as, viral entry inhibitors (Fusion inhibitors, PIs), Reverse Transcrip-
tase inhibitors (RTIs) and Protease inhibitors (PIs) have been developed to attack the
virus on different phases of its life cycle during HIV infection. Use of ARTs has led to
a profound reduction in the viral load and has prevented the patients from progressing
to full-blown stage and from AIDS-related opportunistic diseases.
In Kenya the most common ARTs in use are: Nucleoside analogue Reverse Transcrip-
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tase Inhibitors (NRTIs) such as Zidovudine(AZT), Lamivudine (3TC), Non-nucleoside
Reverse Transcriptase Inhibitors (NNRTIs) such as Efavirenz (EFV), Delavirdine (DLV)
and Protease Inhibitors (PIs) such as Ritanourvir (RTV), Indinavir (IDV) (NASCOP,
2016). The NNRTIs and NRTIs inhibits the Reverse Transcription process. This is
because HIV is a retrovirus and it carries a copy of its own RNA. Consequently, HIV
has to be reverse transcribed into DNA using an enzyme it carries called reverse tran-
scriptase. Therefore, if NRTIs and NNRTIs are introduced in the human body they
will block the reverse transcription process of the HIV RNA to HIV DNA, thus reduc-
ing cellular infection and the viral spread. Similarly, the PIs interfere with the viral
protease enzyme necessary in the production of mature virions upon budding from the
host cell. Consequently, the virions produced by the infected cells after the introduc-
tion of PIs are defective and non-infectious (Hattaf and Yousfi, 2012b).
Many researchers (Musicco et al., 1994; Castilla et al., 2005), have pointed out that
ARTs help in the reduction of HIV transmission by 80 percent. The results from the
work done by Sullivan et al. (2009) in Zambia indicates that the infected people tak-
ing ARTs were less likely to transmit the virus to their sex partners than those who
remained untreated. In addition during acute infection there is high risk for transmis-
sion and researchers have established that if patients are treated during this period there
might be a reduction of latently infected cells (Chomont et al., 2009). Finaly, according
to Vo et al. (2008) use of ARTs for viral suppression has a big impact as far as con-
trolling secondary transmission is concerned. It allows HIV-status-discordant couples
to live a normal life with their partner at a lower risk. It is in this regard that the WHO
has recommended early HIV treatment to help in the prevention of HIV transmission.
From the various studies aforementioned it is evident that ARTs play a vital role in
reducing viral replication and this in turn reduce the risk of deaths and severe HIV
associated illness and more importantly the broader population level prevention bene-
fits. However, despite the effectiveness of ARTs in suppressing the virus and reducing
viral progression, it is evident that they cannot completely get rid of the virus and the
patients have to rely on them for life. Use of the current combinations of ARTs for a
long period is difficult to maintain and they cannot be considered as ideal drugs. This
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is because prolonged use of ARTs is associated with many challenges such as drug
resistance, side effects, high cost, life style change, and problems with adherence (Am-
massari et al., 2001; Adams et al., 2005; Miron and Smith, 2010). Nevertheless, even
with their disadvantages, use of ARTs is currently the most optimal way to manage
HIV. Consequently, many researchers continue with the search of optimal treatment
strategies that can decrease virus mutations, pharmaceutical side effects, and complex
and expensive medication burdens (Culshaw et al., 2004).
Various mathematical models have been proposed in order to analyze the effects of
ARTs. For instance, Srivastava et al. (2009) developed a simple therapy model that
incorporated the use of reverse transcriptase inhibitors shown in system (2.4).
dT
dt




= kTV − (µ1 + α + b)T1∗,
dT ∗
dt
= (η − 1)αT1∗ − δT ∗,
dV
dt
= NδT ∗ − cV.
(2.4)
The state variables T, T1, T ∗ and V in equations (2.4) represent the susceptible CD4+
T-cells, infected CD4+ T-cells before reverse transcription, infected CD4+ T-cells in
which reverse transcription is completed and HIV virions respectively. The param-
eters for the model in (2.4) are described as: s is the production rate of the CD4+
T-cells and µ is the rate at which they die naturally. The parameter k is the infection
rate of CD4+ T-cells and µ1 is death rate of infected cells. The parameter α is the
transition rate from pre-RT infected CD4+ T-cells class to productively infected class
(post-RT). The parameter b is the reverting rate of infected cells to uninfected class due
to non-completion of reverse transcription. The parameter δ represents the death rate
of actively infected CD4+ T-cells and includes the possibility of death by bursting of
infected CD4+ T-cells, c is the clearance rate of virus andN is the total number of viral
particles produced by an infected CD4+ T-cell. In addition, 0 < η < 1 is the efficacy
of the RT inhibitor. The study established that the use of therapy when the viral load
is still low could result to long-term control of HIV progression. This is because early
therapy would prevent HIV from overwhelming the immune system. However, this
study had some deficiencies since it only included one control variable representing
22
the RTIs.
Rong et al. (2008) presented mathematical models with the inclusion of treatment and
time delay. The study was aimed at fitting the data to the already presented mathemat-
ical models. The research provided very important insight as far as viral replication
is concerned. For instance, the study established how the ARTs affects the emergence
of drug resistance during treatment, and how a low level of virus and latently infected
cells can persist in infected individuals for a prolonged period of time despite an ap-
parently effective antiretroviral therapy.
Hattaf and Yousfi (2012a) tried to address that gap by extending the model presented
by Srivastava et al. (2009) by including two control variables as shown below;
dx
dt
= sT − dx− (1− u1(t))βV1x+ ry,
dy
dt
= (1− u1(t))βV1x− (a+ r)y,
dV1
dt
= (1− u2(t))ky − µV1,
dVN1
dt
= u2(t)ky − µVN1 ,
(2.5)
where x, y, V1 and VN1 represent the non-infected cells, infected cells, infectious virus
and the non-infectious virus respectively. Uninfected CD4+ T-cells are produced at a
the rate s, die at a rate d and become infected by virus at a rate β. Infected cells die
at a rate α. The parameter k is the rate at which the free virus is produced and µ the
rate at which they are cleared. In addition, through therapy, a part of infected cells may
also revert to the uninfected state by loss of all cccDNA from their nucleus at a rate
r. The control functions u1(t) and u2(t), are bounded, Lebesgue integrable functions.
The control u1(t) represents the efficiency of drug therapy in blocking new infection,
so that the infection rate in the presence of drug is (1 − u1(t))β. The control u2(t),
represents the efficiency of drug therapy in inhibiting viral production, such that the
virion production rate under therapy is (1− u2(t))k.
The study developed a therapy model with two-control variables one to prevent HIV
from infecting cells by blocking the integration of the HIV viral code into the host cell
genome and the other prevents infected cells from replication of infectious virus par-
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ticles that is, RTIs and PIs respectively. The study assumed that some of the infected
cells get cured after the introduction of PIs because infected CD4+ T-cells return to
the uninfected state by loss of all covalently closed circular DNA from their nucleus.
Inclusion of such parameters should be considered with caution since from the onset
of this epidemic no cure has been reported. The study concluded that depending on the
amount of the drugs used the viral load decreases. This means that the more the drug
concentration the less the viral load. Unfortunately, the study failed to account for the
side effects that might arise due to high concentration of the drug.
Zarei et al. (2011) developed a five dimensional in-vivo HIV model. The study in-
cluded concentration of healthy CD4+ T-cells, concentration of infected CD4+ T-cells,
cytotoxic T-cells which were divided into precursors CTLp and effectors and the free
virions. This study assumed that CTL response depends on CD4+ T-cell help, and
that HIV virions impairs T-helper cell function. Consequently, the proliferation of the
CTLp population is proportional to both infected cells in the body and the number of
uninfected T-helper cells. The simulated results indicated the importance of the CTL
cells in the HIV model. The study included two controls, that is, the Reverses Tran-
scriptase inhibitors and the Protease inhibitors aimed at performing the optimal control
analysis to maximize the CD4+ T-cell counts and minimize both the viral load and cost
of drugs. The study however, failed to put into account the entry inhibitors such as the
Fusion inhibitors.
Rivadeneira et al. (2014) used mathematical modelling to study HIV dynamics af-
ter antiretroviral therapy initiation. The model described the interaction between the
healthy CD4+ T-cells, infected CD4+ T-cells and free viruses with the inclusion of the
Reverses Transcriptase inhibitors and the Protease inhibitors. However, as much as the
study contained only three compartments it provided important insight as far as reduc-
ing the drug side effects is concerned. In addition, the study computed drug amounts
directly, in the optimal controls which is easier to interpret by physicians and patients.
The study also included the long-term drug optimization taking into account the risk
of treatment-resistant mutations, within the framework of the switching systems.
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Ogunlaran and Oukouomi (2016) used mathematical modelling to analyze the most
effective way of managing HIV infection. The study applied two drug therapies to
block the infection of new cells and to prevent the production of new free virions. This
study provided very important insight on the role played by the entry inhibitors which
has not been analyzed by other researchers. The results also indicated the importance
of early diagnosis with immediate commencement of the use of approved antiretroviral
drugs before CD4+ T-cells levels fall below 350 cells/mm3, regardless of whether or
not a person is showing signs of HIV. This is in line with the WHO recommendations
which stipulate that all people living with the HIV be put on ARTs irrespective of their
CD4+ counts (World Health Organization, 2014).
On the other hand, Arruda et al. (2015), constructed a system of five-dimensional non-
linear ordinary differential equations (ODEs) model showing the interactions between
CD4+ T-cells, virions, defense cells and ARTs.
dx
dt
= λx − µxx− βvxv − u1x,
dy
dt
= βvxv − µyy − ρyyza − u2y,
dv
dt
= kvµyy − µvv − ρvvza,
dz
dt
= λz − µzz − βzzv,
za
dt
= βzzv − µzza,
(2.6)
where, x represents the CD4+ T-cells, y the infected CD4+ T-cells, v the virus, z the
defense cells and za the activated defense cells. The parameters in system (2.6) are
described as follows. The parameter λx is the rate at which the non-infected CD4+ T-
cells are produced and µx is the rate at which they decay. In addition, βv represents the
rate at which the CD4+ T-cells are infected by the virus. The infected CD4+ T-cells,
are produced from the interaction of their uninfected counterparts and the viruses, at
the rate βv, they decay at the rate µy and are eliminated by the activated defense cells
at the rate ρy. Free virions are generated from infected cells at the rate kv, they decay
at the rate µv and are eliminated by means of the activated defense cells at the rate ρv.
The defense cells, in turn, are generated at a constant rate λz and they decay at the
rate µz. Furthermore, they become activated by the virus at the rate βz. The activated
defense cells are generated from the defense cells in the presence of the virus at rate βz
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and decay at the rate µz. The controls u1 and u2 represent the RTIs and PIs respectively.
The study by Arruda et al. (2015) showed different compromises between the drug’s
effectiveness and side effects. It is evident from the study that different treatment poli-
cies must be adopted in order to maximize the benefits of treatment while keeping the
medication side effects at a minimum level. As much as this model included the de-
fense cells, it failed to account for the defective and the non-infectious viruses released
by the infected CD4+ T-cells after the introduction of PIs. Inclusion of such variables
would provide insights on the efficiency of PIs.
2.4 Optimization Process
HIV treatment design is a field that would immensely benefit from the contributions of
researchers in the field of optimization and control (Shirazian and Farahi, 2010; Gan
et al., 2017). Optimization is the process of maximizing or minimizing some function
relative to some set of controls, often representing a range of choices available in a
certain situation aimed at determining which might be best. Optimal control (dynamic
optimization) has been widely used in various studies (Rivadeneira et al., 2014; Ar-
ruda et al., 2015; Ogunlaran and Oukouomi, 2016) of HIV progression especially in
analyzing the efficacy of the various ARTs combinations.
The control objective functions for all the HIV models that have been developed to
date, are governed by the main purpose for the study. In particular, optimal control
function for HIV model with therapy seeks to maximize on the benefits of the ARTs,
minimize on the costs of treatment, reduce the side effects and decrease the viral load.
The above four objectives of the study are interrelated for instance, the study may be
aimed at maximizing the level of healthy CD4+ T-cells and minimizing the cost of
treatment, maximizing immune response and minimizing both the cost of treatment
and viral load, maximizing both the level of healthy CD4+ T-cells and immune re-
sponse and minimizing the cost of treatment, maximizing the level of healthy CD4+
T-cells while minimizing both the side effects and drug resistance or maximizing sur-
vival time of patient subject to drug cost. According to Ogunlaran and Oukouomi
(2016) for the aforementioned objectives, to be achieved any optimal control problem
must have an objective function J(x(t), u(t)), a set of state variables (x(t) ∈ X) and
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a set of control variable (u(t) ∈ U) in time t, 0 ≤ t ≤ tf .
Various studies have examined and established therapeutic regimes of HIV through
control and optimization process. For instance, Shirazian and Farahi (2010) employed
the objective function defined by equation (2.7) to help in maximizing the non-infected










where α is a scalar and represents the control function (RTIs). However, many factors
come into play during the process of HIV infection and treatment. Therefore, the con-
trol function defined by equation (2.7) is the most basic since the study considered only
one control variable. Use of one control variable is likely to give biased information
since currently ARTs are taken as a combination of more than one class of drugs. To
study the effects of ARTs, Arruda et al. (2015) considered two control functions to rep-
resent the effects of RTIs and the PIs. The study improved the objective function given









p − c2u21 − c3u22
]
dt (2.8)
where c1, c2 and c3 are non-negative scalars. The control variable u1 corresponds to
RTIs, u2 to the PIs and xp represents the protected cells by the RTIs. The objective
function aimed at maximizing the protected cells while extenuating the drug side ef-
fects.
2.5 Bifurcation Analysis
Sastry (2013) defines bifurcation as a change in the nature of a solution of trajectories
due to a parameter change. A transcritical bifurcation is a bifurcation where there is
an exchange of stability between two equilibrium points at a bifurcation point where
the stability is transferred from one equilibrium point to another. In infectious disease
models, the exchange of stability occurs between a disease free equilibrium (DFE)
point and the endemic equilibrium point when the basic reproduction number is equal
to one (R0 = 1). At this point DFE point looses its stability and the endemic equilib-
rium point becomes stable depending on the conditions on R0. A transcritical bifur-
cation occurs in two forms, that is, forward or backward bifurcation (Britton, 2012).
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During forward bifurcation, the DFE point looses its stability when it passes through
the bifurcation point and endemic equilibrium gains its stability ensuring that the en-
demic equilibrium point is locally stable when R0 > 1. A backward bifurcation in
epidemic models occurs when there is existence of two sub-critical endemic equilibria
forR0 < 1. The initial direction of the bifurcation curve is such that as one moves away
from the bifurcation point, R0 will decrease as the level of infection increase. Back-
ward bifurcation is important in determining the control of the HIV infection. This is
because it is possible for the disease to progress even when R0 < 1. Consequently,
there is need to further reduceR0 to ensure that the disease is eliminated from the body.
Rahmoun et al. (2016) presented a four dimensional mathematical model to analyze
the bifurcation of in-vivo HIV model. The study applied the Lyapunov Schmidt ap-
proach in analyzing the bifurcation around the chronic equilibrium point. The results
indicated the existence of a parameter that affects the model in such away that the
disease may progress even when R0 < 1. Furthermore, the study emphasized on the
effects that the parameter has on the qualitative dynamical properties and structural
stability of the infection evolution dynamics.
Yu and Zou (2012) on their study on bifurcation analysis on the HIV-1 model with
constant injection of recombinant found the existence of a bifurcation parameter in the
model which represented the injection rate η. The results indicated that an appropri-
ate injection rate can help eliminate the HIV virus. This is because the mathematical
solutions indicated the presence of a critical reproduction number Rη which depended
on the injection rate. The HIV free equilibrium point for the model were found to be
globally asymptotically stable when the basic reproduction number, R0 < Rη and un-
stable when R0 > Rη.
From the literature it is evident that disease models exhibit bifurcation where the sta-
ble disease free equilibrium co-exists with a stable endemic equilibrium, that is, there
exist two sub-critical endemic equilibria for R0 < 1. The parameters that lead to such
existence have been found to have a profound impact on the control of the infections.
Biologically, bi-stability may lead to unexpected adverse consequences for ARTs and
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existence of backward bifurcation may provide an explanation for several phenomena
observed clinically among HIV patients. It is therefore paramount for researchers in
the field of HIV to put into consideration the behaviour of the model at the steady
states.
2.6 Management of HIV-positive individuals
One of the threats to health in a sexually active population is sexually transmitted
infections (STIs) especially HIV. To date, HIV has no cure and management of the
infected persons has been and is still the most important aspect. However, with the in-
creased survival rate of patients treated with ART, the management of HIV has become
much the same as for any other long-term condition. For management purpose clini-
cians have outlined some areas that need to be looked into, which include: emotional
aspects, education and stigmatization.
2.6.1 Emotional aspects
For the achievement of vision 2030, where it is projected that there should be a Kenya
free of new HIV infections, stigma, and AIDS related deaths, it is important that all
stakeholders when dealing with medical aspects of sexual health and the presence of
HIV infection to be sensitive to the emotive nature of all aspects of care. For instance,
newly diagnosed patients are likely to need much emotional support. Some may have
been unaware of their risk until diagnosed (eg, during antenatal screening). Education
would play a vital role in sensitizing the stakeholders. Many infected persons fail to
disclose their status, because disclosure may have potential risk for the infected indi-
vidual, such as disruption of family relationship, stigma and rejection/discrimination,
blame and emotional abuse (Medley et al., 2004). Lack of disclosure has increased the
rate of new infections and also many people who should be on ARTs fail to take them
due to the consequences.
2.6.2 Education and stigmatization
Education plays a very important role as far as HIV progression on the infected per-
son is concerned. The main reasons for HIV/AIDS education on the infected person
is to improve quality of life for HIV positive people. Too often, HIV/AIDS educa-
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tion is seen as being something which should be targeted only at people who are not
infected with HIV in order to prevent them from becoming infected. When AIDS edu-
cation with HIV positive people is considered at all it is frequently seen only in terms
of preventing new infections by teaching HIV positive people about the importance
of not passing on the virus (Campbell and MacPhail, 2002). An important and com-
monly neglected aspect of AIDS education with HIV positive people is enabling and
empowering them to improve their quality of life. HIV positive people have varying
educational needs, but among them are the needs to be able to access medical services,
drug provision, adherence to the ARTs and the need to be able to find appropriate emo-
tional and practical support and help.
In Kenya, there is a great deal of fear and stigmatization of people who are HIV posi-
tive. Stigma and discrimination are some of the main issues that have made the effort
on HIV prevention, treatment, care, and support unfruitful (Leary and Schreindorfer,
1998). The fear of stigma is too often accompanied by ignorance, resentment, and
ultimately, anger. The people living with the virus are still treated as different by those
who are uninfected. Research shows that this fear discourages people living with HIV
to disclose their status, even to family members and to their sexual partners, and un-
dermines their ability and willingness to access and adhere to treatment and may lead
to drug discontinuation. It is evident that education is an integral and very fundamental
aspect as far as HIV management is concerned.
Gallant and Maticka-Tyndale (2004) in their study on the School-based HIV preven-
tion programmes for African youth established the importance of education in chang-
ing knowledge and attitudes and under certain conditions, behaviours of the youths. In
Kenya the young generation contributes the highest percentage of new infections hence
it is important to put in programmes that would lead to reduction of HIV transmission.
2.7 Summary
The study of in-vivo HIV infection remains a vital research area. There is an increas-
ing need to obtain novel and efficient therapeutic mathematical models of HIV in-vivo.
Many mathematical models of HIV dynamics, disease progression and therapy have
been developed and exploited since the first cases of HIV were reported in Africa in
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early 80s. It is evident that mathematical models on HIV dynamics analyze various
processes taking place in HIV patients by use of various assumptions on the virus
immune system interaction and the effects of ARTs. Irrespective of technological im-
provement in the different combinations of ARTs, no case has been reported on the
cure of the virus. This implies that rigorous research on optimal management of the
virus is paramount.
Different authors have formulated and discussed many mathematical in-vivo HIV mod-
els. These models have provided some insights into HIV progression, benefits of treat-
ment as well as the cost and the risk of drug resistance. However, many more questions
remain unanswered. It is evident that CD8+ T-cells play a major role in curbing the
virus progression although the exact mechanism on how they do it is not yet well
understood. Nonetheless, it is unfortunate to note that, a vast majority of models in
the literature have not incorporated the CD8+ T-cells and their activation process in
fighting the virus. Failure of models to incorporate the CD8+ T-cells shows that the
researchers are making the assumptions that in absence of ARTs there is no natural
anti-HIV response. Such an assumption implies that the only mechanism of fighting
HIV is by use of ARTs. However, in reality CD8+ T-cells help in fighting the virus
though their effectiveness may vary from patient to patient. Presumably, the stronger
the CD8+ T-cells response, the less the ARTs required to reduce the HIV progres-
sion. Therefore, it is paramount for researchers to analyze the relationship between the
CD4+ T-cells and the CD8+ T-cells.
This study has applied mathematical modelling to establish such relationship and pro-
vide insights on what could be done to increase the strength and the effectiveness of
the CD8+ T-cells in fighting the HIV. Furthermore, due to lack of literature on the in-
clusion of Fusion inhibitors as one of the control variables as well as non-infectious
virus that results from the use of PIs, this study addressed the gap by incorporating
the aforementioned in the control model. The study established a treatment regime
that will address the shortcomings such as the drug side effects, drug resistance, high
cost of treatment, toxicity and one that have maximum benefits to the patient and the
country through the social economic contribution of the infected people.
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Chapter 3
In-Vivo Dynamics of HIV Subject to
the Influence of the CD8+T-cells
3.1 Introduction
Studies on in-vivo HIV dynamics have been done over the years, aimed at understand-
ing the interaction mechanism of the immune system and the HIV virus. The infor-
mation arising from such studies has proved so valuable especially in the development
of ARTs and in HIV management. In the recent years, mathematical models of vari-
ous complexity level have been used in the simulation and analysis of HIV dynamics
(Adams et al., 2005; Chandra, 2009; Alizon and Magnus, 2012; Arruda et al., 2015).
However, various issues in the in-vivo HIV dynamics remain unanswered by the cur-
rent models. Therefore, there is need to come up with more models for the study of
the in-vivo HIV dynamics.
In this chapter, an in-vivo HIV dynamics model with the inclusion of the immune
cells, without treatment, has been formulated with the aim of establishing the core
role played by the CD8+ T-cells as far as controlling HIV replication is concerned.
The positivity and boundedness of the model have been established and the expression
for the basic reproduction number derived by applying the next Generation Matrix
Method (van den Driessche and Watmough, 2002). In addition, both the disease free
and endemic equilibrium points have been determined, their stability established and
bifurcation analysis for the model carried out. Finally the numerical simulations for
the in-vivo model have been presented.
3.2 Model Formulation
A mathematical model for the in-vivo interaction of the HIV virions and the immune
cells has been considered. The model has been classified into five compartments. The
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variables for the model are: the healthy CD4+ T-cells (T ), the infectious HIV virions
(V ), the infected CD4+ T-cells (I), the CD8+ T-cells (Z) and the activated CD8+ T-
cells (Za).
The healthy CD4+ T-cells are recruited at a constant rate λT from the bone marrow
and die naturally at a constant rate µT . The infected CD4+ T-cells are as a result of the
interaction between the uninfected CD4+ T-cells and the HIV virions at a rate χ. They
die naturally at a rate µI and are also eliminated by the activated CD8+ T-cells at the
rate α. In addition, the infected CD4+ T-cells produce an average of εV virions. The
new mature virions produced, infect other CD4+ T-cells. The HIV virions population
increases due to the budding of the infected CD4+ T-cells at a rate εV and die at the rate
µV . The CD8+ T-cells (Z), are generated from the thymus at a constant rate λZ , and
die naturally at a constant rate µZ . Due to the presence of the infected CD4+ T-cells
the CD8+ T-cells became activated at the rate β. The activated CD8+ T-cells (Za) are
recruited from the CD8+ T-cells in the presence of the infected CD4+ T-cells, at the
rate β and die naturally at a rate µZa . Definitions of variables and parameters for the
model are summarized in Table 3.1 and Table 3.2, respectively.
Table 3.1: Variables for HIV in-vivo model
Variable Description
T (t) The concentration of the non-infected CD4+T-cells per cubic millimetre
at any time t.
I(t) The concentration of the infected CD4+T-cells per cubic millimetre at
any time t.
V (t) The concentration of HIV virions copies per milliliter at any time t.
Z(t) The concentration of the CD8+T-cells per cubic millimetre at any time
t.
Za(t) The concentration of the activated CD8+T-cells per cubic millimetre at
any time t.
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Table 3.2: Parameters for HIV in-vivo model
Parameter Description
λT The rate at which the non-infected CD4+ T-cells are produced per unit
time.
µT The rate at which the non-infected CD4+T-cells decay or die.
χ The rate at which the CD4+T- cells are infected by the virus.
µI The death rate of the infected CD4+T-cells.
εV The rate in which HIV virions are generated from the infected CD4+T-
cells.
µV The death rate of the infectious virus.
α The rate at which the infected cells are eliminated by the activated
CD8+T-cells.
λZ The rate at which the CD8+ T-cells are produced per unit time.
µZ The death rate of the CD8+ T-cells.
β The rate at which the CD8+ T-cells are activated by the presence of the
virus and the infected CD4+ T-cells.
µZa The rate at which the activated defence cells decay.
A compartmental representation of model is presented as in Figure 3.1 which repre-












Figure 3.1: A compartmental representation of the in-vivo HIV Dynamics.
From Figure 3.1, the following model of non-linear ordinary differential equations for
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the in-vivo HIV dynamics model has been derived:
dT
dt
= λT − µTT − χTV,
dI
dt
= χTV − µII − αIZa,
dV
dt
= εV µII − µV V,
dZ
dt
= λZ − µZZ − βZI,
dZa
dt




Before commencing on the steady-states analysis of the system (3.1), it is important to
look at some properties to ensure existence of biologically meaningful solutions.
3.3.1 Positivity and the boundedness of the solutions
In this section the non-negativity of the state variables of the system (3.1) implying
that the solutions must be non-negative for all t ≥ 0 and must be bounded for all t ≥ 0
in an invariant region has been presented. The invariant region represents the domain
in which the model solutions are well posed mathematically and epidemiologically
meaningful.
Theorem 3.1. Let the parameters for the system (3.1) be non-negative constants. A
non-negative solution (T (t), I(t), V (t), Z(t), Za(t)) for the system (3.1) exists for all
state variables with non-negative initial conditions (T (0) ≥ 0, I(0) ≥ 0, V (0) ≥
0, Z(0) ≥ 0, Za(0) ≥ 0) for all t ≥ 0.




= λT − µTT − χTV,
dT
dt
≥ −µTT − χTV.
(3.2)











Taking the initial conditions at t = 0 and T (0) = T0 then, equation (3.3) reduces to
T ≥ T0e
∫ t
0 −(µT+χV (s))ds > 0. (3.4)
Hence T is non-negative for all t > 0.
Similarly the population of the infected CD4+ T-cells is given by
dI
dt
= χTV − µII − αIZa,
dI
dt
≥ −(µII + αIZa).
(3.5)




Taking the initial conditions at t = 0 and I(0) = I0 then equation (3.6) changes to
I ≥ I0e
∫ t
0 −(µI+αZa(s))ds > 0. (3.7)
Hence I is non-negative for all t > 0.
Similarly the differential equation for the HIV virions is,
dV
dt





By integration and separation variables equation (3.8) gives,
V ≥ Ce−µV t. (3.9)
Taking the initial conditions at t = 0 and V (0) = V0 then equation (3.9) becomes
V ≥ V0e−µV t > 0. (3.10)
Hence V is non-negative for all t > 0.
For the immune cells, part four of system (3.1) gives,
dZ
dt
= λZ − µZZ − βZI,
dZ
dt
≥ −(µZ + βI)Z.
(3.11)
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By separation of variables and integrating both sides with respect to the corresponding




Taking the initial conditions at t = 0 and Z(0) = Z0 then equation (3.12) becomes
Z ≥ Z0e
∫ t
0 −(µZ+βI(s))ds > 0. (3.13)
Hence Z is non-negative for all t > 0.
Finally, the differential equation for the activated immune cells is,
dZa
dt





By integration and separation of variables equation (3.14) becomes,
Za ≥ Ce−µZa t. (3.15)
Taking the initial conditions at t = 0 and Za(0) = Za0 then equation (3.15) becomes
Za ≥ Za0e−µZa t > 0. (3.16)
Hence Za is non-negative for all t > 0.
Thus, all the state variables are non-negative. Hence, the solutions of the system (3.1)
remain positive for all t ≥ 0.
3.3.2 Invariant region
Notably, all the state variables of the system (3.1) have been proved to be non-negative.
In addition, parameters of system (3.1) monitors cell population, hence they are also
non-negative for all, t > 0. Consequently, the system (3.1) analysis is done in the
region Γ that is biologically meaningful.
Theorem 3.2. All solutions (T (t), I(t), V (t), Z(t), Za(t)) ∈ R5 of system (3.1) are
bounded and there exist a biological feasible region Γ for the system (3.1) given as:
Γ =
{
(T (t), I(t), V (t), Z(t), Za(t)) ∈ R5 |
T (t) > 0, I(t) > 0, V (t) > 0, Z(t) > 0, Za(t) > 0} .
(3.17)
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Proof. The total population of the CD4+ T-cells, T + I = N4(t), is clearly a non-
constant value. Hence, according to system (3.1) the evolution equation representing
the change in the population of the CD4+ T-cells is;
dN4(t)
dt
= λT − µTT − µII − αIZa,
dN4(t)
dt
≤ λT − µTN4(t).
(3.18)








µT ≤ lnC + t.
(3.19)
Thus, inequality (3.19) can be written as
(λT − µTN4(t)) ≤ Ce−µT t. (3.20)
But at t = 0 and denoting N4(0) = N40 , inequality (3.20) reduces to,
C = λT − µTN40 . (3.21)
Substituting for C in inequality (3.21) in equation (3.20), then the inequality for the

















































Similarly the total number of the CD8+ T-cells, Z + Za = N8(t), is given by;
dN8(t)
dt
= λZ − µZN8(t). (3.28)








µZ ≤ lnC + t.
(3.29)
Thus, inequality (3.29) can be written as
(λZ − µZN8(t)) ≤ CeµZt. (3.30)
At t = 0 and denoting N8(0) = N80 inequality (3.30) reduces to
C = λZ − µZN80 . (3.31)
Substituting equation (3.31) into inequality (3.30) then, the inequality for the total

















































Finally, according to system (3.1) the evolution equation representing the change in
the population of the HIV virions, V , is given by,
dV (t)
dt
≤ εV µII − µV V. (3.38)

















By integration, inequality (3.39) gives
dV
dt








At t = 0 and denoting V (0) = V0 inequality (3.40) becomes






















, we have, V (t) ≤ εV µIλT
µTµV
, ∀ t. (3.44)
Therefore, from inequalities (3.43) and (3.44) we have







Thus at any time t > 0, we have



















Consequently the feasible solution for the system (3.1) are bounded. Since all state
variables are positive and bounded in R5, then the region Γ is positively invariant.




(T (t), I(t), V (t), Z(t), Za(t)) ∈ R5,





















with initial conditions (T (0), I(0), V (0), Z(0), Za(0) > 0), is positively invariant and
attracting for all t > 0. The domain Γ is positively invariant under the flow induced by
system (3.1). Therefore, the system (3.1) is biologically meaningful and it is feasible
to analyze the model in the domain Γ.
3.4 Equilibria and Reproductive Number
In the absence of infection by HIV virions the model as represented by system (3.1),
has a unique feasible HIV-free steady state solution called the disease-free equilibrium.
It is obtained by setting the derivatives of the infectious classes in system (3.1) to zero,
that is, V = I = Za = 0. Thus, disease free equilibrium (DFE) of the system (3.1) is
given by:










3.4.1 Basic Reproductive Number
Researchers in the field of in-vivo HIV modelling aim at finding the threshold con-
ditions that determine whether HIV virions will spread into susceptible CD4+ T-cells
when it is introduced in the body. In order to do this, researchers consider the basic
reproductive number (R0). According to Diekmann et al. (1990), the basic reproduc-
tive number represents the number of secondary infections that would result from one
infected cell. In other words, it represents the average number of secondary infections
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generated by a dying infected CD4+ T-cell in the absence of ARTs to control the viral
progression. HIV virions, once in the body, will continue infecting the CD4+ T-cells.
Whether the HIV virions become persistent or die out depends on the magnitude of the
basic reproductive number.
Stability of equilibrium points can be analyzed using R0. The disease free equilib-
rium is locally asymptotically stable if R0 < 1 and unstable if R0 > 1. If R0 < 1
then on average, a dying infected CD4+ T-cell produces less than one newly infected
CD4+ T-cell over the course of the infection period. Then, the infection may die out.
Conversely, if R0 > 1, it implies that each infected CD4+ T-cell produces, on average
more than one new infection, the infection will be able to spread in the body and the
infected person will eventually die due to the resulting opportunistic diseases. A large
value of R0, therefore, indicates endemicity. Consequently, in order to control viral
replication it is important to ensure that the disease free equilibrium is stable, that is,
0 < R0 < 1.
3.4.2 Computation of R0
In computing the basic reproduction number this study has adopted the next Genera-
tion Matrix method as given by Diekmann et al. (1990), and van den Driessche and
Watmough (2002). Mathematically R0 is given by
R0 = ρ(FV
−1), (3.50)
where ρ is defined as the spectral radius of the next generation matrix (Wiah and Mo-
hammed, 2014), F is defined as the rate of appearance of new infections in a com-
partment while V is the transfer of individuals out of infectious compartment (van den
Driessche and Watmough, 2002). The R0 for the disease free equilibrium is calculated
as the largest eigenvalue of the next generation matrix as follows. The matrix of the






The matrix that represents the transfer of infection between compartments at the disease-













Thus, the next generation matrix FV −1 is given by,
FV −1 =
 χεV λTµV µT χλTµTµV
0 0
 . (3.54)
The eigenvalues of the matrix given by (3.54) are; χεV λT
µV µT
and 0.







The basic reproductive number, R0, as given by (3.55) represents the number of sec-
ondary infections resulting from a dying infected cell over its average life time 1
µV
.
Notably, the infection would die out if R0 < 1 while the HIV infection becomes en-
demic if R0 > 1. In particular, from (3.55), it is evident that any intervention that
would reduce the rate of infection, χ, would go along way in reducing the R0.
3.5 Sensitivity Analysis of R0 with respect to the Model
Parameters
The aim of researchers especially in the field of HIV modelling is to understand the
dynamics of HIV so as to control it. This is mainly done by targeting some parameters
to which the R0 is sensitive. This study has applied the normalized forward index
method in the sensitivity analysis.
Definition 3.1. The normalized forward sensitivity index of R0 with respect to the












where P represents a parameter in the expression of the basic reproductive number.
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From the basic reproductive number given by equation (3.55) the sensitivity indices of


























Table 3.3 gives normalized forward sensitivity indices of R0 irrespective of the values
of the parameters .







From the sensitivity indices it is evident that R0 is most positively sensitive to param-
eters χ and εV . This implies that to maintain a small number of the R0, these two
parameters, χ and εV , must be reduced; whereas increasing them would lead to an in-
crease in the R0. Furthermore, R0 is most negatively sensitive to parameter µV and εV .
This implies that increasing any of these parameters (or both) would lead to a decrease
in the value of R0.
Remark 3.2. Since both λT and µT represents a naturally occurring phenomena in the
body, they are not included in sensitivity analysis.
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3.5.1 Effect of R0 on the in-vivo HIV dynamics
In this subsection the effects of R0 on the dynamics of infected cells and the HIV
virions is established. The parameter values given in Table 3.4 are used in the analysis.
Table 3.4: Parameters for in-vivo HIV model
Parameters Value Source
λT 10 cell/mm3/day Attarian and Tran (2017).
µT 0.01 day−1 Srivastava et al. (2009).
χ 0.000024 mm3 vir−1 day−1 Attarian and Tran (2017).
µI 0.5 day−1 Wodarz and Nowak (2000).
εV 100 vir. cell−1 day−1 Mbogo et al. (2013).
µV 3 day−1 Mbogo et al. (2013).
α 0.02 day−1 Arruda et al. (2015).
λZ 20 cell/ mm3/day Arruda et al. (2015).
µZ 0.06 day−1 Arruda et al. (2015).
β 0.004 day−1 Arruda et al. (2015).
µZa 0.004 day
−1 Arruda et al. (2015).
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Population of the infected CD4+ T-cells Population of the HIV virions
Figure 3.2: The HIV and infected CD4+ T-cells dynamics for R0 > 1 and R0 < 1
From Figure 3.2, it is evident that change in R0 have a big impact on the magnitude
of infected cells and the HIV viral load. Notably, from Figure 3.2 an increase in R0,
that is, having R0 > 1 leads to an increase in the number of the HIV virions and con-
sequently the infected cells. This implies that the body’s immunity is at risk and the
infected person is likely to progress to AIDS stage. However, whenR0 < 1 the number
of the HIV virions in the blood reduce significantly, thus, the infection is likely to die
out. From the research findings on R0 the study deduce that, for medical practitioners
to reduce the magnitude of HIV infection it is important to ensure that R0 < 1. This
may be done by developing controls, interventions and management policies that if
implemented would ensure that R0 < 1.
In the next sub-section the stability of the disease-free equilibrium point of the in-vivo
HIV model in system (3.1) is investigated and results presented.
3.5.2 Local stability of the disease-free equilibrium (DFE)
Theorem 3.3. The disease-free equilibriumE0 of system (3.1) is locally asymptotically
stable if R0 < 1 and unstable if R0 > 1.
The epidemiological implication of the Theorem 3.3 is that whenever R0 < 1 the
disease would be eliminated provided the initial size of the infected CD4+ T-cells
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population of the model in system (3.1) is sufficiently small.
Proof. This study applies linearization method to study and prove the local stability of
the disease-free equilibrium. According to this method the disease-free equilibrium,
E0, is locally asymptotically stable if all the eigenvalues of the Jacobian matrix of the
system (3.1), computed at the DFE, E0, have negative real parts. The Jacobian matrix
associated with the system (3.1) is given by:
J =

−µT − χV 0 −χT 0 0
χV −µI − αZa χT 0 −αI
0 εV µI −µV 0 0
0 −βZ 0 −µZ − βI 0
0 βZ 0 βI −µZa

(3.62)




−µT 0 −χλTµT 0 0
0 −µI χλTµT 0 0









The eigenvalues of the Jacobian matrix (3.63) are −µT ,−µZ , −µZa and the solutions
to the characteristic equation,










Note that R0 = χλTµT
εV
µV
< 1. Therefore, the disease free equilibrium is locally asymp-
totically stable for R0 < 1 otherwise it is unstable.
3.6 The Endemic Equilibrium
The endemic equilibrium, E1, is the state in which HIV infection may persist in the
body, characterized by very high viral load and a decrease in the number CD4+T-
cells. To analyze for the stability of the endemic equilibrium this study has adopted the
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assumption made by Culshaw et al. (2004) that the free virus spread the infection and
there is no cell-to-cell transfer of the HIV virions. The endemic equilibrium, E1, exists
when, T (t) > 0, I(t) > 0, V (t) > 0, Z(t) > 0, Za(t) > 0. An endemic equilibrium,
E1 = (T
∗, I∗, V ∗, Z∗, Za
∗), satisfies
λT − µTT ∗ − χT ∗V ∗ = 0,
χT ∗V ∗ − µII∗ − αI∗Za∗ = 0,
εV µII
∗ − µV V ∗ = 0,
λZ − µZZ∗ − βZ∗I∗ = 0,
βZ∗I∗ − µZaZa∗ = 0.

(3.66)
Hence, the endemic equilibria of the system (3.1) correspond to the positive solutions
of the model (3.66). The model (3.66) is solved in terms of Za∗ to obtain the endemic
equilibrium as
T ∗ =
λTµV β(λZ − Z∗aµZa)


























a + Φ0) = 0, (3.68)
where,
Φ2 = −4βµZaµZ(µZaµI + αλZ) ≤ 0,









V (R0 − 1).
 (3.69)
System (3.69) can be re-written as
Φ2 = 4βµZaµZ(µZaµI + αλZ),












The scenario, Z∗a = 0 in equation (3.68), represents the disease-free equilibrium ob-






a + Φ0 = 0, (3.71)







Consequently, depending on the signs of Φ1 and Φ0 the quadratic equation (3.72) may
have unique, two or no positive roots. The three scenarios are analyzed as follows.
Case 1:








a + Φ1) = 0.
(3.73)
Therefore,











corresponds to a unique
positive equilibrium point. This is the critical equilibrium point.
Case 2:
If R0 > 1 then Φ0 < 0,Φ1 < 0,Φ2 > 0. According to Descartes rule of signs, the
sign of the coefficients of the quadratic equation (3.68) changes once. So there is one
unique positive equilibrium point, Z∗a1 > 0. Consequently, there exist at least one
endemic equilibrium point.
Case 3:
If R0 < 1 (which implies Φ0 > 0), then Φ1 determines the existence of an equilibrium
point. If Φ1 ≥ 0 or Φ1 > 4Φ2Φ0 then there are no positive solutions for the quadratic
equation (3.68). However, if Φ1 < 0, Φ1 > 4Φ2Φ0 or Φ1 < −2
√
Φ2Φ0 then, according
to Descartes rule of signs, the sign of the coefficients of the quadratic equation (3.68)
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changes twice. So there are two positive equilibrium points corresponding to two
endemic equilibria. Consequently, Za∗ has two positive turning points, implying that
at R0 < 1 there is a possibility for the model to exhibit backward bifurcation.
Theorem 3.4 summarizes the existence of endemic equilibria of the system (3.1).
Theorem 3.4. The system (3.1) has:
1. no endemic equilibrium if R0 < Rc < 1, where Rc is the critical R0.
2. at least one endemic equilibrium in Γ, if R0 > 1.
3. two endemic equilibria for some parameter values for which R0 lies within the
range Rc < R0 < 1.
4. no endemic equilibrium, otherwise.
3.6.1 Backward bifurcation analysis
A bifurcation is defined as a change in the nature of a solution of trajectories due to
a parameter change. In the simplest words backward bifurcation, in epidemic model
is where a stable disease-free equilibrium co-exists with a stable endemic equilibrium
for R0 < 1. Thus, backward bifurcation occurs in models that have multiple endemic
equilibria when R0 < 1. Consequently, the classical epidemiological requirement of
having R0 < 1 is necessary but not a sufficient indicator for effective disease control
or elimination (Mukandavire et al., 2009).
In addition, Greenhalgh and Griffiths (2009) indicated that a bifurcation diagram pro-
vides a clear picture to the modellers on how the equilibrium solutions depend on R0.
In particular, the study revealed that there is a change in the qualitative behaviour of the
model when R0 = 1, in that, the disease free equilibrium bifurcates into a branch rep-
resenting the endemic equilibrium and another branch for the disease free equilibrium.
Therefore, the basic reproductive number must be further reduced in order to avoid
endemic states and guarantee viral elimination (Buonomo and Lacitignola, 2011). The
aim of investigating backward bifurcation, is because it plays a fundamental role in
disease control and eradication.
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Various researchers such as Sharomi et al. (2008) have established that disease models
exhibit the phenomenon of backward bifurcation where the stable disease free equilib-
rium co-exists with a stable endemic equilibrium; that is, there exists two sub-critical
endemic equilibria for R0 < 1. Furthermore, Huo et al. (2015) on the study of the ef-
fect of vaccines on backward bifurcation, emphasized the importance of establishing a
new critical value at the turning point rather than R0 that should work as a threshold of
disease eradication. Li and Wang (2014) in their study on the use of ARTs, discovered
that existence of the multiple endemic equilibria was associated with backward bifur-
cations which resulted in catastrophic behaviours of HIV. In particular, it indicated the
rebound of HIV viral load when a patient stops taking the ARTs which also explained
the viral blips during ARTs suppression of HIV. The importance of establishing the
bifurcation point as documented in the literature cited is to provide insights on the best
control methods that would lead to the eradication of HIV virions in the body.
In this study bifurcation analysis for the system (3.1) is carried out aimed at analyzing
the behaviour of the model at the endemic state.
Remark 3.3. The system given by (3.1) exhibits a backward bifurcation point atR0 = 1
if and only if Φ1 < 0 and Φ21 − 4Φ2Φ0 > 0.
To obtain the critical reproductive number, Rc, the discriminant Φ21 − 4Φ2Φ0 of the
equation (3.71) is set to zero and R0 is made the subject of the relation.













(λ2Tβ(−αλZ − 2µIµZa) + µZaµZ(λTµ2I + µ2V )
)
,









If Rc > 1 then the system (3.1) has a trans-critical bifurcation, and if Rc < 1 then
the system (3.1) exhibits backward bifurcation. It is important to note that existence
of a backward bifurcation with endemic equilibrium when Rc < 1 is very interest-
ing in applications. Notably, it has very important consequences in the strategies and
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control policies designed for HIV viral eradication. Basically, a backward bifurcation
implies the occurrence of multiple endemic equilibria and the coexistence of a sta-
ble endemic equilibrium with the stable disease-free equilibrium. Consequently, from
the epidemiological point of view reducing R0 below unity is no longer a guarantee
that the HIV virions will be eliminated completely or reduced to non-detectable level.
In addition, this affects HIV virus control since it can be possible for the disease to
progress even when R0 < 1. Furthermore, when backward bifurcation occurs, the
diseases-free equilibrium may not be globally asymptotically stable even when the ba-
sic reproduction rate is less than unity and thus a stable endemic equilibrium coexists
with the diseases-free equilibrium.
In summary, public policy makers, clinicians and researchers in the field of HIV should
find ways of ensuring that the control measure put in place guarantees the existence of
R0 < Rc < 1. This, in turn, will lead to eradication of the HIV virions.
3.7 Global Stability of the Disease-Free Equilibrium
Due to the existence of backward bifurcation for the system (3.1) we conclude that
disease-free equilibrium is globally stable if and only if R0 < Rc, where Rc is the crit-
ical reproductive point. To prove this, we have applied the approach given by Castillo-
Chavez et al. (2002), in studying the global stability of the disease-free equilibrium for
the system (3.1). Using this approach two key conditions are listed in the study and that
if met will guarantee the global asymptotic stability of the disease-free equilibrium.









G(X, 0) = 0. (3.78)
where the column vector components of X ∈ RM denote the uninfected population
and the components of W ∈ Rn denote the infected population. Let E0 = (X∗, 0) be
the disease-free equilibrium for the model.
Then E0 = (X∗, 0) is globally asymptotically stable if and only if:
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(1) R0 < 1, that is, locally asymptotically stable.
(2) dX
dt
= H(X, 0), X∗ is globally asymptotically stable.
(3) G(X,W ) = PG − Ĝ(X,W ), Ĝ(X,W ) ≥ 0 for (X,W ) ∈ ΩH , where P =
DWG(X
∗, 0) is an M-matrix (the off diagonal elements of P are non negative)
and ΩH is the region where the model makes biological sense.
If the system (3.1) satisfies the conditions mentioned in Theorem 3.5 then the fixed
point E0 = (X∗, 0) is a globally asymptotically stable equilibrium of system (3.1)
provided that R0 < Rc. For system (3.1) the result is stated and proved in Proposition
3.1.
Proposition 3.1. The disease-free equilibrium point,E0 = (X∗, 0), is a globally asymp-
totically stable equilibrium of system (3.1) provided that R0 < Rc and the conditions
(2) and (3) in Theorem 3.5 are satisfied.






= G(X,W ), G(X, 0) = 0.
(3.79)
where X = (T, Z, Za) and W = (I, V ). Here, X ∈ R3 denotes the non-infected
compartments and W ∈ R2 denotes the HIV infected compartments. The disease-free
equilibrium for the system (3.1) is denoted as E0 = (X∗, 0).
H(X,W ) =

λT − µTT − χTV








 = dXdt . (3.81)












Lemma 3.1. The biologically feasible region ΩH defined by the compact set;
ΩH =
{
















with initial conditions (T (0), Z(0), Za(0) > 0), is positively invariant for all t > 0.




= λT − µTT,
dT
dt
+ µTT = λT .
(3.84)
















+ Ce−µT t. (3.87)
Applying the initial condition, at t = 0, and denoting T (0) = T0, equation (3.87) gives



























= λZ − µZZ,
dZ
dt
+ µZZ = λZ .
(3.91)
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Applying the initial condition, at t = 0, and denoting Z(0) = Z0, then,































By integration, equation (3.99) reduces to
Za = Ce
−µZa t. (3.100)
Applying the initial conditions at t = 0 and denoting Za(0) = Za0 then,
Za0 = C. (3.101)
Hence substituting equation (3.101) the inequality for the activated CD8+ T-cells is
given by
Za ≤ Za0e−µZa t. (3.102)
Thus at any time t ≥ 0, Za is bounded. Equations (3.90), (3.97) and (3.102) imply that
any solution (T (t), Z(t), Za(t)), at t ≥ 0, in R3 will always remain confined in ΩH .
Hence, the region ΩH is positively invariant for the system (3.81).
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For condition (2) in Theorem (3.5) the Bendixson criterion and Dulac criterion for au-
tonomous model as described by Li et al. (1995) is applied in proving non-existence
of the periodic solutions in model (3.81). This is done by first showing that the au-
tonomous model (3.81) is an invariant linear subspace.
The Jacobian matrix, J(T, Z, Za), of the model (3.81) is given by






Notably, J is a leading diagonal matrix and the eigenvalues of such a matrix are its
main diagonal entries. Thus, the eigenvalues of J are −µT ,−µZ and − µZa . Since
all the eigenvalues are negative then the steady state X∗ for the model (3.81) is locally
asymptotically stable. We now proceed to show that this unique steady state is globally
asymptotically stable. Here, Dulacs criteria is applied in ruling out the existence of
periodic orbits in ΩH .
Definition 3.2 (Bendixson-Dulacs Criterion). Suppose D is a simple connected open
set of R3 and B(x, y, z) is a real-valued function in D.










If the expression is not identically zero and does not change sign in D, then there are
no periodic solutions of the autonomous model in D. The function B(x, y, z) is called
a Dulac function. It is worth noting that the Dulacs criterion is a generalization of
Bendixsons Criterion, in the special case where B(x, y, z) = 1.
Let
M(T, Z, Za) = λT − µTT,
N(T, Z, Za) = λZ − µZZ,
K(T, Z, Za) = −µZaZa.
(3.105)
also let
Θ(T, Z, Za) =
1
TZZa
for T > 0, Z > 0 and Za > 0 (3.106)













then, equations (3.106) and (3.107) give
ø = − µT
TZZa









From equation (3.108) it is evident that the model (3.81) has no periodic solutions (or
limit cycles) in the compact set ΩH . Consequently, from the fact that the steady points
of model (3.81) have been proved to be locally asymptotically stable, then from the
Poincare- Bendixson Theorem (Dulac criterion), the unique equilibrium points X∗ of
the model (3.81) is globally asymptotically stable.
The study finally proves the satisfaction of condition (3) of Theorem 3.5.
Let G(X,W ) = PG− Ĝ(X,W ), Ĝ(X, 0) ≥ 0 ∀ (X,W ) ∈ ΩH ,
G(X,W ) =
χTV − µII − αZaI
εV µII − µV V
 . (3.109)
Since every element of the matrix G(X,W ) contains virions or infected components















Since αZaI ≥ 0 then, Ĝ(X,W ) ≥ 0 for (X,W ) ∈ ΩH . Hence the disease-free
equilibrium (E0) is globally stable. That is, X∗ = (λTµT , 0, 0,
λZ
µZ
, 0) is globally asymp-
totically stable equilibrium solution of dX
dt
= H(X, 0). Consequently, by the Proposi-
tion 3.1, the disease-free equilibrium of the system (3.1) is globally symptomatically
stable.
Proposition 3.1 implies that when R0 < Rc a small influx of free HIV virions into
the body cells, would not lead to the disease progressing AIDS stage. The subsequent
numbers of those infected cells would be less than that of their predecessors and even-
tually the disease may be reduced to non-detectable level.
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Remark 3.4. From Theorem 3.1 the disease-free equilibrium, E0, for the system (3.1)
is globally asymptotically stable if R0 < 1. However, due to the existence of multiple
endemic equilibrium then the study conclude that system (3.1) is globally asymptoti-
cally stable if and only if R0 < Rc < 1, where Rc denotes the critical reproduction
number.
3.8 Numerical Simulations
Parameter values given in Table 3.4 are used in the numerical simulations and in illus-
trating the general dynamics of the system (3.1) with respect to time.
Figure 3.3 shows the dynamics of the CD4+ T-cells. The hallmark of HIV/AIDS
Figure 3.3: The Rate of Change of the CD4+T-cells with respect to time.
pathogenesis is the depletion of CD4+ T-cell populations. It is evident from Figure 3.3
that as the disease progresses the number of CD4+ T-cells per micro litre decreases.
However, due to the immune system mechanism the reduction of the CD4+ T-cells
is followed by an increase in the number of the CD4+ T-cells which coincides with
immune system reconstruction. This could be explained by the fact that the body
mechanism will always try to be at an equilibrium. However, as the immune system
weakens the body is unable to reconstruct itself, and that is why there is an occurrence
of a straight line after the second year. The results in this study are in agreement with
clinical observation (Reimann et al., 1996; Nishimura et al., 2005; Okoye and Picker,
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2013). It has been indicated that initial destruction of the cells is counteracted by
CD4+ memory T-cell regeneration that preserves CD4+ T-cell numbers. The number,
however, does not go back to pre-infection stage. This process is not maintained for a
longer period, this explains the drastic drop in the level of the CD4+ T-cells. In HIV
as the number of the cells decreases the body immunity lacks the ability to fight other
infection. That is why HIV infected people are prone to many opportunistic deceases
as the CD+ T-cells goes below 350 cells/mm3.
Figure 3.4 shows the dynamics of the infected CD4+ T-cells. It is evident that at
Figure 3.4: The number of the infected CD4+T-cells with respect to time.
acute infection the number of the infected cells increases at a very sharp rate. Then
decreases exponentially. However, after 100 days the level increases, but since the
body has a way of balancing the cells, an increase is followed by a decrease hence the
existence of a non-harmonic system. The non-harmonic oscillations are maintained up
to 500 days. Due to the weak immune system the number of infected cells remains
at a constant rate after 600 days. HIV has proved to have no cure so far, therefore,
researchers need to find ways of killing all the infected cells before they bud out and
produce mature HIV virions. This is because HIV-induced cell death actually increases
HIV replication (Su et al., 2005; Bren et al., 2009).
Figure 3.5 represents the dynamics of the HIV virions in the first 1000 days after
infection. It is evident that the number of HIV virions increases in the first few days
after infection. Afterwards the number of HIV virions decreases. This is attributed to
the recruitment of the cytotoxic cells to fight the free virus. After about three months
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Figure 3.5: The number per mm3 of the HIV-virions with respect to time.
the level increases exponentially; due to the many infected cells bust releasing a higher
number of the virions. Since the cytotoxic cells kill the infected cells then indirectly
they reduce the number of HIV virions produced. A sharp increase after three months
is therefore, followed by a decrease in the number of HIV virions. After 500 days, the
number of HIV virions remains at a constant rate. It is important to note that new HIV
virions are released from an infected CD4+ T-cell, via the bursting of the cell. This
implies that a single burst produces a large pool of new HIV virions.
Figure 3.6 represents the dynamics of the of the CD8+ T-cells in the first 1000 days
Figure 3.6: The number of cytotoxic/CD8+ T-cells with respect to time.
after infection. These are specialized cells of the adaptive immune system capable of
finding and eliminating pathogen-infected cells. They are responsible for destroying
and killing the infected cells, and in turn helps to restore the immune system. They
arise from the bone marrow and later relocate to the thymus for maturation. During
this process they are able to express a unique antigen-binding molecule known as the
T-cell receptor. The receptor enables them to monitor all cells of the body, ready to
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destroy any cell posing as a threat to the organism. Nonetheless, for the cytotoxic cells
to fight and destroy any infected cell they must be activated and the dynamics of the
activated cells is shown in Figure 3.6. The activation takes place at the surface of acces-
sory cells, which mature during the innate immune responses triggered by an infection.
From Figure 3.7 it is evident that the number of the activated CD8+ T-cells increases
Figure 3.7: The number of the activated cytotoxic T-cells with respect to time.
exponentially for the first one month. The cells are activated in preparation to kill the
already infected CD4+ T-cells. The number then reduces to a minimum after 5 months
(150 days) though not to the level of the pre-infection period. This coincides with the
reduction in the number of the free HIV virions. Onward a non-harmonic curve is
observed for the dynamics of the activated cytotoxic cells.
3.9 Conclusion
In this Chapter a deterministic model for the in-vivo HIV dynamics has been pre-
sented. The model analyzed HIV in-vivo dynamics focusing on the highly dynamic
interaction between HIV virions, uninfected CD4+ T-cells, infected CD4+ T-cells and
CD8+ T-cells. The inclusion of the immune response to viral infection is a key feature
in examining the course of HIV infection. The model aimed at analyzing the mech-
anism of the HIV virus during the entry time up to the maturation time and the role
played by the activated CD8+ T-cells in fighting and killing the HIV virions. The study
starts by proving that the model is epidemiologically well posed. Afterwards, the ex-
pression of the basic reproductive number, R0, is derived by use of the next generation
matrix. The analytical results indicate that the disease-free equilibrium point of system
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(3.1) is locally stable for R0 < 1 and globally stable for R0 < Rc < 1. Numerical
results are presented to show the importance of maintaining the R0 below one. The
numerical simulations for the model also indicates the importance of the CD8+T-cells
as far as fighting the HIV virions is concerned. At the primary phase of HIV infection
the patients experience a period of increasing viral load and a decline in the number
of CD4+T-cells. Flu like symptoms have been associated with this phase. However,
as much as this study has only established the role played by the immune cells at the
acute infection, researchers such as Wodarz (2001) have shown that patients who do
not progress to AIDS after 15 years or longer have significantly higher levels of im-
mune cells compared to HIV-infected patients. It is therefore, paramount to maintain a
positive population of the CD8+ T-cells so as to ensure that if viral load does rebound,
the immune system will be in a position to fight and kill the infected CD4+ T-cells.
Therefore, for this to be realized the best ARTs should be administered. In this regard
we extended the system (3.1) to include the various drug regimes.
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Chapter 4
Mathematical Models for In-vivo HIV
Dynamics Subject to Therapy
4.1 Introduction
About a third of HIV-infected individuals living in sub-Saharan Africa and who are el-
igible for antiretroviral therapy (ART), receive combined ARTs. Despite the increased
roll-out of combined antiretroviral therapy, a meaningful decrease in the incidence of
AIDS-associated malignancies is yet to be realized. It is therefore, apparent that, sup-
pression, and not eradication, is most likely the best that can be achieved with the use
of current regime of ARTs.
However, it is very unfortunate to note that the current strategy of continuous com-
bination therapy is difficult to maintain for long periods of time due to short- and long-
term toxicities (metabolic abnormalities, body habitual changes, lipid abnormalities,
mitochondrial toxicity and liver toxicity) as well as adherence challenges inherent in
these complicated pill regimes, cost, and the development of resistance to medications.
In this chapter, a mathematical model for the in vivo HIV dynamics with treatment
has been formulated. In order to study the effect of treating HIV infection by the use
of a cocktail of drugs, three control variables: u1, u2 and u3 which represent Fusion
inhibitors (FIs), Reverse Transcriptase inhibitors (RTIs) and the Protease inhibitors
(PIs), respectively, have been introduced. This study differs from other researches that
had incorporated both the HIV therapy and the CD8+ T-cells in their models such as
Culshaw et al. (2004); Hattaf and Yousfi (2012a); Arruda et al. (2015); Silva and Tor-
res (2015); by considering the Fusion inhibitors as a control variable in the model and
the non-infectious virus as a result of the use of Protease inhibitors. In this study it is
assumed that there is no drug resistant virions before the initiation of ARTs.
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4.2 Model Description
To study the effect of treating HIV infection with the use of a cocktail of drugs, an in-
vivo HIV model with the three control variables u1, u2 and u3 has been formulated and
the analyzes given. HIV virus targets the CD4+ T-cells (T ). Thus, through the interac-
tion of the CD4+ T-cells and the HIV virus (V ), the susceptible cells become infected
at a rate χ. Then, the infected CD4+ T-cells (I) produce more HIV virions through
budding at a rate εV . However, if the infected person is under treatment through the
use of Protease inhibitors, a small proportion of the virus produced will be immature
and non-infectious (Vn). In addition, the presence of the infected CD4+ T-cells, leads
to the activation of the CD8+ T-cells to destroy infected CD4+ T-cells.
In this chapter therefore, a model with seven compartments is developed to represent
the interaction between the HIV virions, the body immune cells and the HIV drugs.
The state variables for the model used in this study are: susceptible CD4+ T-cells, T ;
infected CD4+ T-cells, I; latently infected CD4+ T-cells, Il; HIV virions, V ; non-
infectious/immature HIV virions, Vn; CD8+ T-cells, Z and activated CD8+ T-cells
(cytotoxic cells), Za.
Furthermore, three treatment parameters u1, u2 and u3 are introduced to the model.
Parameter u1 represents the use of FIs that inhibit the fusion process, hence the virus
does not enter into the CD4+ T-cells membrane. Parameter u2 represents RTIs that
prevent the reverse transcription process from taking place. Parameter u3 represents
PIs that inhibits the release of protease enzymes needed for the maturity of HIV virions
hence it leads to the production of non-infectious and immature virions. This in turn
reduces the amount of HIV virions in the body.
The summary for the state variables, treatment parameters and the model parameters
are summarized in Tables 4.1, 4.2 and 4.3, respectively.
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Table 4.1: Variables for HIV in-vivo model with therapy
Variable Description
T (t) Population of the non-infected CD4+T-cells at any time t.
I(t) Population of the infected CD4+T-cells at any time t.
Il(t) Population of latently infected CD4+ T-cells at any time t.
V (t) Population of HIV virions at any time t.
Vn(t) Population of the immature non-infectious virions at any time t.
Z(t) Population of the CD8+T-cells at any time t.
Za(t) Population of the activated CD8+T-cells at any time t.
Table 4.2: Treatment Parameters for HIV in-vivo model
Treatment Parameters Description
u1 Fusion inhibitors.
u2 Reverse Trancriptase inhibitors.
u3 Protease inhibitors.
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Table 4.3: Parameters for HIV in-vivo with therapy model
Parameter Description
λT The rate at which the non-infected CD4+ T-cells are produced per unit
time.
µT The rate at which the non-infected CD4+T-cells decay.
χ The rate at which the CD4+T-cells are infected by the virus.
µI The death rate of the infected CD4+T-cells.
µIl The death rate of the latently infected CD4
+ T-cells.
εV The rate in which HIV virions are generated from the infected CD4+T-
cells.
µV The death rate of the infectious virus.
µVn The death rate of the non-infectious virions.
α The rate at which the infected cells are eliminated by the activated
CD8+T-cells.
λZ The rate at which the CD8+ T-cells are produced per unit time.
µZ The death rate of the CD8+ T-cells.
β The rate at which the CD8+ T-cells are activated by the presence of the
virus and the infected CD4+ T-cells.
µZa The rate at which the activated defense cells decay.
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Figure 4.1: A compartmental representation of the in-vivo HIV Dynamics with therapy.
From the description of state variables, treatment parameters and the model parameters
in Tables 4.1, 4.2 and 4.3 respectively and Figure 4.1, the following system of ordinary
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differential equations representing the in-vivo dynamics of HIV is derived.
dT
dt
= λT − µTT − (1− u1)χTV,
dI
dt
= (1− u1)(1− u2)χTV − µII − αIZa,
dIl
dt
= (1− u1)u2χTV − µIlIl,
dV
dt
= (1− u3)εV µII − µV V,
dVn
dt
= u3εV µII − µV nVn,
dZ
dt
= λZ − µZZ − βZI,
dZa
dt




4.3.1 Positivity of the solutions
Since the in-vivo HIV model aims at monitoring cells population, it is then paramount
to show that if the model in system (4.1) starts with non-negative initial conditions of
the variables and the parameters then the solutions of the model remain non-negative
for all t ∈ [0,∞]. Then there exists a suitable feasible region Γ for the system (4.1)
which gives biologically meaningful solutions. That is,
Γ =
{




We now state and prove a theorem for the non-negativity of the variables in system
(4.1) as follows:
Theorem 4.1. Given that in system (4.1) the state variables, T (t) ≥ 0, V (t) ≥
0,Vn(t) ≥ 0, I(t) ≥ 0, Il(t) ≥ 0, Z(t) ≥ 0, Za(t) ≥ 0 for all t > 0. Then, the
solutions (T (t), V (t), Vn(t), I(t), Il(t), Z(t), Za(t)) of the model remain positive for
all time t > 0, and the region Γ is positively invariant.
Proof. To show positivity of solutions, it is enough to show that each of the trajectories
of system (4.1) is non-negative for all t > 0.
From the first part of system (4.1) the population of the CD4+ T-cells is
dT
dt
= λT − µTT − (1− u1)χTV. (4.3)
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Then, the differential inequality describing the evolution of the susceptible population
of the CD4+ T-cells over time is given by,
dT
dt
≥ −µTT − (1− u1)χTV,
= −(µT + (1− u1)χV )T,
dT
dt
+ (µT + (1− u1)χV )T ≥ 0.
(4.4)







ψ(t) = µT + (1− u1)χV. (4.6)
Taking the initial conditions t = 0 and denoting T (0) by T0 then, the complete solution
to the inequality (4.5) for the susceptible population of the CD4+ T-cells is given by,
Teψ(t) ≥ T0,
T ≥ T0e−ψ(t) ≥ 0.
(4.7)
The same argument can be used to prove the non-negativity of I, Il, V, Vn, Z, and Za
for t > 0.
4.3.2 Boundedness of solutions
Similarly we show that the state variables for the system (4.1) are bounded above.
Taking the total number of the CD4+ T-cells as N4(t), that is, T + I + Il = N4(t), we




= λT − µTT − (µI + αZa)I − µIlIl. (4.8)
From equation (4.8) the differential inequality for the total population of the CD4+
T-cells is given as
dN4(t)
dt
≤ λT − µTT,
dN4(t)
dt
+ µTT ≤ λT .
(4.9)
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Using a suitable integrating factor, that is, I.f = eµT t, the differential inequality (4.9)












µT t − T0 ≤
λT
µT






















From inequality (4.11) the state variables describing the evolution of the total popu-
lation of the CD4+ T-cells is less or equal to the maximum value between the initial
conditions and the ratio of the recruitment rate over the natural mortality rate.
Similarly let the total population of the HIV virions beNV (t), that is, V +Vn = NV (t).
Then from system (4.1) the differential equation for the HIV virions is;
dNV
dt
= εV µII − µV V − µVnVn. (4.12)
Since Vn = NV − V , then equation (4.12) reduces to;
dNV
dt
= εV µII − (µV − µVn)V − µVnNV . (4.13)













= H , equation (4.13) reduces to
dNV (t)
dt
≤ εV µIH − µVnNV . (4.14)






Consequently, at any t > 0 the HIV virions are bounded by;




Finally, let the total population of the CD8+ T-cells be denoted as, Z + Za = NZ(t),




≤ λZ − µZN8(t). (4.17)
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By separation of variables method for solving differential inequality, inequality (4.17)






By integration, inequality (4.18) becomes
ln(λZ − µZN8(t))
− 1
µZ ≤ C. (4.19)
At t = 0 and denoting N8(0) = N80 equation (4.19) reduces to
C = λZ − µZN80 . (4.20)
Substituting equation (4.20) into equation (4.19) then, the inequality for the total pop-





































Then for all t > 0 the C8+ T-cells are bounded.
Since all the state variables are positive and bounded then the system (4.1) is biologi-
cally meaningful and it is feasible to analyse the model in the domain Γ.
4.4 Disease-Free Equilibrium and the Basic Reproduc-
tive Number
In this section we establish the existence of the disease-free equilibrium point of the
























Then the system (4.1) becomes
0 = λT − µTT − (1− u1)χTV,
0 = (1− u1)(1− u2)χTV − µII − αIZa,
0 = (1− u1)u2χTV − µIlIl,
0 = (1− u3)εV µII − µV V,
0 = u3εV µII − µV nVn,
0 = λZ − µZZ − βZI,
0 = βZI − µZaZa.

(4.27)
In absence of infection by the HIV virions the system (4.1), has a steady state solution











4.4.1 Basic Reproductive Number
In this section we derive the basic reproductive number using the next generation ma-
trix. The infected compartments are selected for the analysis, that is, I, Il, V and Vn.
Theorem 4.2. The basic reproductive number R0 of system (4.1) is given by
R0 = ρ(FV1) =
(1− u1)(1− u2)(1− u3)χεV λT
µV µT
. (4.29)
Proof. Following Diekmann et al. (1990) and van den Driessche and Watmough (2002)
the basic reproductive number R0 of system (4.1) is calculated by using the next gen-
eration matrix. It is given by the spectral radius of the FV −1 so that;
R0 = ρ(FV
−1). (4.30)
Let F (X) denote the appearance of new infection in a compartment and V (X) be the
rate of transfer of the infection in the compartments I, Il, V and Vn. Then
F =

0 0 (1− u1)(1− u2)χλTµT 0
0 0 (1− u1)u2χλTµT 0
0 0 0 0





µI 0 0 0
0 µIi 0 0
−(1− u3)εV µI 0 µV 0
−u3εV µI 0 0 µVn
 . (4.32)
Since the reproductive number is given by the spectral radius of the matrix FV −1, then
































0 0 0 0
0 0 0 0
 . (4.34)
The eigenvalues of the matrix (4.34) are given by
Λ =
(1− u1)(1− u2)(1− u3)χεV λT
µV µT
,Λ2 = Λ3 = Λ4 = 0. (4.35)
Hence, the basic reproductive number for the system (4.1) is
R0 = ρ(FV
−1) =
(1− u1)(1− u2)(1− u3)χεV λT
µV µT
. (4.36)
If R0 < 1 in equation (4.36), then the HIV virions cannot invade the body and the
disease will die out over time. However, as much as the time before the virions goes
to non-detectable level depends on how small R0 is, the HIV patients must continue
taking ARTs to avoid the recurrence of the disease. It can be seen from equation (4.36)
that if the drug regimes ,that is, Fusion inhibitors, Reverse Transcriptase inhibitor and
the Protease inhibitor are 100% effective which implies that, u1 = u2 = u3 = 1, then
there is no secondary infections in the cells and the disease will die out.
To determine the best ways of reducing mortality due to HIV/AIDS related illness




The aim of researchers especially in the field of HIV modelling is to understand the
dynamics of HIV so as to establish conditions for controlling it through targeting some
sensitive parameters. This is done by performing a sensitivity analysis on R0. Sensi-
tivity analysis tries to explain the importance of the parameters in relation to disease
progression. In this chapter both the normalized forward index and the Partial rank
correlation coefficients have been applied in the sensitivity analysis.
4.5.1 Normalized forward index













where P represents a parameter in the expression of the basic reproductive number.
From the basic reproductive number given by equation (4.36) the sensitivity indices,


































From the sensitivity indices it is evident that χ and εV are the most positively sensitive
parameters. This means increasing these parameter will lead to an increase in the R0
whereas µV is the most negatively sensitive parameter. This means that increasing this
parameter will decrease the value of R0. In particular, a 1% increase in µV results to
a 1% decrease in R0. Therefore, reducing the most positively sensitive parameters in
the R0 will be the most effective way in reducing viral replication. In conclusion it is
evident that at the disease-free equilibrium the most effective treatment strategy should
always target the infection rate.
4.5.2 Use of Partial rank correlation coefficients (PRCCs) for sen-
sitivity analysis
PRCC is a method that measures the monotonicity between parameters and model out-
put after removing the linear effects of all parameters except the parameter of interest
(Marino et al., 2008). The correlation provides a measure of the strength of a linear
association between an input and an output. A standard correlation coefficient, ρ, for















where {(xi, yi) | xi ∈ x, yi ∈ y} are the set of paired, sampled data, x̄ is the sample
mean of x, and ȳ is the sample mean of y. The PRCC determines the sensitivity of
an output state variable to an input parameter as the linear correlation, ρ, between the
residuals, Xj − X̂j and Y − Ŷ where Xj is the rank transformed, sampled jth input
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parameter, and Y is the rank transformed output state variable, while keeping all other
parameter values fixed. Xj and Y are determined for k samples by the linear regression
models (Wu et al., 2013).









PRCC method has been widely used by researchers in the field of epidemiology in an-
alyzing the parameter sensitivity to R0. The use of PRCCs in sensitivity analysis helps
in the assessment of the statistical relationship between the R0 and the parameters and,
the sign of the PRCC of an input parameter depicts the particular kind of qualitative
affiliation it has with the outcome variable. When a parameter of the R0 has a positive
PRCC value, it means that if it is increased, it will lead to an increase in the value of
the R0 whereas its decrease leads to a decrease in the R0. Using the parameter values
in Table 3.4 the Tornado plots of partial rank correlation coefficients (PRCCs) of the
parameters εV , µV andχ that influence R0 are presented in Figure 4.2.
Figure 4.2: Tornado plot showing the sensitivity of R0 to some of the parameters values
From Figure 4.2 it is evident that a decrease in the rate of HIV virions production εV
would lead to a decrease in the value of R0. This can be done, for example, by intro-
ducing HIV drugs such as the Reverse Transcriptase inhibitors (RTIs) or the Protease
inhibitor (PIs). RTI prevents the production of more HIV virions since it inhibits the
reverse transcription process. If the HIV RNA is not reverse transcribed to HIV DNA
then the virus inside the cells fail to multiply. In addition, use of PIs inhibits the pro-
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duction of protease enzyme that is necessary for the maturation of the HIV virions,
consequently, the virus produced after its introduction would be non-infectious and
immature. Furthermore, a strong immune response would lead to a reduction in the
number of the HIV virions. Activated cytotoxic T-cells fight and kill/remove the in-
fected cells. This, in turn, reduces the number of the HIV virions produced.
Increase in the death rate of free HIV virions would also lead to a decrease in the
R0. This could be done by introducing the ARTs drugs aforementioned. However, it
is important for researchers to establish the most optimal HIV drugs that would lead to
immune reconstruction with minimal side effects.
Remark 4.1. When the parameters with PRCC > 0 are increased, R0 increases
whereas when the parameters with PRCC < 0 are increased, R0 decreases and the
converse is true.
Remark 4.2. Since both λT and µT represents a naturally occurring phenomena in the
body, they are not included in sensitivity analysis.
The two methods convey the same information however, the PRCC index, ranging
from -1 to +1, is more efficient since it provides specific qualitative information on the
relationship between the R0 and its parameters.
4.6 Stability Analysis of the equilibrium points
In this section the analysis for the local stability of the disease-free equilibrium of sys-
tem (4.1) is carried out. The reproductive number has been known to play an important
role as far as propagation of the HIV epidemic is concerned.
4.6.1 Local stability of the disease-free equilibrium
Theorem 4.3. The disease-free equilibrium of the HIV/AIDS system (4.1) is locally





−µT 0 0 −χ(1− u1)λTµT 0 0 0
0 −µI 0 χ (1−u1)(1−u2)λTµT 0 0 0




0 (1− u3)εV µI 0 −µV 0 0 0
0 u3εV µI 0 0 −µVn 0 0
0 −β λZ
µZ
0 0 0 −µZ 0
0 β λZ
µZ




The eigenvalues are −µT ,−µV ,−µIl ,−µVn ,−µZ ,−µZa and those that are solution to
the equation:
Λ2 + (µI + µV )Λ + µIµV
(






The eigenvalues of equation (4.46) have negative real parts if




Note that, R0 = (1 − u1)(1 − u2)(1 − u3)χ λT εVµTµV . Consequently, all the eigenvalues
are negative when R0 < 1. Hence the disease-free equilibrium of the model is locally
asymptotically stable when R0 < 1.
4.7 Numerical Simulations and Analysis of HIV Dy-
namics during Treatment
Numerical integration is used to solve the system (4.1) in MAPLE. The initial values
of the model are set as; T0 = 1000 cells/mm3, I0 = 10 cells/mm3, Il0 = 0 cells/mm3,
V0 = 10 virions/mm3, Vn0 = 0 virions/mm3, Z0 = 500 cells/mm3, Za0 = 30 cells/mm3.
For the first simulation the same drug efficacy of the three drug combinations, that is,
u1 = u2 = u3 = U is used. The parameter values used in the analysis are described in
Tables 3.4 and 5.1.
Figure 4.3 shows the dynamics of CD4+ T-cells over time. It is clear that ARTs play a
very vital role. This is because the level of the susceptible CD4+ T-cells remains high
with increase in the level of the drug efficacy. A small decrease in the number of the
CD4+ T-cells is observed during treatment, which lasts for a short period. Later the
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Figure 4.3: The population of the susceptible
CD4+T-cells.
Figure 4.4: The populations of the latently in-
fected CD4+T-cells.
Figure 4.5: The population of the infected CD4+ T-cells with time.
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number of the CD4+ T-cells increases although not to the pre-infection period. Fur-
thermore, as the drug efficacy increases there is also an increase in the number of the
susceptible CD4+T-cells. However, without treatment the level of the CD4+ T-cells
decreases as one progresses to the disease stage. This can be explained by the fact
that during acute infection there is high multiplication of the virus which lead to a de-
crease in the number of susceptible cells, hence, most of the CD4+ T-cells get infected.
Figure 4.4 represents the change in population of the latently infected cells. It is evi-
dent that introduction of ARTs leads to production of the latently infected cells. The
cells are only produced when RTIs drugs for HIV treatment are used. Fortunately, the
latently infected cells do not produce infectious HIV virions because the RTIs inhibits
the reverse transcription process.
Figure 4.5 represents the number of the infected CD4+ T-cells. The research find-
ings indicate that when no treatment is in use, there is a sharp increase in the number
of infected cells. This is due the high number of HIV virions produced by a single
infected cells. However, in the presence of ARTs, the number of the infected cell in-
creases steadily during the onset of treatment but after two months, the number reduces
although not to the disease free equilibrium.
Figure 4.6 shows that the number of infectious HIV virions increases when the pa-
Figure 4.6: The population of the infectious
virus with respect to time.
Figure 4.7: The population of the Non-
infectious HIV virus.
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tient is under no treatment within the first few weeks and later goes down due to the
antibody response. The population however, remains at a constant level for a period
of time. Nonetheless, with the introduction of treatment the drugs are able to fight the
virions and this, in turn, leads to a decrease of the viral load in the body. It is evident
that as U increases from 0.6 to 0.9 the viral level decreases. Thus, the higher the level
of drug efficacy the lower the viral load which in turn would control HIV transmission.
From the numerical simulations it is evident that, antiretroviral therapies could reduce
the risk of HIV transmission and hence, ARTs should be initiated during acute infec-
tion irrespective of the CD4+ counts of the infected person.
From Figure 4.7 it is evident that without treatment there is no production of non-
infectious virus. This is because the immature virions are as a result of the use of
Protease inhibitors. Furthermore, as the level of drug efficacy increases the number
of non-infectious immature virions also increases. The study noted that, the number
increases exponentially in the first three moths getting to a pick but declines on wards.
It is therefore, important to consider the non-infectious virus in an HIV model. Most
researchers in the field of HIV in-vivo modelling have ignored this part.
Figure 4.8 shows that the number of the CD8+ T-cell decreases in both scenarios,
Figure 4.8: The population of the CD8+ T-
cells.
Figure 4.9: The population of the Activated
CD8+ T-cells.
that is, with and without treatment. However, in cases where treatment is used the
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level of the CD8+ T-cell decreases at a lower rate. This shows that introduction of
ARTs enhances the body immunity, whereas in Figure 4.9 the recruitment of CD8+
T-cells is high without treatment and decreases as the drug efficacy increases.
4.7.1 Comparison between Fusion inhibitors, Reverse Trascrip-
tase inhibitors and the Protease inhibitors
In this section, we are interested in analyzing and determining the best ARTs between
the Fusion inhibitors, Reverse Trascriptases inhibitors and the Protease inhibitors. The
findings are presented in Figures 4.10– 4.16.
In each Figure, five scenarios are represented, that is, no treatment which implies
that u1 = u2 = u3 = 0, curve A which represents the scenario where u1 = 0.1, u2 =
0.4 and u3 = 0.9, curve B which represents u1 = 0.9, u2 = 0.4 and u3 = 0.1, curve
C which represents u1 = 0.3, u2 = 0.9 and u3 = 0.2 and finally curve D where,
u1 = 0.3, u2 = 0.2 and u3 = 0.8. In curve A and B the efficacy of Reverse Tran-
scriptase inhibitor is held constant. As much as all the Figures 4.10– 4.16 support the
importance of the ARTs as far as viral suppression is concerned they also emphasize
the importance of having Proteases inhibitors in the treatment regime. In curve A
where the level of protease inhibitor is high at 0.9 it is evident from Figure 4.10 that
the number of CD4+ T-cells remain high compared to curve B where the protease in-
hibitor efficacy is 0.1. This can also be deduced from Figure 4.12 where the number
of infected cells in curve A are few as compared to the number of infected cells from
scenario B. This clearly shows that Protease inhibitors play a major role in viral sup-
pression compared to Fusion inhibitors. Curves C and D are mainly concerned on the
effectiveness of the Reverse Trascriptase inhibitor in controlling viral load. It is evi-
dent from the number of HIV virions produced that Protease inhibitor is more effective
than the Reverse Trancsriptase inhibitor. This could be deduced from Figure 4.13. The
findings are similar as indicated in the number of the CD4+ T-cells as shown in Figure
4.10. It is evident that Protease inhibitors are the most effective drugs in controlling
viral progression. In Chapter 5, optimal control is applied to compare the results and
to establish the most optimal way for administering the three drugs strategy.
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Figure 4.10: The population of the
susceptible CD4+T-cells.
Figure 4.11: The populations of the
latently infected CD4+T-cells.
Figure 4.12: The population of the in-
fected CD4+ T-cells with time.
A = (u1 = 0.1, u2 = 0.4, u3 = 0.9), B = (u1 = 0.9, u2 = 0.4, u3 = 0.1), C = (u1 =
0.3, u2 = 0.9, u3 = 0.2) and D = (u1 = 0.3, u2 = 0.2, u3 = 0.8).
4.7.2 Delayed Treatment
In this subsection, comparison between the outcomes of early and delayed introduction
of antiretroviral treatment on clinical outcomes is presented. It is evident in Figure 4.17
in treatment delay there is high multiplication of the HIV virions which in turn leads
to a decrease in the level of the susceptible CD4+ T-cells which is quite evident from
Figure 4.18. This clearly gives us insight on the effects that early initiation of HIV
treatment has on improving the infected person immune response and consequently
reducing the rate of HIV transmission.
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Figure 4.13: The population of the infectious
virus with respect to time.
Figure 4.14: The population of the Non-
infectious HIV virus.
A = (u1 = 0.1, u2 = 0.4, u3 = 0.9), B = (u1 = 0.9, u2 = 0.4, u3 = 0.1), C = (u1 =
0.3, u2 = 0.9, u3 = 0.2) and D = (u1 = 0.3, u2 = 0.2, u3 = 0.8).
Figure 4.15: The population of the CD8+ T-
cells.
Figure 4.16: The population of the Activated
CD8+ T-cells.
A = (u1 = 0.1, u2 = 0.4, u3 = 0.9), B = (u1 = 0.9, u2 = 0.4, u3 = 0.1), C = (u1 =
0.3, u2 = 0.9, u3 = 0.2) and D = (u1 = 0.3, u2 = 0.2, u3 = 0.8).
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Figure 4.17: The population of the
CD4+ T-cells.
Figure 4.18: The population of the
HIV virions.
4.8 Conclusion
In this chapter an in-vivo HIV dynamics model with inclusion of the immune response
and administration of three drug regimes, that is, FIs, PIs and RTIs has been formulated
and analysed. From the numerical simulations it is evident that the ability of various
ARTs to inhibit viral production is higher when drug efficacy is high, that is, the higher
the drug efficacy the less the infectious HIV virions produced. This supports the intro-
duction of ARTs to any infected person irrespective of their CD4+ counts.
As much as the cost of ARTs is high especially for the developing countries like Kenya,
the social-economics benefits are worth. The findings in this study support the “Anza
Sasa”campaign by the Government of Kenya through the Ministry of Health and the
National AIDS and STI Control Program (NASCOP). This campaign will go a long
way in assisting the Government to meet its 2020 goals that, by 2020, 90% of all peo-
ple living with HIV will know their HIV status, 90% of all people with diagnosed HIV
infection will receive sustained antiretroviral therapy and 90% of all people receiving
antiretroviral therapy will have viral suppression. “Anza Sasa”campaign may be very
expensive at the outset, but it will be cost effective in the long run and it portends more
benefits for the HIV/AIDS individuals and the society at large.
More experimental research however, on viral dynamics need to be carried out to im-
prove the understanding of the dynamic nature of HIV-1 infection and the viral-drug
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interaction mechanism. This is because the research findings indicated that use of
ARTs is the most efficient way of eradicating HIV and also of reducing viral suppres-
sion. However, the efficacy of these ARTs depends on the possibility of halting viral
replication in all biological compartments which could only be established through
experimental research. Notably, development of more potent HIV drug regimens and
better diagnostic tools will help a great deal in ensuring that HIV is eradicated.
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Chapter 5
Modelling Optimal Control of In-vivo
HIV Dynamics using Different Control
Strategies
5.1 Introduction
Mathematical modelling is one of the many important tools used in understanding the
dynamics of disease transmission. It is also used in developing guidelines that are
important in disease control. In HIV dynamics analysis, mathematical models have
provided a framework for understanding the viral dynamics and have been used in the
optimal allocation of the various interventions against the HIV virions (Mbogo et al.,
2013; Nampala et al., 2014; Ogunlaran and Oukouomi, 2016). A fundamental goal
of developing and applying the aforementioned mathematical models of HIV is to in-
fluence treatment decisions and construct better treatment protocols for HIV-infected
patients. Most of the recent mathematical models that have been developed apply the
optimal control theory.
Optimal control theory is a branch of mathematics developed to find optimal ways of
controlling a dynamical system (Pontryagin, 1987). It has been applied by mathemati-
cians to assist in the analysis of how to control the spread of infectious diseases. The
results are used in making key decisions that involve complex biological mechanism.
In particular, it is used to determine the best dosage for various available vaccines or
treatment in use for controlling infection.
For instance, Gaff and Schaefer (2009) applied optimal theory in evaluating mitiga-
tion strategy that would be highly effective in minimizing the number of people who
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get infected by an infection. The study applied both vaccinations and treatment as
control variables for their various models. The results indicated that as much as treat-
ment is paramount in controlling any infection, the most optimal method would be the
combinations of the two interventions. Futhemore, Bakare et al. (2014) applied opti-
mal control to an SIR model. The study illustrated the use of optimal control theory
in establishing the optimal educational campaign and treatment strategies that would
minimize the population of the infected persons as well as cutting the cost of con-
trolling the various diseases. The results indicated that for controlling infection it is
important to target the uninfected populations and apply measures that will prevent
them from getting the infection.
According to various articles in the literature, optimal control theory has been applied
to study population level as well as in-vivo HIV dynamics. For example, Yusuf and
Benyah (2012) applied optimal theory on HIV-population model. The study was aimed
at determining the best method of controlling the spread of HIV/AIDS within a speci-
fied time frame. The study considered three control variables, that is, safe sex, educa-
tion and ARTs. The numerical results of the objective function for the model indicated
that safe sex practice as well as early initiation of ARTs are the most optimal ways
of mitigating the spread of HIV/AIDS. The study established that implementation of
the the aforementioned strategies would lead to a HIV free nation in 10 years time. In
addition, for in-host model, optimal control theory has been applied in the search of
optimal therapies for HIV infection. Drugs such as Fusion inhibitors (FIs), Reverse
Transcriptase inhibitors (RTIs) and Protease Inhibitors (PIs) have been developed and
applied in various optimal control problems.
In this study, optimal control theory has been applied on the in-vivo HIV treatment
model aimed at establishing the optimal drug combinations for HIV in relation to their
per capita cost.
5.2 Economic Evaluation
In this section the method used by Pontryagin (1987) has been applied, to economically
assess the various drugs strategies. This study has considered an economic evaluation
of using Fusion inhibitors, Reverse Transcriptase inhibitors and Protease inhibitors.
The analysis is aimed at comparing the cost of these drugs and their effectiveness in
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controlling HIV viral replication as well as assist in making informed decisions as to
the most cost effective strategy among the interventions under consideration. In this
regard, the study introduced a cost objective function given in equation (5.1):
P (u1(t), u2(t), u3(t)) =
∫ Tf
0
{(cFu1T (t) + (cR(1− u1)u2 + cPu3) (I(t) + V (t))} e−θtdt,
(5.1)
that needed to be minimized, subject to
dT
dt
= λT − µTT − (1− u1(t))χTV,
dI
dt
= (1− u1(t))(1− u2(t))χTV − µII − αIZa,
dIl
dt
= (1− u1(t))u2(t)χTV − µIlIl,
dV
dt
= (1− u3(t))εV µII − µV V,
dVn
dt
= u3(t)εV µII − µV nVn,
dZ
dt
= λZ − µZZ − βZI,
dZa
dt
= βZI − µZaZa,

(5.2)
where cF , cR, and cP represent per capita cost associated with the use of Fusion in-
hibitors, Reverse Transcriptase inhibitors and Protease inhibitors respectively. The
parameter θ is the discount rate associated with the cost of the drugs and it is taken
to be between 3% − 5% (Okosun et al., 2013; Momoh and Fügenschuh, 2017). In
addition, the exponential curves guarantee a decrease on the cost function with time.
Variables u1, u2 and u3 represent the efficacy associated with the three drug regimes,
that is, Fusion inhibitors, Reverse Transcriptase inhibitors and Protease inhibitors re-
spectively. Let us denote the marginal price for the respective classes as various state
variables as λ1, λ2, λ3, λ4, λ5, λ6, λ7 which represent the change in the objective value
of an optimal solution of an optimization problem by relaxing the constraint by one
unit (Pontryagin, 1987).
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The corresponding Hamiltonian is given by
H = {(cFu1(t)T (t) + (cR(1− u1(t))u2(t) + cPu3(t)) (I(t) + V (t))} e−θt+
λ1(λT − µTT − (1− u1(t))χT (t)V (t)) + λ2((1− u2(t))(1− u1(t))χT (t)V (t)−
µII(t)− αI(t)Za(t)) + λ3(u2(1− u1(t))χT (t)V (t)− µIlIl(t))+
λ4((1− u3(t))εV µII(t)− µV V (t)) + λ5(u3(t)εV µII(t)− µVnVn(t))+
λ6(λZ − µZZ(t)− βZ(t)I(t)) + λ7(βZ(t)I(t)− µZaZa(t)).
(5.3)
Pontryaginś Maximum Principle is applied in finding the marginal prices λ̇i, i =



































= −cFu1(t)e−θt + λ1 (µT + (1− u1(t))χV )− λ2χV (1− u1(t))




= −(cR(1− u1(t)u2(t) + cPu3(t)) e−θt + λ2(µI + αZa)− λ4εV µI








= −(cRu2(t) + cPu3(t)) e−θt + λ1χT (1− u1(t))− λ2χT (1− u1(t))












= λ2αI + λ7µZa ,
(5.4)
where λi(tf ) = 0; i = 1, 2, 3, ..., 7 are the transversality conditions. The assessment of
the drug strategy is done by developing the Hamiltonian equation presented in the next
subsection.
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5.2.1 Economic evaluation of using Fusion inhibitor
The Hamiltonian,H , given in equation (5.3), is differentiated with respect to u1,which













cFT (t)− cR(I(t) + V (t))
)
e−θt
is the total marginal cost of using Fusion inhibitor and(
λ1 − (1− u2)λ2 − u2λ3
)
χT (t)V (t)
is the total marginal benefit of using Fusion inhibitor.
Optimal policy is achieved if and only if the total marginal cost is equal to the total
marginal benefit. The following bounds are then obtained from equation (5.5)
u1 = 0 if
(




λ1 − (1− u2(t))λ2 − u2λ3
)
χTV,
u1 ∈ (0, 1) if
(




λ1 − (1− u2(t))λ2 − u2(t)λ3
)
χTV,
u1 = 1 if
(








It is evident, from equation (5.6), that:
1. If u1(t) = 1 then the total marginal benefit of using Fusion inhibitors is more
than the total marginal cost; hence the gain of optimal protection of the suscep-
tible CD4+ T-cells. Thus, this drug should be recommended to an HIV infected
person to prevent the entry of the virions into the CD4+ T-cells.
2. If u1(t) ∈ [0, 1) then the marginal cost is more than the marginal benefit. Con-
sequently, HIV virions will gain entry into the susceptible CD4+. This, in turn,
will lead to disease progression.
The effective use of this strategy will lead to achievement of the optimal policy which
indicates that increasing the use of Fusion inhibitor will lead to an increase in the
number of the susceptible CD+ T-cells. Hence, the infected person will remain healthy
for a longer period.
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5.2.2 Economic evaluation of Reverse Transcriptase inhibitors
When the Hamiltonian, H , given in equation (5.3), is differentiated with respect to u2
which represents the Reverse Transcriptase inhibitors, we obtain:
∂H
∂u2(t)
= cR(1− u1(t))e−θt (I(t) + V (t))− (λ2 − λ3) (1− u1(t))χT (t)V (t), (5.7)
where
cR(1− u1(t))e−θt (I(t) + V (t))
is the total marginal cost of using Reverse Transcriptase inhibitors and
(λ3 − λ2) (1− u1(t))χT (t)V (t)
is the total marginal benefit of using Reverse Transcriptase inhibitors.
Optimal policy is achieved if and only if the total marginal cost is equal to the total
marginal benefit. From equation (5.7) the following bounds are obtained:
u2 = 0 if cR(1− u1(t))e−θt (I(t) + V (t)) > (λ3 − λ2) (1− u1(t)χTV,
u2 ∈ (0, 1) if cR(1− u1(t))e−θt (I(t) + V (t)) = (λ3 − λ2) (1− u1(t))χTV,
u2 = 1 if cR(1− u1(t))e−θt (I(t) + V (t)) < (λ3 − λ2) (1− u1(t))χTV.
(5.8)
From equation (5.8) it is evident that:
1. If u2(t) = 1 then the total marginal benefit of using Reverse Transcriptase in-
hibitors is more than the total marginal cost; hence the gain of optimal prevention
of the infected CD4+ T-cells from undergoing a full life cycle. This drug should
be recommended to an HIV infected person since it will aid in preventing the
virions from undergoing the reverse trancsription process. This will lead to pro-
duction of latently infected cells and consequently, reducing the number of HIV
virions released back to the blood stream.
2. If u2(t) ∈ [0, 1) then the marginal cost is more than the marginal benefit and
consequently, the HIV-RNA will be reverse transcribed to HIV-DNA, hence the
virions manage to make new copies which upon maturity are released back to
the body.
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The effective use of this strategy will lead to the achievement of optimal policy which
implies that, increasing the use of Reverse Transcriptase inhibitors will lead to an de-
crease in the number of the HIV virions which would emerge from the infected CD+
T-cells.
5.2.3 Economic evaluation of Protease inhibitors
When the Hamiltonian, H , given in equation (5.3), is differentiated with respect to




−θt (I(t) + V (t))− (λ4 − λ5) εV µII(t), (5.9)
where
cP e
−θt (I(t) + V (t))
is the total marginal cost of using Protease inhibitors and
(λ5 − λ4) εV µII(t)
is the total marginal benefit of using Protease inhibitors.
Optimal policy is achieved if and only if the total marginal cost is equal to the total
marginal benefit. From equation (5.9) the following bounds are obtained:
u3 = 0 if cP e−θt (I(t) + V (t)) > (λ5 − λ4) εV µII,
u3 ∈ (0, 1) if cP e−θt (I(t) + V (t)) = (λ5 − λ4) εV µII,
u3 = 1 if cP e−θt (I(t) + V (t)) < (λ5 − λ4) εV µII.
(5.10)
From equation (5.10) it is evident that:
1. If u3(t) = 1 then the total marginal benefit of using Protease inhibitors is more
than the total marginal cost; hence the gain of optimal prevention from the re-
lease of mature HIV virions from HIV infected CD4+ T-cells. Hence, this drug
should be recommended to an HIV infected person since it will lead to produc-
tion of immature non-infectious HIV virions. This in turn will reduce the number
of infectious virions in the body of the infected person.
2. If u3(t) ∈ [0, 1) then the marginal cost is more than the marginal benefit conse-
quently, some of the infected cells will undergo all the life cycle stages and this
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will lead to production of HIV virions in the blood. The implication of this is
that more CD4+ T-cells will be attacked by the HIV virions, this, in turn will
make the body vulnerable to many optimistic infections.
The effective use of this strategy will lead to the achievement of optimal policy which
indicates that increasing the use of Protease inhibitors will lead to production of im-
mature non-infectious HIV virions hence a decrease in the number of the free virions
that results from the infected CD4+ T-cells.
5.3 Optimization process
For HIV, control efforts are carried out to limit the spread of the disease, and in some
cases, to prevent the the side effects associated with the various HIV drugs. Optimal
control theory is a method that has been widely used to solve for an extremum value
of an objective functional involving dynamic variables. In this section, optimal con-
trol theory has been applied in deriving optimal drug treatments as functions of time.
The control variables as used in system (4.1) are described as follows: The control
u1(t) represents the effect of Fusion inhibitors, which are the drugs that protect the
uninfected CD4+ T-cells by preventing the entry of the virus into the CD4+T-cells
membrane. The control variable u2(t) simulates the effect of Reverse Transcriptase
inhibitors. These drugs hinder the reverse transcription process. The third control
variable u3(t) simulates the effect of Protease inhibitors, which prevent the already
infected cells from producing mature-infectious virions.
The aforementioned controls represent effective chemotherapy dosage bounded be-
tween 0 and 1. The situation u1(t) = u2(t) = u3(t) = 1 represents total efficacy of the
Fusion inhibitors, Reverse Transcriptase inhibitors and Protease inhibitors respectively
and u1(t) = u2(t) = u3(t) = 0 represents no treatment. It is worth noting that the con-
trol variables aforementioned are bounded Lebesques integrable functions. The study
aimed at maximizing the levels of the healthy CD4+ T-cells, as well as the levels of
the CD8+ T-cells (Z(t)) while minimizing the viral load (V (t)) and at the same time
keeping cost and side effects of treatment at a minimum. With the above description
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the following objective function (5.11) need to be maximized:










subject to system (4.1).
T (t), Z(t) and V (t) are the solutions of the system (4.1). The quantities w1 and w2
represent the cost associated with maximizing the number of CD4+ T-cells and the
CD8+ T-cells respectively, while w3 represents the cost associated with minimizing
the viral load. In addition, A1, A2 and A3 are non-negative constants representing
the relative weights attached to the current cost of each treatment regime and Tf is
a fixed terminal time of the treatment programme subject to the ordinary differential
equations described in system (4.1). This study assumed that the cost of controls are
of quadratic form. Furthermore, it is also based on the fact that there is no linear
relationship between the effect of treatment on CD4+ T-cells, CD8+ T-cells or the HIV
virions. Consequently, u1(t), u2(t) and u3(t) are Lebesgue integrable; that is, they are
piecewise continuous and integrable. The fundamental aim of this therapeutic strategy
is to maximize the objective functional defined in equation (5.11) by increasing the
number of the uninfected CD4+ T-cells and the CD8+T-cells, decreasing the viral load
(V (t)) and minimizing the harmful side effects and cost of treatment over the given
time interval [0, Tf ]. Therefore, the study aimed at determining the optimal control
u1(t)





3(t)) = max {J(u1(t), u2(t), u3(t)) : (u1, u2, u3) ∈ U} , (5.12)
where U is a set of all measurable controls defined by:
U = {u = (u1, u2, u3) : ui measurable, 0 ≤ ui(t) ≤ 1, t ∈ [0, Tf ]} . (5.13)
In the next section the existence of an optimal control for the system (4.1) is determined
and the optimality system derived.
5.4 Characterization of the Optimal Control
The necessary conditions that an optimal control must satisfy come from the Pontrya-
gins Maximum Principle (Pontryagin, 1987).
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Theorem 5.1. Suppose the objective function










is maximized subject to the controls and state variables given in system (4.1) with
T (0) = T0, I(0) = I0, Il(0) = Il0, V (0) = V0, Vn(0) = Vn0, Z(0) = Z0
and Za(0) = Za0.









3(t)) = max {J(u1(t), u2(t), u3(t)) : (u1, u2, u3) ∈ U} .
Proof. The existence of the solution can be shown using the results obtained in Flem-
ing and Rishel (2012), since:
1. The class of all initial conditions with controls u1(t), u2(t) and u3(t) in the
control set U are non-negative values and are non-empty where ui, i = 1, 2, 3 is
a Lebesgue-integrable function on [0, Tf ].
2. The right hand side of system (4.1) is bounded by a linear function of the state
and control variables and the solutions exist.
By definition, each right hand side of system (4.1) is continuous and can be writ-
ten as a linear function of U with coefficients depending on time and state. Fur-
thermore, all the state and control variables T (t), I(t), Il(t), V (t), Vn(t), Z(t),
Za(t), u1(t), u2(t), and u3(t) are bounded on [0, Tf ]. In particular considering
the system (4.1) with initial conditions T0, I0, Il0 , V0, Vn0 , Z0, Za0 , then it can be
written in the form:














is the vector of the state variables and A and F (Y ) are as defined in equations
(5.17) and (5.18), respectively:
A =

−µT 0 0 0 0 0 0
0 −µI 0 0 0 0 0
0 0 −µIl 0 0 0 0
0 0 0 −µV 0 0 0
0 0 0 0 −µVn 0 0
0 0 0 0 0 −µZ 0
0 0 0 0 0 0 −µZa

, (5.17)
F (Y ) =

λT − (1− u1(t))χTV
(1− u1(t))(1− u2(t))χTV − αIZa






The system (5.15) is a non-linear system with a bounded coefficient. Let,
B(Y ) = RY + F (Y ) (5.19)
then, the second term on the right-hand side of (5.19) satisfies
|F (Y1)− F (Y2)| ≤ K1 |T1(t)− T2(t)|+K2 |I1(t)− I2(t)|+K3 |Il1(t)
−Il2(t)|+K4 |V1(t)− V2(t)|+K5 |Vn1(t)− Vn2(t)|
+K6 |Z1(t)− Z2(t)|+K7 |Za1(t)− Za2(t)|
≤ K |T1(t)− T2(t)|+ |I1(t)− I2(t)|+ |Il1(t)− Il2(t)|+
|V1(t)− V2(t)|+ |Vn1(t)− Vn2(t)|+ |Z1(t)− Z2(t)|
+ |Za1(t)− Za2(t)| ,
(5.20)
where the positive constant K = max (Ki, i = 1, 2, 3..., 7) is independent of
the state variables. In addition, B(Y1) − B(Y2) ≤ K |Y1 − Y2|, where K =∑7
i=1 Ki + ||M | | < ∞. So, it follows that the function B(Y ) is uniformly
Lipschitz continuous. From the definition of the controls u1, u2 and u3 and the
restrictions on the non-negativeness of the state variables then the solutions of
the system (5.15) exists.
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3. By definition the control set U is convex and closed.
A set K ∈ Rn is said to be a convex set if and only if
λx+ (1− λ)y ∈ K,
for all x, y ∈ K, and all λ ∈ [0, 1].
This condition is satisfied by the control set U since taking any pair of controls
in u1, u2, u3 ∈ U and let λ ∈ [0, 1] then,
0 ≤ λu1(t) + (1− λ)u2(t). (5.21)
Clearly from (5.21), λu1(t) ≤ λ and (1− λ)u2(t) ≤ (1− λ). Thus,
λu1(t) + (1− λ)u2(t) ≤ λ+ (1− λ) = 1. (5.22)
Then from inequalities (5.21) and (5.22) it is evident that
0 ≤ λu1(t) + (1− λ)u2(t) ≤ 1 ∀ ui ∈ U, i = 1, 2, 3 and λ ∈ [0, 1]. (5.23)
Therefore, the control set U is convex, and bounded and condition 3 is satisfied.




w1T (t) + w2Z(t)− w3V (t)− A1u21(t)− A2u22(t)− A3u23(t)
)
, (5.24)
of the objective functional is concave on U . We apply the Hessian matrix method
in proving that the integrand is concave as shown below. A function of many






≤ 0 ∀ x 6= 0.






3) where Li ∈ L then the Hessian matrix H





























Since Li ∈ L, the integrand L is concave on U .
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5. There exists constants b1 > 0, b2 > 0 and β > 1 such that the integrand of the
objective function equation (5.14), J(U, t) is bounded by
L(t, T, V, Vn, I, Il, Z, Za, u1, u2, u3) ≤ b2 − b1(|u1|2 + |u2|2 + |u3|2)
β
2 . (5.26)
From the objective function (5.14),




w1T (t) + w2Z(t)− w3V (t)− A1u21 − A2u22 − A3u23
)
,
J(u1, u2, u3) ≤ w1T (t) + w2Z(t) + w3V (t)− A1u21 − A2u22 − A3u23.
(5.27)
Suppose, A1 = A2 = A3 = A in equation (5.27) then,










w1T (t) + w2Z(t) + w3V (t)−A
(
u21 − u22 − u23
)
≤ b2 − b1(|u1|2 + |u2|2 + |u3|2),
(5.29)
where b1 depends on the upper bound on T, Z and V and b1 > 0 sinceA1, A2, A3 >
0 according to the definition. Equation (5.28) can then be written as,
J(u1, u2, u3) ≤ b2 − b1(u1, u2, u3)2. (5.30)
It is evident from equation (5.30) that β = 2 > 1, and b1, b2 > 0. Thus the
condition given by (5.26) is satisfied.
Since all the above conditions are satisfied then there exists optimal controls u1∗, u2∗ and u3∗.
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5.5 Necessary conditions of the Optimal Control
In this section we apply Pontryagin’s maximum principle in defining the Lagrangian
(Hamiltonian augmented) (Pontryagin, 1987) as follows:
L(T, I,Il, V, Vn, Z, Za, λ1, λ2, λ3, λ4, λ5, λ6, λ7, u1, u2, u3)
= w1T + w2Z − w3V − A1u21 − A2u22 − A3u23 + λ1(λT − µTT
− (1− u1(t))χTV ) + λ2(((1− u1(t))1− u2(t))χTV − µII − αIZa)
+ λ3((1− u1(t))u2(t)χTV − µIlIl) + λ4((1− u3(t))εV µII − µV V )
+ λ5(u3(t)εV µII − µVnVn) + λ6(λZ − µZZ − βZI) + λ7(βZI − µZaZa)
+ w11u1(t) + w12(1− u1(t)) + w21u2(t) + w22(1− u2(t))
+ w31u3(t) + w32(1− u3(t)),
(5.31)
where wij(t) ≥ 0 are the penalty multipliers which ensure the boundedness of the
control variables u1(t), u2(t) and u3(t) and satisfies the following conditions:
w11u1 = w12(1− u1) = 0 at u∗1,
w21u2 = w22(1− u2) = 0 at u∗2,






3 represent the optimal controls.
Therefore, the Pontryagin’s maximum principle gives the existence of adjoint variables
which are obtained by differentiating the Lagrangian given by equation (5.31), with
respect to the state variables T, I, Il, V, Vn, Z and Za.
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= w3 + λ1χT (1− u1(t))− λ2χT (u1(t))(1− u2(t))












= λ2αI + λ7µZa ,
(5.33)
where,
λi(Tf ) = 0, i = 1, ..., 7, (5.34)
are the transversality conditions.
By maximization of the Lagrangian with respect to the control variables u1, u2, u3 we















Therefore, differentiating the Lagrangian L given in equation (5.31) with respect to u1
on the set U : t|0 ≤ u1(t) ≤ 1, we obtain the following optimality equation;
∂L
∂u1
= −2A1u1 + χTV
(
λ1 − (1− u2(t))− u2(t)
)
+ w11 − w12 = 0. (5.36)







λ1 − (1− u2(t))λ2 − u2(t)λ3
)
+ w11 − w12
2A1
. (5.37)
To determine an explicit expression for an optimal control u∗1 without w11 and w12, the
following three cases have been considered :
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1. On the set (t|0 < u∗1 < 1), suppose w11 = w12 = 0 in equation (5.37). Then the








2. Similarly, on the set (t|u∗1 = 1) let w11 = 0 and w12 ≥ 0. Then equation (5.37)
gives
u∗1 = 1 =
χTV
(





Equation (5.39) can be reduced to;
χTV
(
λ1 − (1− u2(t))− u2(t)
)
2A1
≥ 1 = u∗1. (5.40)








3. Finally, on the set (t|u∗1 = 0), let w12 = 0 and w11 ≥ 0 then equation (5.37)
gives
u∗1 = 0 =
χTV
(












Consequently, combining all the three cases given by equations (5.38), (5.41), and




































We use the same argument to obtain an explicit expression for an optimal control u∗2
without w21 and w22. We differentiate the Lagrangian L given in equation (5.31) with




= −2A2u2 + χTV (λ3 − λ2) + w21 − w22 = 0 at u2 = u∗2. (5.46)
Therefore, solving equation (5.46) the optimal control u∗2 is given as
u∗2 =
χTV (1− u1(t))(λ3 − λ2) + w21 − w22
2A2
. (5.47)
According to the conditions given by equation (5.32) the following distinct three cases
have been derived;
1. On the set (t|0 < u∗2 < 1), we let w21 = w22 = 0 in equation (5.47). Then the
optimal u∗2 control is given by
u∗2 =
χTV (1− u1(t))(λ3 − λ2)
2A2
. (5.48)
2. On the set (t|u∗2 = 1), let w21 = 0 and w22 ≥ 0 then from equation (5.47) the
control u∗ becomes
u∗2 = 1 =
χTV (1− u1(t))(λ3 − λ2) + w22
2A2
. (5.49)
Rearranging equation (5.49) reduces to,
χTV (1− u1(t))(λ3 − λ2)
2A2
≥ 1 = u∗2. (5.50)









3. Finally, on the set (t|u∗2 = 0), let w22 = 0 and w21 ≥ 0. Then from equation
(5.47) the control u∗2 becomes
u∗2 = 0 =




χTV (1− u1(t))(λ3 − λ2)
2A2
≤ 0. (5.53)
Consequently, combining all the three cases given by equations (5.48), (5.51) and





if 0 < χTV (1−u1(t))(λ3−λ2)
2A2
< 1,
0 if χTV (1−u1(t))(λ3−λ2)
2A2
≤ 0,














The expression for optimal control u∗3 is obtained by differentiating equation (5.31)




= −2A3u3 − εV µIIλ4 + w31 − w32 = 0. (5.56)
Let u3 = u∗3 in equation (5.56) then the optimal control u
∗
3 is obtained as
u∗3 =
−εV µIIλ4 + w31 − w32
2A3
. (5.57)
1. On the set (t|0 < u∗3 < 1), let w31 = w32 = 0 in equation (5.57). Then the





2. On the set (t|u∗3 = 1), let w31 = 0 and w32 ≥ 0 then from equation (5.57) we
have
u∗3 = 1 =




Equation (5.59) can be reduced to
−εV µIIλ4
2A3
≥ 1 = u∗3. (5.60)








3. Finally, on the set (t|u∗3 = 0), let w32 = 0 and w31 ≥ 0 then from equation (5.57)
the control u∗3 becomes
u∗3 = 0 =







Consequently, combining all the three cases given by equations (5.58), (5.61) and





if 0 < −εV µIIλ4
2A3
< 1,
0 if −εV µIIλ4
2A3
≤ 0,














It is worth noting that from the mathematical formulations that the optimal controls
depend on the adjoint λ1, λ2, λ3, and λ4 since the adjoint corresponds to the state vari-
ables, T, I, Il, V and the first four equations of system (4.1) contain the control terms.
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5.5.1 Optimality system
The optimality system comprising of the state system together with the adjoint system,
the optimal control, and the transversality conditions is given as:
dT
dt




























χTV (1− u1(t))(λ3 − λ2)
2A2
)))














































εV µII − µV Vn,
dZ
dt
= λZ − µZZ − βZI,
dZa
dt
= βZI − µZaZa,

(5.66)
with the initial conditions,
T (0) ≥ 0, I(0) ≥ 0, Il(0) ≥ 0, V (0) ≥ 0, Vn(0) ≥ 0, Z(0) ≥ 0, Za(0) ≥ 0. (5.67)
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The adjoint equations are;

































































λ5εV µI + λ6βZ − λ7βZ,
λ̇3 = λ3µIl ,















































λ̇5 = λ5µVn ,
λ̇6 = −w2 + λ6(µZ + βI)− λ7βI,
λ̇7 = λ2αI + λ7µZa ,

(5.68)
and the transversality equations:
λi(Tf ) = 0, i = 1, ..., 7. (5.69)
The optimality system given by (5.66), (5.67), (5.68) and (5.69) cannot be solved ana-
lytically. Instead numerical methods are used to approximate the solutions and display
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the results. The next section represents the numerical solutions for the optimality sys-
tem.
5.6 Numerical Simulation
In this section, we investigate the effect of optimal strategy on HIV by applying Runge-
Kutta forth order scheme on the optimality system. The optimality system is obtained
by taking the state system together with the adjoint system, the optimal control, and the
transversality conditions. The dynamical behaviour of the models in relation to various
control are also studied. The optimal strategy is achieved by obtaining a solution for
the state system (4.1) and co-state system (5.33). An iterative scheme is explored and
used in determining the solution for the optimality system.
The numerical method utilized is the forward-backward sweep method which incorpo-
rates iterative Runge-Kutta fourth order progressive-regressive schemes. The progres-
sive scheme is used in obtaining the solutions of the state ODEs given in system (4.1)
with the initial conditions while the regressive scheme is applied in obtaining the solu-
tions of the adjoint system given by system (5.33) with transversality conditions given
in equation (5.34). The controls are updated at the end of each iteration using the for-
mula for optimal controls. The iterations are carried out until convergence is achieved.
This is a two-point boundary-value problem, with separated boundary conditions at
times t0 = 0 and t = Tf . This explains why the fourth-order Runge-Kutta scheme is
applied in the numerical analysis. For the numerical simulation we take T = 310 days
or 10 months. This value represent the time in which treatment is stopped. Further-
more, the values of the weight function are taken as: A1 = A2 = A3 = 0.01. Table
5.1 consists of the parameter values that are used in the numerical simulations of the
in-vivo model while Table 5.3 consists of the proposed initial values of the state vari-
ables. The initial values given in Table 5.3 have been chosen in such away that they
reflect a patient during acute infection stage. This is in line with the WHO recommen-
dations which stipulate that all people living with the HIV be put on ARTs irrespective
of their CD4+ counts unlike in the past where the CD4+ count had to be below 350
cell/mm3 (World Health Organization, 2014).
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Table 5.1: Parameters and controls for HIV in-vivo with therapy model
Parameters Value Source
λT 10 cell/mm3/day Nowak et al. (1996).
µT 0.01 day−1 Srivastava and Chandra (2010).
χ 0.00024 mm3 vir−1 day−1 Alizon and Magnus (2012).
µI 0.5 day−1 Wodarz and Nowak (2000).
µIl 0.5 day
−1 Wodarz and Nowak (2000).
εV 100 vir. cell−1 day−1 Estimate.
µV 2 day−1 Mbogo et al. (2013).
µVn 3 day
−1 Estimate.
α 0.02 day−1 Arruda et al. (2015).
λZ 20 cell/ mm3/day Arruda et al. (2015).
µZ 0.04 day−1 Arruda et al. (2015).
β 0.004 day−1 Arruda et al. (2015).
µZa 0.004 day
−1 Arruda et al. (2015).
Table 5.2: Controls strategy for HIV in-vivo with therapy model




5.6.1 Results and discussion
Figure 5.1 represents the various control strategies. It is evident that the control u1
remains at minimum for the first two months and raises to a maximum between the
second up to the seventh month. It later reduces gradually to a minimum while control
u2 remains at maximum for the first four and a half months then drops to 30% between
the sixth and the ninth month. In addition, the control u2 drops to the minimum after
the tenth month. The control strategy u3 on the other hand, remains at a maximum
for the first nine months only dropping to a minimum at the tenth month. From these
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Table 5.3: The initial values for the variables for HIV in-vivo model
Variable Values
T (t) T (0) = 500 cell/mm3.
I(t) I(0) = 100 cell/mm3.
Il(t) Il(0) = 0 cell/mm3.
V (t) V (0) = 100 virion/mm3.
Vn(t) Vn(0) = 0 virion/mm3.
Z(t) Z(0) = 100 cell/mm3.
Za(t) Za(0) = 10 cell/mm3.
results it is evident that the Protease inhibitor could be administered for a longer pe-
riod of time with minimum side effects. Furthermore, it is clear that Fusion inhibitor
should not be initiated to a person who is not on any other HIV drug treatment. This is
in agreement with clinical findings.
110
Control u1 Control u2
Control u3 Controls u1 and u2
Controls u1 and u3 Controls u2 and u3 Controls u1, u2 and u3
Figure 5.1: Simulated control strategies
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With control u1 With control u2
With control u3 With controls u1 and u2
With controls u1 and u3 With controls u2 and u3 With controls u1, u2 and u3
Figure 5.2: The population of the CD4+ T-cells in various control strategies
Figure 5.2 presents the population of the susceptible CD4+ T-cells in different treat-
ment strategies. In all the considered cases it is evident that the introduction of the
ARTs play a significant role as far as controlling HIV is concerned. Nonetheless, it is
evident that when Fusion inhibitor (u1(t)) is used without other controls the numbers
of CD4+ T-cells reduces significantly and takes a longer time before the number in-
creases. In particular, the drug effectiveness seems to be felt after the first two months.
These findings indicate that it is difficult to control the HIV virions by targeting their
cell-entry mechanism at acute infection. The use of Protease inhibitors however, leads
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to an increase in the number of the CD4+ T-cells. In addition, it is evident that a com-
bination of the three drugs evoke a more pronounced CD4+ T-cells increase than in
mono therapy or two drugs combination.
Figure 5.3 presents the dynamics of the latently infected cells after the introduction of
With control u1 With control u2
With control u3 With controls u1 and u2
With controls u1 and u3 With controls u2 and u3 With controls u1, u2 and u3
Figure 5.3: The population of the latently infected CD4+ T-cells in various control strategies
the various control strategies. It is evident that the latently infected cells are produced
after the initiation of Reverse Transcriptase inhibitor to an HIV infected cell. Since
the latently infected cells do not produce infectious HIV virions then it is important
to administer RTIs to an infected person. This would reduce the number of virions
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producing cells.
Figure 5.4 shows the change in the population of the infected CD4+ T-cells with time
With control u1 With control u2
With control u3 With controls u1 and u2
With controls u1 and u3 With controls u1 and u2 With controls u1, u2 and u3
Figure 5.4: The population of the infected CD4+ T-cells in various control strategies
in different control strategies. From the simulated results it is evident that ARTs play
a fundamental role especially in controlling the rate of HIV infection. Notably, when
the Fusion inhibitors are introduced in the body the number of the infected cells are
observed to increase for the first few months. This clearly emphasizes the difficult in
controlling the HIV virions at the entry level. The reason would probably be based on
the fact that HIV uses a complex series of steps to deliver its genome into the host cell
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cytoplasm while simultaneously evading the host immune response.
Figure 5.5 shows the change in the population of the HIV virions in different drug
With control u1 With control u2
With control u3 With controls u1 and u2
With controls u1 and u3 With controls u2 and u3 With controls u1, u2 and u3
Figure 5.5: The population of the HIV-virions in various control strategies
combination(s). It is evident that control u1 and u2 are not very as effective as PIs in
controlling viral progression. In particular, it is evident from Figure 5.5 that the num-
ber of virions are high when control u1 is in use. This is because Fusion inhibitors
block the entry of the virions into the CD4+ T-cells hence reducing their removal rate
from the body. Researchers such as (Kramer et al., 2012) suggest that viruses blocked
by entry inhibitors such as the Fusion inhibitors are likely to be redistributed to the
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plasma, where they artificially increase the number of HIV virions. This may proba-
bly be the reason why there is an indication of having high number of viral load even
when control u1 is applied. In addition, Fusion inhibitors prevent the entry of the viri-
ons unlike the other two drugs which allow the entry of the HIV virions into the cells,
confirming the absorption effect. Simulated results indicate that Protease inhibitors
play a significant role in reducing viral progression and it is the best single drug in use
for viral suppression. This is in agreement with some of the work done in the field
of in-vivo HIV dynamics which concluded that Protease inhibitors are more effective
HIV drugs than Reverse Transcriptase inhibitors and Fusion inhibitors in terms of viral
load reduction in HIV infected patient (Shen et al., 2011; Allers and Schneider, 2015;
Shi et al., 2016). The simulated results also emphasize the importance of using a com-
bination of the various ARTs for HIV treatment.
From Figure 5.6 it is evident that non-infectious virus result from the introduction of
the Protease inhibitor in the body. Introduction of PIs to a HIV infected cells gener-
ates a pool of immature HIV virions, that leads to the transfer of non-infectious virus
across the virological synapse. This therefore implies that the virus produced would
not infect more susceptible CD4+ T-cells.
Figure 5.7 shows the population of the CD8+ T-cells in different treatment strategy.
From the findings it is evident that both the RTIs and PIs cause a substantial increase
in the population of the CD8+ T-cells in HIV-infected patients. However, it is evident
that as much as these two drugs play a major role, the combination of all the three
controls produces a higher immune system reconstitution with sustained increase in
circulating number of CD8+T-cells.
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With control u1 With control u2
With control u3 With controls u1 and u2
With controls u1 and u3 With controls u2 and u3 With controls u1, u2 and u3
Figure 5.6: The population of the non-infectious HIV-virions in various control strategies
117
With control u1 With control u2
With control u3 With controls u1 and u2
With controls u1 and u3 With controls u2 and u3 With controls u1, u2 and u3
Figure 5.7: The population of the CD8+ T-cells in various control strategies
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With control u1 With control u2
With control u3 With controls u1 and u2
With controls u1 and u3 With controls u2 and u3 With controls u1, u2 and u3
Figure 5.8: The population of the Activated CD8+ T-cells in various control strategies
Figure 5.8 shows the population of the activated CD8+ T-cells. The activation process
plays a major role in controlling the HIV virus. This is because the cells fight, destroy
and kill the infected CD4+ T-cells. This, in turn, reduces the number of HIV virions
produced. From the simulated results it is evident that after the introduction of the
ARTs, the number of activated CD8+ T-cells reduced significantly. The reduction is
attributed to the reconstitution of the immune system and the reduction of the retroviral
activity on the cells (Autran et al., 1997). However, the question such as the clinical




In this chapter a seven-dimensional in-vivo HIV model with inclusion of three drug
combinations, that is, FIs, RTIs and PIs has been formulated and analysed. Optimal
control theory has been applied in determining the optimal treatment regime. In partic-
ular, the Pontryagin’s maximum principle has been applied in deriving the conditions
necessary for existence of optimal control drugs strategy. The systems of ordinary dif-
ferential equations, the state system and the adjoint system have been solved numer-
ically by both forward and backward Runge-Kutta forth order scheme. Results from
the numerical simulations indicate that FIs and RTIs should be used for the first four
months and later the doctors should consider changing the drugs and introduce another
treatment regime whereas the PIs could be used for a longer period of time without
necessarily leading to major side effects. However, the inferiority of mono therapy
compared with combination therapies has been observed in the simulated result espe-
cially in suppression of viral replication, CD4+ and CD8+ T-cells reconstitution, and
in controlling disease progression.
ARTs are seen to play a significant role as far as viral suppression is concerned. There-
fore, they should be recommended to all patients immediately after one is diagnosed
HIV positive regardless of the CD4+ count. The findings in this chapter support the
WHO guidelines and recommendation on ARTs for all. However, the simulated results
suggest that PIs is possibly the best single drug and Fusion inhibitor the worst drug in
terms of viral load and infected cells reduction. From the results the study recommends
that RTIs should be used as initial therapy for HIV while FIs should be introduced to





In this study we have developed mathematical models to study the in-vivo dynamics of
HIV. At first, a five-dimensional deterministic model without treatment has been for-
mulated and analysed. Later three drug regimes have been incorporated into the model
and investigations done for optimal drug combinations.
In Chapter 2, the study reviewed some of the mathematical models that have been
formulated over the years for in-vivo HIV dynamics. This Chapter also highlighted
the various gaps that have not been addressed by researchers in the field of HIV mod-
elling such as: the role played by the CD8+ T-cells, the role of the Fusion inhibitors
and the emergence of the non-infectious virus due to the use of Protease inhibitors.
In Chapter 3, an in-vivo HIV dynamics model that had five compartments represent-
ing the healthy CD4+ T-cells (T ), the infectious HIV virions (V ), the already infected
CD4+ T-cells (I), the defence cells (Z), that is, CD8+ T-cells and the activated immune
cells (Za) has been presented. The model has been proved to be mathematically well
posed and biologically meaningful. In particular, the state variables for the model have
been shown to be non-negative and bounded. In addition, the existence of disease-free
and endemic equilibrium points has been investigated. Next generation matrix method
has been applied in deriving the expression for the basic reproductive number R0. The
results indicate that the disease-free equilibrium points is locally asymptotically stable
and globally asymptotically stable for R0 < 1. However, since our model has two en-
demic equilibrium point then having R0 < 1 does not necessary mean that the system
is globally stable. However, this is true if and only if the basic reproductive number
is less than the critical reproductive Rc number, that is, R0 < Rc < 1. Sensitivity
analysis of the model has been carried out on the parameters in R0 aimed at estab-
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lishing the ones that play a significant role in the dynamics of the HIV infection. It
is evident from the computations that the infection rate, χ, greatly influence the basic
reproductive number. Numerical simulations have been carried out for the model and
the findings presented.
In Chapter 4, the model has been extended to incorporate HIV treatment at acute in-
fection. This analysis is motivated by the new HIV campaign in Kenya dubbed the
“Anza Sasa”which recommends the initiation of ARTs at early the stages of HIV in-
fection without any consideration of the CD4+ counts. The numerical results indicate
the importance of ARTs especially at acute infection. In addition, from the numerical
simulations it is evident that the combination of ARTs with higher efficacy is the most
effective way of HIV viral suppression. Unfortunately, from the findings, ARTs alone
are unlikely to kill the HIV virions but are able to control the HIV transmission and
improve the life expectancy of the infected person consequently. This will for sure
alter the current trends of HIV incidence in Kenya.
In Chapter 5, optimal control theory has been applied on the treatment model. The
aim is to identify the optimal therapy that would lead to improvement of the infected
person immunity, at minimum cost and side effects. In particular, two objective prob-
lems have been developed. They include a cost minimization objective and a maxi-
mization objective function. The cost objective function aimed at minimizing the drug
marginal cost in relation to the marginal benefit while the maximization objective func-
tion aimed at maximizing the concentration of uninfected CD4+ T-cells, concentration
of CD8+ T-cells while minimizing the concentrations of infected cells and HIV free
virions in the body with an optimal dose of combination of drug therapies in order to
avert the adverse effects associated with excessive use of drug. Three control strategies
representing Fusion inhibitors, Reverse Transcriptase inhibitor and Protease inhibitor
have been applied in the optimal model. The Pontryagins maximum principle has been
applied in characterizing the optimality control, which have been solved numerically
by the Runge-Kutta fourth order progressive-regressive schemes. The numerical re-
sults emphasize the importance of early initiation of ARTs. Furthermore, the research
findings indicate that Protease inhibitor is the most effective mono therapy for HIV
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control. Nonetheless, any combination of the three control strategies is more benefi-
cial in eliminating the HIV infection.
6.2 Contribution
1. This is the first time an in-vivo HIV model using non-linear ordinary differential
equations has been formulated with the inclusion of the immune cells with three
control variables representing three drug regimes.
2. This study applied the Pontryagins principle in evaluating the marginal cost ver-
sus the marginal benefit associated with use of each drug regime. This kind of
evaluation had not been done before on in-vivo HIV models.
6.3 Recommendation
Although there is no known cure for HIV/AIDS, presently there are antiretroviral HIV
drugs which block infection of new cells and reduce viral load in the body and so HIV
positive individual can now enjoy relatively good health and increased life expectancy.
ARTs should be initiated to the HIV infected persons immediately after they test posi-
tive. The Government of Kenya should, in particular, ensure the “Anza Sasa”campaign
is launched in all the 47 counties. This will go along way in assisting the Government
to meet its 2020 goals that, by 2020, 90% of all people living with HIV will know their
HIV status, 90% of all people with diagnosed HIV infection will receive sustained
antiretroviral therapy and 90% of all people receiving antiretroviral therapy will have
viral suppression. The government should also be aggressive in educating the citizens
on the need of taking and adhering to the ARTs.
6.4 Future work
Even though the results obtained in this study are very promising in improving the
quality of life of those infected by HIV, there is still a wide margin for improvement
related to this work, with the primary objective of knowing more about the infection,
and even improving the therapies currently available on the market. Some of the areas
that could be improved in this study are listed below.
1. The deterministic models presented in this study did not consider the wild type
and the naive type CD4+ T-cells nor the different types of the HIV virions, such
as, the drug resistant virus and wild type virus in the formulations. Considering
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these state variables may provide a better understanding of the HIV dynamics,
and give informative results.
2. Clinicians have indicated that the number of the CD8+ T-cells in the body de-
pends on the infected cells and not entirely on their recruitment from the thymus.
Such relationship needs to be considered.
3. Our model and approach in this research is deterministic. Reviewing all analyses
and comparing the results obtained with stochastic modelling approach would
enable researchers to choose the best approach for analyzing HIV in-vivo dy-
namics.
4. Co-infection between HIV and age or lifestyle illness should be considered with
inclusion of drug resistance. Drug resistance is a big issue in HIV, considering it
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This appendix is aimed at providing some useful mathematical background material,
used throughout our study. In particular concepts such as existence and uniqueness of a
solution, Routh-Hurwitz criteria, dilac criterion,optimal control etc. will be explained.
The mathematical introduction in this chapter will be necessarily abrupt. One can
find more detail in the various textbooks on dynamical systems and bifurcation theory
that aided in the preparation of this chapter (Fleming and Rishel, 2012; Athans and
Falb, 2013; Lenhart and Workman, 2007; Pontryagin, 1987).
A.2 Well-posedness for ordinary differential equations
A first order ordinary differential with initial value
dy
dt
= F (x, y) y(x0) = y0 (A.1)
whose solutions satisfy the initial constraints is said to be well possed mathematically
if and only if:
1. its solutions exists
2. the solutions are unique
3. the solutions continuously depends on the initial values
We introduce the Lipschitz condition A.1 which guarantee well-posed solution of an
initial value problem.
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Definition A.1 (Lipschitz condition). A family of vector fields F (x, y) satisfies a Lip-
schitz condition in a region R of (x, y) in the domain D there exist Lipschitz constant
k such that
{k > 0, (x, t) ∈ R, (y, t) ∈ R |F (x, t)− F (y, t)| ≤ k(x− y|} (A.2)
Theorem A.1 (Existence). Suppose that F (x, y) with initial values (x0, y0) is a con-
tinuous function defined in some region
R = (x, y) : x0 − δ < x < x0 + δ, y0 − ε < y < y0 + ε (A.3)
containing the point (x0, y0). Then there exists a number δ1 < δ so that solution of
(A.1), that is, y = f(x) is defined for x0 − δ1 < x < x0 + δ1.
Theorem A.2 (Uniqueness). Suppose that both F (x, y) and ∂F
∂y
(x, y) are continuous
functions defined on a region R as in Theorem A.1. Then there exists a constant value
δ2 < δ1 so that the solution y = f(x) to (A.1), whose existence was guaranteed by
Theorem A.1, is the unique solution to (A.1) for x0 − δ2 < x < x0 + δ2.
Theorem A.3 (Continuity Theorem). Let x(t) and y(t) be any two solutions of the
differential equation (A.1) in t ∈ [T1, T2], where F(x, y) is continuous and satisfies the
Lipschitz condition A.1 in some region R such that (x(t), y(t) ∈ R are defined. Then
‖x(x0 + h)− y(y0 + h)‖ ≤ e
k
h |x0 − y0| (A.4)
Definition A.2 (Invariant region/set). A set of states S ⊆ Rn of (A.1) is called an
invariant set of (A.1) if for all y0 ∈ S and for all t ≥ 0, y(t) ∈ S (image).
A.2.1 Stability analysis
It is paramount for modellers to analyses the stability of equilibrium points for the
models at hand. This is because physical stability of an equilibrium solution to a
system of differential equations addresses the behaviour of solutions that start nearby
the equilibrium solution. In this study we shall first drive the basic reproductive number
of the model and then analyze the local and global stability.
Definition A.3 (Equilibrium points).
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= 0 ∀ t ∈ R. (A.5)
Definition A.4 (Stability).
An equilibrium point x∗ is said to be stable if for any ε > 0 and any t0 ∈ R+ there
exists a δ(t0, ε) such that;
‖x0 − x∗‖ ≤ δ →
∥∥∥x(t, x0, α)− x∗∥∥∥ < ε, t ≥ t0 (A.6)
Definition A.5 (Asymptotically stable).
An equilibrium is said to be asymptotically stable if it is stable, and ∀ t0 ∈ R+ there
exists a η(t0) > 0 such that if ‖x0x∗‖ ≤ η then
lim
t→∞
∥∥∥x(t, x0, α)− x∗∥∥∥ = 0. (A.7)
The equilibrium is globally asymptotically stable if η is arbitrary.
Definition A.6 (Unstable).
An equilibrium is said to be unstable if it is not stable.
Definition A.7 (The basic reproductive number).
According to Diekmann et al. (1990) basic reproductive number represents the number
of secondary infection that results from a single infected cells throughout its life. This
concept is fundamental to the study of epidemiology as it helps determine whether or
not an infectious disease can spread through a population. When R0 < 1 the infection
is likely to die off in the long run, which means each infected cells produces, on aver-
age, less than one new infected cells. Furthermore, there exist only one equilibrium,
the disease-free equilibrium, and it is locally asymptotically stable. Alternatively when
R0 > 1 the infection will persist and invade the population. For a larger number of R0
the researchers are advised on the best control measures, and at what size, would be
most effective in reducing R0 below unity, to prevent sustained spread of the infection,
thus providing important guidance for public health initiatives.
Definition A.8 (The next generation matrix method). In this research we applied the
next generation matrix method when computing R0 (van den Driessche and Wat-
mough, 2002).
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Suppose we have nth dimensional disease compartments and mth non-disease com-
partments, and let x ∈ Rn and y ∈ Rm be the sizes of these compartments. Also, let Fi
denote the rate of secondary infection increase of the ith disease compartments and Vi
be the rate of disease progression, death and recovery decrease of the ith compartment,




= Fi(x, y)− Vi(x, y), i = 1...n
dyi
dt
= Gi(x, y), i = 1...m
(A.8)
The next generation method for calculation R0 is based on the linearization of the
ordinary differential equations (ODE) model at the disease free-equilibrium. Thus the
following assumptions ensure that Theorem A.1 is satisfied.
1. If x ∈ Rn and y ∈ Rm then Fi(x, y) > 0, Vi(x, y) > 0 for 1 ≤ i ≤ n. Therefore
all the rate in the models will be non-negative.
2. If xi = 0, then Vi(x, y) = 0. There can be no movement of individuals out of
that compartment since there are no individuals in the infected compartment.
3. Fi(x, y) = 0. There can be no infections entering classes that are defined as
non-infectious.
4. If x ∈ y, then Fi(x, y) = 0 and Vi(x, y) = 0 for 1 ≤ i ≤ n. If there is no
infection in the population, there can be no input into the infectious populations.
Hence, the disease-free subspace is invariant.
5. Assume the disease-free system
dy
dt
= G(0, y) (A.9)
has a unique equilibrium that is asymptotically stable. That is, if Fi(x) = 0
then, all the eigenvalues of the corresponding Jacobian at the disease-free equi-
librium point have negative real part. This implies that in the in absence of new
infections, the disease-free equilibrium point is locally asymptotically stable.










where i, j = 1...m
Then the basic reproductive number is given by dominant eigenvalue of the next gen-
eration matrix given by FV −1.
Definition A.9 (Poincare-Perron).
LetA be a constant matrix in the system dy
dt
= Ay with eigenvalues λi, i = 1, 2, ..., n
then,
1. the system is stable, if Re(λi) ≤ 0, i = 1, 2, ..., n.
2. the system is uniformly stable if either Re(λi) ≤ 0, i = 1, 2, ..., n, Re(λi) <
0 i = 1, 2, ..., n and there is no zero repeated eigenvalue.
3. the system is asymptotically stable if and only if Re(λ) < 0, i = 1, 2, ..., n.
4. The solutions of the system are unstable if Re(λi) > 0, i = 1, 2, ..., n.
Remark A.1. If any of the eigenvalues have a positive real numbers, the equilibrium is
defined as a source, and thus, unstable while if all of the real parts of the eigenvalues
are negative real numbers, the equilibrium is defined as a sink, and thus, stable (Perko,
2013).
Definition A.10 (Routh-Hurwitz criteria).
Given a polynomial
P (λ) = λn + a1λ
n−1 + ...+ an−1λ+ an (A.11)
where ai i = 1, 2, ...n are real constants which defines the n Hurwitz matrices using



















a1 1 0 0 . . . 0
a3 a2 a1 0 . . . 0
a5 a4 a3 a2 . . . 0
a7 a6 a5 a4 . . . 0
. . . . . . . .
. . . . . . . .
. . . . . . . .
0 0 0 0 . . . an

(A.15)
if detHi,j ≥ 0 j = 1, 2, ...n aj = 0 if j > n then all the roots of the polynomial
P (λ) are negative hence the steady state of the model considered are stable.
Definition A.11 (Simply Connected Set).
A simply connected set in D ⊂ R2 is a connected set having the property that every
simple closed curve in D cannot continuously shrink (within D) to a point, that is,
whenever a simple closed curve C lies entirely in D, then its interior also lies entirely
in D.
Definition A.12 (Bendixsons Criterion).
















if and equation (A.17) does not change sign in D then there are no periodic orbits of
the autonomous system (A.16), that is, there has no closed trajectories inside D.
Definition A.13 (Dilac Criterion).
Let D be a simply connected region of the phase plane. If there exists a continuously
differentiable function Ω(x, y) such that
∂
∂x
(Ω(x, y)F (x, y)) +
∂
∂y
(Ω(x, y)G(x, y)) (A.18)
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does not change sign in D then the dynamical system
dx
dt





has no closed orbits wholly contained in D.
Definition A.14 (Convex set).
A function V (t) is said to be convex on [a, b] if
V (t1) + (1− χ)V (t2) ≥ V (t)(χt1 + (1− χ) t2 (A.20)
for all 0 ≤ χ ≤ 1 and for all a ≤ t1, t2 ≤ b
Definition A.15 (Concave set).
A function V (t) is said to be convex on [a, b] if
V (t)(χt1 + (1− χ) t2 ≥ aV (t1) + (1− χ)V (t2) (A.21)
for all 0 ≤ χ ≤ 1 and for all a ≤ t1, t2 ≤ b
Remark A.2. If V is concave and differentiable, then it is bounded above by its first-
order
V (t2) ≤ V (t1)− V̇ (t1)[t2 − t1] (A.22)
A.3 Sensitivity analysis
Sensitivity analysis technique in the context of deterministic dynamical model system
refers to how sensitive a model is to changes in the values of its parameters. Sensitivity
analysis is always aimed at identifying the critical inputs of a model and determining
how they affect the model outcomes. In the epidemiological modelling the analysis is
mainly done on the parameters on R0. This is to determine how reactive each param-
eter is to disease transmission and somewhat tries to discover parameters that have a
high impact on R0 and should be targeted by intervention strategies. They are various
method that have been used in calculating the basicR0 such as the the sensitivity index
and partial Rank Correlation Coefficients.
Definition A.16 (The normalized forward sensitivity). The normalized forward sensi-







Definition A.17 (Partial Rank Correlation Coefficients (PRCCs)). The use of PRCCs
in sensitivity analysis helps in the assessment of the statistical relationship between
the R0 and the parameters and, the sign of the PRCC of an input parameter depicts the
particular kind of qualitative affiliation it has with the outcome variable.
A.4 The optimal control problem
A.4.1 Dynamical Constraints
An optimal control is an extension of the calculus of variations and optimization
method for deriving control policies. It deals with the problem of finding a control
law for a given system such that a certain optimality criterion is achieved (Berkovitz,
2013). Optimal control allow mathematicians to make fundamental decision on the
biological problems. The optimal control can be derived using Pontryagins maximum
principle or solving the Hamilton-JacobiBellman equation.
Suppose we have we have a control function u(t) that we want to maximize
J (u(t)) = θ[y(t), u(t), tf ] (A.24)
subject to the state equations
dy
dt
= f(y(t), u(t)) (A.25)
and the boundary conditions
Φ[y(t), u(tf ), tf ] = 0 (A.26)
Here t represents independent time variable, indices t0 and tf indicates the initial and
final time, respectively, y(t) ∈ Rn is a vector of representing the state variables, u(t) ∈
Rn denotes a vector of control variables to be optimized and the initial conditions are




{f(y(t), u(t))} dt (A.27)
then from Pontryagins maximum principle we have the Hamiltonian for the objective
function given by
H = λi(t)f(y(t), u(t)) (A.28)
where λi denotes the adjoint and is dependent on (t, y(t)) and u(t) with the following
properties.
144
1. λi(t)f(y(t), u(t)) + µ(t) has a maximum value at u(t) = u∗(t). where













∂H(λi(t), y(t), u(t), t)
∂λi
(A.31)
4. The control u∗ must maximize H . So, if the necessary partial derivatives exist,
then we must have,
∂H(λi(t), y(t), u(t), t)
∂u
= 0 (A.32)
A.5 Runge-Kutta Forth order Scheme
Due to the complexity of the optimal control problem analytical solutions can not be
achieved hence the need to apply numerical methods. The fourth order Runge-Kutta




= F (x, y) at y(0) = y0 (A.33)
The fourth order Runge-Kutta method is based on the following general equation.
y(i+1) = yi + (a1k1 + a2k2 + a3k3 + a4k4)h (A.34)
where from knowing the value of y = yi at the point xi, we can find the value of
y = y(i+1) at the point xi+1, and h = xi+1xi is the step size. The equation (A.34) gives
the first five terms of the taylors series.







f ′′(xi, yi)h3 +
1
4!
f ′′′(xi, yi)h4 (A.35)
Based on the equation (A.35), we have,
y(i+1) = yi +
h
6
(k1 + 2k2 + 2k3 + k4) (A.36)
where,



























1 f u n c t i o n [ R C ] = c a l c u l a t i o n ( p a r a )
2 % lambda = 1 0 / 8 . 4 ;
3 % lambda = 1 ;
4 % d = 1 / ( 1 2 * 7 0 ) ;
5 f o r i = 1 : 1 0 0 0 ;
6
7 lambdaT ( i ) = p a r a ( i , 1 ) ;
8 muT( i ) = p a r a ( i , 2 ) ;
9 x i ( i ) = p a r a ( i , 3 ) ;
10 muv ( i ) = p a r a ( i , 4 ) ;
11 ev ( i ) = p a r a ( i , 5 ) ;
12 % Computa t ion o f t h e b a s i c r e p r o d u c t i o n number .
13 R N ( i ) = lambdaT ( i ) . * x i ( i ) . * ev ( i ) ;
14 R D ( i ) = muT ( i ) . * muv ( i ) ;
15 R C ( i ) = R N ( i ) . / R D ( i ) ;
16 end
1 % I have t o run LHS f i r s t , t h e n d e f i n e a new m a t r i x C t o
be p a r a .
2
3 f o r i = 1 : 1 0 0 0 ;
4 lambdaT ( i ) = p a r a ( i , 1 ) ;
5 muT( i ) = p a r a ( i , 2 ) ;
6 x i ( i ) = p a r a ( i , 3 ) ;
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7 muv ( i ) = p a r a ( i , 4 ) ;
8 ev ( i ) = p a r a ( i , 5 ) ;
9 % Computa t ion o f t h e b a s i c r e p r o d u c t i o n number .
10 R N ( i ) = lambdaT ( i ) . * x i ( i ) . * ev ( i ) ;
11 R D ( i ) = muT ( i ) . * muv ( i ) ;
12 R C ( i ) = R N ( i ) . / R D ( i ) ;
13 end
1 c l e a r ;
2 % C a l l i n g program t o g e n e r a t e d PRCC f o r LHS ; c a l l t h e LHS
program which
3 % g e n e r a t e s t h e sample ; a l l i n p u t v a r i a b l e s a r e i n c l u d e d
i n t h e LHS program
4 % and o u t p u t o f t h e program i s t h e m a t r i x CC from Blower ’
s t e c h n i q u e p a p e r
5
6 LHS ; % c a l l t h e LHS program
7 b = s i z e ( l a t i n o u t p u t ) ;
8 c = l e n g t h ( l a t i n o u t p u t ) ;
9 % t e s t 1 = 1 . / l a t i n o u t p u t ( : , 7 ) ;
10 % t e s t 2 = 1 . / l a t i n o u t p u t ( : , 8 ) ;
11 % t e s t 3 = 1 . / l a t i n o u t p u t ( : , 9 ) ;
12 %
13 % l a t i n o u t p u t ( : , 7 ) = t e s t 1 ;
14 % l a t i n o u t p u t ( : , 8 ) = t e s t 2 ;
15 % l a t i n o u t p u t ( : , 9 ) = t e s t 3 ;
16
17 num = b ( 2 ) ;
18
19 % d e c l a r e i n i t i a l p a r a m e t e r s
20
21 r ank ou t come = z e r o s ( 1 0 0 0 , 1 ) ;
22 r ank = z e r o s ( 1 0 0 0 , 1 0 ) ;
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23 outcome = z e r o s ( 1 0 0 0 , 1 0 0 ) ;
24 p a r a m e t e r s = z e r o s ( 1 0 0 0 , 1 0 ) ;
25 CC = z e r o s ( 1 0 , 10) ;
26 l e n g t h o f m a t r i x = b ( 2 ) ;
27 % r e a d i n d a t a from LHS ; program c r e a t e s m a t r i c e s
outcome and
28 % p a r a m e t e r s t h a t a r e used t o c a l c u l a t e t h e PRCCs
29 % v a r i a b l e s a r e t h e n r an ke d and r e s u l t s a r e p u t i n t o
r ank ou t come
30 % m a t r i x which i s f e d i n t o c r e a t e r a n k m a t r i x which
c r e a t e s a m a t r i x o f t h e r a n k s o f each
31 % p a r a m e t e r f o r each s i m u l a t i o n ; t h e CC m a t r i x t h e n
c r e a t e d i n t h e l a s t
32 % program
33
34 [ p a r a m e t e r s , outcome ] = r e a d i n d a t a (N, num ,
l a t i n o u t p u t ) ;
35 [ r ank ou t come ] = c r e a t e o u t c o m e r a n k (N, num , outcome
) ;
36 [ rank , r a n k s ] = c r e a t e r a n k m a t r i x (N, num ,
p a r a m e t e r s , rank , r ank ou t come ) ;
37 [CC] = make c m a t r i x (N, num , r ank ) ;
38 s e t ( 0 , ’ d e f a u l t t e x t i n t e r p r e t e r ’ , ’ t e x ’ ) ;
39 f i g 1 5 = f i g u r e ( 1 5 ) ;
40 ba rh (CC ( 1 : l e n g t h (CC)−1, l e n g t h (CC) ) )
41 s e t ( gca , ’ YTick ’ , 1 : 5 )
42 s e t ( gca , ’ YTickLabel ’ ,{ ’\ lambda T ’ , ’\mu T ’ , ’\ c h i ’ , ’\mu V ’ ,
’\ e p s i l o n V ’ } )
B.2 Model ODE and Paarameters Values
1 f u n c t i o n ymm = fuc t ionCC ( t , y )
2 lambdaT = 1 0 ; muT = 0 . 0 1 ; x i = 0 . 0 0 0 0 2 4 ; muI = 0 . 5 ;
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3 a l p h a = 0 . 0 2 ; muIl = 0 . 5 ; epsV = 100 ; muV = 2 ; N1 = 100 ;
4 muVn = 3 ; lambdaZ = 2 0 ; muZ = 0 . 0 4 ; b e t a = 0 . 0 0 4 ; muZa =
0 . 0 0 4 ;
5 % omega pg 67 e q t n s 4 . 6 6
6 % omega = 1 ;
7 % o1 = omega ; o2 = omega ; o3 = omega ;
8 % % w e i g h t s o f drug
9 % aa = 0 . 0 1 ;
10 % A1 = aa ; A2 = aa ; A3 = aa ;
11 % % i n i t i a c o n d i t i o n s
12 % x10 = 600 ; x20 = 1 0 ; x30 = 0 ; x40 = 1 0 ; x50 = 0 ; x60 =
500 ; x70 = 1 0 ;
13 % y0 =[ x10 , x20 , x30 , x40 , x50 , x60 , x70 ] ;
14 % time
15 ymm = z e r o s ( 7 , 1 ) ;
16 ymm( 1 ) =lambdaT−muT*y ( 1 )−x i *y ( 1 ) *y ( 4 ) ;
17 ymm( 2 ) = x i *y ( 1 ) *y ( 4 )−muI*y ( 2 )−a l p h a *y ( 2 ) *y ( 7 ) ;
18 ymm( 3 ) =−1*muIl *y ( 3 ) ;
19 %ymm( 3 ) =0;
20 ymm( 4 ) =epsV*muI*y ( 2 )−muV*y ( 4 ) ;
21 ymm( 5 ) =−1*muVn*y ( 5 ) ;
22 %ymm( 5 ) =0;
23 ymm( 6 ) =lambdaZ−muZ*y ( 6 )−b e t a *y ( 6 ) *y ( 2 ) ;
24 ymm( 7 ) = b e t a *y ( 6 ) *y ( 2 )−muZa*y ( 7 ) ;
B.3 Optimality System
1 f u n c t i o n y= p u r i t y a a ( lambdaT , muT , xi , muI , a lpha , muIl , epsV ,
muV, muVn , lambdaZ , muZ , be t a , muZa , o1 , o2 , o3 , A1 , A2 , A3 , x10 ,
x20 , x30 , x40 , x50 , x60 , x70 , t f )
2 d e l t a = 0 . 0 0 1 ;
3 t e s t =−1;
4 N=1000;
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5 t = l i n s p a c e ( 0 , t f ,N+1) ;
6 h= t f /N;
7 h2=h / 2 ;
8
9 u1= z e r o s ( 1 ,N+1) ;
10 u2= z e r o s ( 1 ,N+1) ;
11 u3= z e r o s ( 1 ,N+1) ;
12
13 x1= z e r o s ( 1 ,N+1) ;
14 x2= z e r o s ( 1 ,N+1) ;
15 x3= z e r o s ( 1 ,N+1) ;
16 x4= z e r o s ( 1 ,N+1) ;
17 x5= z e r o s ( 1 ,N+1) ;
18 x6= z e r o s ( 1 ,N+1) ;
19 x7= z e r o s ( 1 ,N+1) ;
20
21 x1 ( 1 ) =x10 ;
22 x2 ( 1 ) =x20 ;
23 x3 ( 1 ) =x30 ;
24 x4 ( 1 ) =x40 ;
25 x5 ( 1 ) =x50 ;
26 x6 ( 1 ) =x60 ;
27 x7 ( 1 ) =x70 ;
28
29 lambda1= z e r o s ( 1 ,N+1) ;
30 lambda2= z e r o s ( 1 ,N+1) ;
31 lambda3= z e r o s ( 1 ,N+1) ;
32 lambda4= z e r o s ( 1 ,N+1) ;
33 lambda5= z e r o s ( 1 ,N+1) ;
34 lambda6= z e r o s ( 1 ,N+1) ;
35 lambda7= z e r o s ( 1 ,N+1) ;
36
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37 u =[ u1 u2 u3 ] ’ ;
38 x =[ x1 x2 x3 x4 x5 x6 x7 ] ’ ;
39 lambda =[ lambda1 lambda2 lambda3 lambda4 lambda5 lambda6
lambda7 ] ’ ;
40 w h i l e ( t e s t <0)
41
42 o ldu1 =u1 ;
43 o ldu2 =u2 ;
44 o ldu3 =u3 ;
45 o ldu =u ;
46 o ldx1 =x1 ;
47 o ldx2 =x2 ;
48 o ldx3 =x3 ;
49 o ldx4 =x4 ;
50 o ldx5 =x5 ;
51 o ldx6 =x6 ;
52 o ldx7 =x7 ;
53 old lambda1 =lambda1 ;
54 old lambda2 =lambda2 ;
55 old lambda3 =lambda3 ;
56 old lambda4 =lambda4 ;
57 old lambda5 =lambda5 ;
58 old lambda6 =lambda6 ;
59 old lambda7 =lambda7 ;
60 o ld lambda =lambda ;
61
62 f o r i =1 :N
63 k11=lambdaT−muT*x1 ( i )−(1−u1 ( i ) ) * x i *x1 ( i ) *x4 ( i ) ;
64 k12=(1−u1 ( i ) ) (1−u2 ( i ) ) * x i *x1 ( i ) *x4 ( i )−muI*x2 ( i )−
a l p h a *x2 ( i ) *x7 ( i ) ;
65 k13=(1−u1 ( i ) ) u2 ( i ) * x i *x1 ( i ) *x4 ( i )−muIl *x3 ( i ) ;
66 k14=(1−u3 ( i ) ) *epsV*muI*x2 ( i )−muV*x4 ( i ) ;
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67 k15=u3 ( i ) *epsV*muI*x2 ( i )−muV*x5 ( i ) ;
68 k16=lambdaZ−muZ*x6 ( i )−b e t a *x6 ( i ) *x2 ( i ) ;
69 k17= b e t a *x6 ( i ) *x2 ( i )−muZa*x7 ( i ) ;
70
71 k21=lambdaT−muT*( x1 ( i ) ++h2*k11 ) −(1−0.5*( u1 ( i ) +u1 (
i +1) ) ) * x i * ( x1 ( i ) +h2*k11 ) * ( x4 ( i ) +h2*k14 ) ;
72 k22 =(1−0.5*( u1 ( i ) +u1 ( i +1) ) ) *(1−0.5*( u2 ( i ) +u2 ( i +1)
) ) * x i * ( x1 ( i ) +h2*k11 ) * ( x4 ( i ) +h2*k14 )−muI *( x2 ( i )
+h2*k12 )−a l p h a * ( x2 ( i ) +h2* k12 ) * ( x7 ( i ) +h2*k17 ) ;
73 k23 =(1−0.5*( u1 ( i ) +u1 ( i +1) ) ) * 0 . 5 * ( u2 ( i ) +u2 ( i +1) ) *
x i * ( x1 ( i ) +h2*k11 ) * ( x4 ( i ) +h2*k14 )−muIl * ( x3 ( i ) +
h2*k13 ) ;
74 k24 =(1−0.5*( u3 ( i ) +u3 ( i +1) ) ) *epsV*muI * ( x2 ( i ) +h2*
k12 )−muV*( x4 ( i ) +h2*k14 ) ;
75 k25 = 0 . 5 * ( u3 ( i ) +u3 ( i +1) ) *epsV*muI * ( x2 ( i ) +h2*k12 )−
muVn*( x5 ( i ) +h2*k15 ) ;
76 k26=lambdaZ−muZ*( x6 ( i ) +h2*k16 )−b e t a * ( x6 ( i ) +h2*k16
) * ( x2 ( i ) +h2*k12 ) ;
77 k27= b e t a * ( x6 ( i ) +h2*k16 ) * ( x2 ( i ) +h2*k12 )−muZa *( x7 ( i
) +h2*k17 ) ;
78
79 k31=lambdaT−muT*( x1 ( i ) ++h2*k21 ) −(1−0.5*( u1 ( i ) +u1 (
i +1) ) ) * x i * ( x1 ( i ) +h2*k21 ) * ( x4 ( i ) +h2*k24 ) ;
80 k32 =(1−0.5*( u1 ( i ) +u1 ( i +1) ) ) *(1−0.5*( u2 ( i ) +u2 ( i +1)
) ) * x i * ( x1 ( i ) +h2*k21 ) * ( x4 ( i ) +h2*k24 )−muI *( x2 ( i )
+h2*k22 )−a l p h a * ( x2 ( i ) +h2* k22 ) * ( x7 ( i ) +h2*k27 ) ;
81 k33 =(1−0.5*( u1 ( i ) +u1 ( i +1) ) ) * 0 . 5 * ( u2 ( i ) +u2 ( i +1) ) *
x i * ( x1 ( i ) +h2*k21 ) * ( x4 ( i ) +h2*k24 )−muIl * ( x3 ( i ) +
h2*k23 ) ;
82 k34 =(1−0.5*( u3 ( i ) +u3 ( i +1) ) ) *epsV*muI * ( x2 ( i ) +h2*
k22 )−muV*( x4 ( i ) +h2*k24 ) ;
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83 k35 = 0 . 5 * ( u3 ( i ) +u3 ( i +1) ) *epsV*muI * ( x2 ( i ) +h2*k22 )−
muVn*( x5 ( i ) +h2*k25 ) ;
84 k36=lambdaZ−muZ*( x6 ( i ) +h2*k26 )−b e t a * ( x6 ( i ) +h2*k26
) * ( x2 ( i ) +h2*k22 ) ;
85 k37= b e t a * ( x6 ( i ) +h2*k26 ) * ( x2 ( i ) +h2*k22 )−muZa *( x7 ( i
) +h2*k27 ) ;
86
87 k41=lambdaT−muT*( x1 ( i ) ++h*k31 )−(1−u1 ( i +1) ) * x i * ( x1
( i ) +h*k31 ) * ( x4 ( i ) +h*k34 ) ;
88 k42=(1−u1 ( i +1) ) *(1−u2 ( i +1) ) * x i * ( x1 ( i ) +h*k31 ) * ( x4 (
i ) +h*k34 )−muI *( x2 ( i ) +h*k32 )−a l p h a * ( x2 ( i ) +h* k32
) * ( x7 ( i ) +h*k37 ) ;
89 k43=(1−u1 ( i +1) ) *u2 ( i +1) * x i * ( x1 ( i ) +h*k31 ) * ( x4 ( i ) +h
*k34 )−muIl * ( x3 ( i ) +h*k33 ) ;
90 k44=(1−u3 ( i +1) ) *epsV*muI * ( x2 ( i ) +h*k32 )−muV*( x4 ( i )
+h*k34 ) ;
91 k45=u3 ( i +1) *epsV*muI * ( x2 ( i ) +h*k32 )−muVn*( x5 ( i ) +h*
k35 ) ;
92 k46=lambdaZ−muZ*( x6 ( i ) +h*k36 )−b e t a * ( x6 ( i ) +h* k36 )
* ( x2 ( i ) +h*k32 ) ;
93 k47= b e t a * ( x6 ( i ) +h*k36 ) * ( x2 ( i ) +h*k32 )−muZa *( x7 ( i ) +
h* k37 ) ;
94
95
96 x1 ( i +1)=x1 ( i ) +( h / 6 ) * ( k11 +2* k21 +2* k31+k41 ) ;
97 x2 ( i +1)=x2 ( i ) +( h / 6 ) * ( k12 +2* k22 +2* k32+k42 ) ;
98 x3 ( i +1)=x3 ( i ) +( h / 6 ) * ( k13 +2* k23 +2* k33+k43 ) ;
99 x4 ( i +1)=x4 ( i ) +( h / 6 ) * ( k14 +2* k24 +2* k34+k44 ) ;
100 x5 ( i +1)=x5 ( i ) +( h / 6 ) * ( k15 +2* k25 +2* k35+k45 ) ;
101 x6 ( i +1)=x6 ( i ) +( h / 6 ) * ( k16 +2* k26 +2* k36+k46 ) ;




105 f o r i =1 :N
106 j =N+2− i ;
107 k11=−o1 +(muT+(1−u1 ( j ) ) * x i *x4 ( j ) ) * lambda1 ( j )−x i
*(1−u1 ( j ) ) *(1−u2 ( j ) ) *x4 ( j ) * lambda2 ( j )−x i *(1−u1
( j ) ) *u2 ( j ) *x4 ( j ) * lambda3 ( j ) ;
108 k12 =( muI+ a l p h a *x7 ( j ) ) * lambda2 ( j )−epsV*muI*(1−u3 ( j
) ) * lambda4 ( j )−muI*N1*u3 ( j ) * lambda5 ( j ) + b e t a *x6 (
j ) * lambda6 ( j )−b e t a *x6 ( j ) * lambda7 ( j ) ;
109 k13=muIl * lambda3 ( j ) ;
110 k14=o3+ x i *x1 ( j ) *(1−u1 ( j ) ) * lambda1 ( j ) + x i *x1 ( j ) *(1−
u1 ( j ) ) *(1−u2 ( j ) ) * lambda2 ( j ) + x i * lambda3 ( j ) *x1 ( j
) *(1−u1 ( j ) ) *u2 ( j ) +muV* lambda4 ( j ) ;
111 k15=muVn* lambda5 ( j ) ;
112 k16=−o2 +(muZ+ b e t a *x2 ( j ) ) * lambda6 ( j )−b e t a *x2 ( j ) *
lambda7 ( j ) ;
113 k17= a l p h a *x2 ( j ) * lambda2 ( j ) ;
114
115 k21=−o1 +(muT+(1−0.5*( u1 ( j ) +u1 ( j −1) ) ) * x i * 0 . 5 * ( x4 ( j
) +x4 ( j −1) ) ) * ( lambda1 ( j )−h2*k11 )−x i *(1−0.5*( u1 (
j ) +u1 ( j −1) ) ) *(1−0.5*( u2 ( j ) +u2 ( j −1) ) ) * 0 . 5 * ( x4 ( j
) +x4 ( j −1) ) * ( lambda2 ( j )−h2*k12 )−x i *(1−0.5*( u1 ( j
) +u1 ( j −1) ) ) * 0 . 5 * ( u2 ( j ) +u2 ( j −1) ) * 0 . 5 * ( x4 ( j ) +x4 (
j −1) ) * ( lambda3 ( j )−h2*k13 ) ;
116 k22 =( muI+ a l p h a * 0 . 5 * ( x7 ( j ) +x7 ( j −1) ) ) * ( lambda2 ( j )−
h2*k12 )−epsV*muI *(1−0.5*( u3 ( j ) +u3 ( j −1) ) ) * (
lambda4 ( j )−h2*k14 )−muI*N1 * 0 . 5 * ( u3 ( j ) +u3 ( j −1) )
* ( lambda5 ( j )−h2*k15 ) + b e t a * 0 . 5 * ( x6 ( j ) +x6 ( j −1) )
* ( lambda6 ( j )−h2*k16 )−b e t a * 0 . 5 * ( x6 ( j ) +x6 ( j −1) )
* ( lambda7 ( j )−h2*k17 ) ;
117 k23=muIl * ( lambda3 ( j )−h2*k13 ) ;
154
118 k24=o3+ x i * 0 . 5 * ( x1 ( j ) +x1 ( j −1) ) *(1−0.5*( u1 ( j ) +u1 ( j
−1) ) ) * ( lambda1 ( j )−h2*k11 ) + x i * 0 . 5 * ( x1 ( j ) +x1 ( j
−1) ) *(1−0.5*( u2 ( j ) +u2 ( j −1) ) ) * ( lambda2 ( j )−h2*
k12 ) + x i * ( lambda3 ( j )−h2*k13 ) * 0 . 5 * ( x1 ( j ) +x1 ( j −1)
) * 0 . 5 * ( u2 ( j ) +u2 ( j −1) ) +muV*( lambda4 ( j )−h2*k14 ) ;
119 k25=muVn*( lambda5 ( j )−h2*k15 ) ;
120 k26=−o2 +(muZ+ b e t a * 0 . 5 * ( x2 ( j ) +x2 ( j −1) ) ) * ( lambda6 ( j
)−h2*k16 )−b e t a * 0 . 5 * ( x2 ( j ) +x2 ( j −1) ) * ( lambda7 ( j )
−h2*k17 ) ;
121 k27= a l p h a * 0 . 5 * ( x2 ( j ) +x2 ( j −1) ) * ( lambda2 ( j )−h2*k12 )
;
122
123 k31=−o1 +(muT+(1−0.5*( u1 ( j ) +u1 ( j −1) ) ) * x i * 0 . 5 * ( x4 ( j
) +x4 ( j −1) ) ) * ( lambda1 ( j )−h2*k21 )−x i *(1−0.5*( u1 (
j ) +u1 ( j −1) ) ) *(1−0.5*( u2 ( j ) +u2 ( j −1) ) ) * 0 . 5 * ( x4 ( j
) +x4 ( j −1) ) * ( lambda2 ( j )−h2*k22 )−x i *(1−0.5*( u1 ( j
) +u1 ( j −1) ) ) * 0 . 5 * ( u2 ( j ) +u2 ( j −1) ) * 0 . 5 * ( x4 ( j ) +x4 (
j −1) ) * ( lambda3 ( j )−h2*k23 ) ;
124 k32 =( muI+ a l p h a * 0 . 5 * ( x7 ( j ) +x7 ( j −1) ) ) * ( lambda2 ( j )−
h2*k22 )−epsV*muI *(1−0.5*( u3 ( j ) +u3 ( j −1) ) ) * (
lambda4 ( j )−h2*k24 )−muI*N1 * 0 . 5 * ( u3 ( j ) +u3 ( j −1) )
* ( lambda5 ( j )−h2*k25 ) + b e t a * 0 . 5 * ( x6 ( j ) +x6 ( j −1) )
* ( lambda6 ( j )−h2*k26 )−b e t a * 0 . 5 * ( x6 ( j ) +x6 ( j −1) )
* ( lambda7 ( j )−h2*k27 ) ;
125 k33=muIl * ( lambda3 ( j )−h2*k23 ) ;
126 k34=o3+ x i * 0 . 5 * ( x1 ( j ) +x1 ( j −1) ) *(1−0.5*( u1 ( j ) +u1 ( j
−1) ) ) * ( lambda1 ( j )−h2*k21 ) + x i * 0 . 5 * ( x1 ( j ) +x1 ( j
−1) ) *(1−0.5*( u1 ( j ) +u1 ( j −1) ) ) *(1−0.5*( u2 ( j ) +u2 (
j −1) ) ) * ( lambda2 ( j )−h2*k22 ) + x i * ( lambda3 ( j )−h2*
k23 ) * 0 . 5 * ( x1 ( j ) +x1 ( j −1) ) *(1−0.5*( u1 ( j ) +u1 ( j −1)
) ) * 0 . 5 * ( u2 ( j ) +u2 ( j −1) ) +muV*( lambda4 ( j )−h2*k24 )
;
155
127 k35=muVn*( lambda5 ( j )−h2*k25 ) ;
128 k36=−o2 +(muZ+ b e t a * 0 . 5 * ( x2 ( j ) +x2 ( j −1) ) ) * ( lambda6 ( j
)−h2*k26 )−b e t a * 0 . 5 * ( x2 ( j ) +x2 ( j −1) ) * ( lambda7 ( j )
−h2*k27 ) ;
129 k37= a l p h a * 0 . 5 * ( x2 ( j ) +x2 ( j −1) ) * ( lambda2 ( j )−h2*k22 )
;
130
131 k41=−o1 +(muT+(1−u1 ( j −1) ) * x i *x4 ( j −1) ) * ( lambda1 ( j )−
h* k31 )−x i *(1−u1 ( j −1) ) *(1−u2 ( j −1) ) *x4 ( j −1) * (
lambda2 ( j )−h*k32 )−x i *(1−u1 ( j −1) ) *u2 ( j −1)*x4 ( j
−1) * ( lambda3 ( j )−h*k33 ) ;
132 k42 =( muI+ a l p h a *x7 ( j −1) ) * ( lambda2 ( j )−h* k32 )−epsV*
muI*(1−u3 ( j −1) ) * ( lambda4 ( j )−h*k34 )−muI*N1*u3 ( j
−1) * ( lambda5 ( j )−h*k35 ) + b e t a *x6 ( j −1) * ( lambda6 ( j
)−h*k36 )−b e t a *x6 ( j −1) * ( lambda7 ( j )−h*k37 ) ;
133 k43=muIl * ( lambda3 ( j )−h*k33 ) ;
134 k44=o3+ x i *x1 ( j −1)*(1−u1 ( j −1) ) * ( lambda1 ( j )−h* k31 ) +
x i *x1 ( j −1)*(1−u1 ( j −1) ) *(1−u2 ( j −1) ) * ( lambda2 ( j )
−h*k32 ) + x i * ( lambda3 ( j )−h* k33 ) *x1 ( j −1)*(1−u1 ( j
−1) ) *u2 ( j −1)+muV*( lambda4 ( j )−h* k34 ) ;
135 k45=muVn*( lambda5 ( j )−h*k35 ) ;
136 k46=−o2 +(muZ+ b e t a *x2 ( j −1) ) * ( lambda6 ( j )−h*k36 )−
b e t a *x2 ( j −1) * ( lambda7 ( j )−h*k37 ) ;
137 k47= a l p h a *x2 ( j −1) * ( lambda2 ( j )−h*k32 ) ;
138
139 lambda1 ( j −1)=lambda1 ( j )−(h / 6 ) * ( k11 +2* k21 +2* k31+
k41 ) ;
140 lambda2 ( j −1)=lambda2 ( j )−(h / 6 ) * ( k12 +2* k22 +2* k32+
k42 ) ;
141 lambda3 ( j −1)=lambda3 ( j )−(h / 6 ) * ( k13 +2* k23 +2* k33+
k43 ) ;
156
142 lambda4 ( j −1)=lambda4 ( j )−(h / 6 ) * ( k14 +2* k24 +2* k34+
k44 ) ;
143 lambda5 ( j −1)=lambda5 ( j )−(h / 6 ) * ( k15 +2* k25 +2* k35+
k45 ) ;
144 lambda6 ( j −1)=lambda6 ( j )−(h / 6 ) * ( k16 +2* k26 +2* k36+
k46 ) ;





149 temp1= x i *x1 . * x4 . * ( lambda1−(1−u 2 ) * lambda2−u2* lambda3 )
/ ( 2 * A1 ) ;
150 u11=max ( 0 , min ( 1 , temp1 ) ) ;
151 %u11=min ( 1 , max ( 0 , temp ) ) ;
152 u1 = 0 . 5 * ( u11 + o ldu1 ) ;
153
154 temp2= x i *x1 . * x4 .*(1− u1 ) * ( lambda3−lambda2 ) / ( 2 * A2 ) ;
155 u22=max ( 0 , min ( 1 , temp2 ) ) ;
156 %u22=min ( 1 , max ( 0 , temp ) ) ;
157 u2 = 0 . 5 * ( u22 + o ldu2 ) ;
158
159 temp3=−epsV*muI* lambda4 / ( 2 * A3 ) ;
160 u33=max ( 0 , min ( 1 , temp3 ) ) ;
161 %u33=min ( 1 , max ( 0 , temp ) ) ;
162 u3 = 0 . 5 * ( u33 + o ldu3 ) ;
163 %u1 = z e r o s ( 1 , l e n g t h ( u1 ) ) ;
164 u2 = z e r o s ( 1 , l e n g t h ( u1 ) ) ;
165 u3 = z e r o s ( 1 , l e n g t h ( u1 ) ) ;
166 u =[ u1 u2 u3 ] ’ ;
167 x =[ x1 x2 x3 x4 x5 x6 x7 ] ’ ;
157
168 lambda =[ lambda1 lambda2 lambda3 lambda4 lambda5 lambda6
lambda7 ] ’ ;
169 o ldx =[ o ldx1 o ldx2 o ldx3 o ldx4 o ldx5 o ldx6 o ldx7 ] ’ ;
170 o ld lambda =[ o ld lambda1 old lambda2 old lambda3 old lambda4
old lambda5 old lambda6 old lambda7 ] ’ ;
171
172
173 temp1= d e l t a *sum ( abs ( u ) )−sum ( abs ( oldu−u ) ) ;
174 temp2= d e l t a *sum ( norm ( x ) )−sum ( norm ( oldx−x ) ) ;
175 temp3= d e l t a *sum ( norm ( lambda ) )−sum ( norm ( oldlambda−
lambda ) ) ;
176 t e s t =min ( temp1 , min ( temp2 , temp3 ) ) ;
177
178 end
179 y ( 1 , : ) = t ;
180 y ( 2 , : ) =x1 ;
181 y ( 3 , : ) =x2 ;
182 y ( 4 , : ) =x3 ;
183 y ( 5 , : ) =x4 ;
184 y ( 6 , : ) =x5 ;
185 y ( 7 , : ) =x6 ;
186 y ( 8 , : ) =x7 ;
187 y ( 9 , : ) =u1 ;
188 y ( 1 0 , : ) =u2 ;
189 y ( 1 1 , : ) =u3 ;
B.4 Output Code
1 c l e a r a l l ;
2 c l o s e a l l ;
3 c l c ;
4 lambdaT = 1 0 ; muT = 0 . 0 1 ; x i = 0 . 0 0 0 0 2 4 ; muI = 0 . 5 ;
5 a l p h a = 0 . 0 2 ; muIl = 0 . 5 ; epsV = 100 ; muV = 2 ;
158
6 muVn = 3 ; lambdaZ = 2 0 ; muZ = 0 . 0 4 ; b e t a = 0 . 0 0 4 ; muZa =
0 . 0 0 4 ;
7 %omega pg 67 e q t n s 4 . 6 6
8 %omega = 1 ;
9 o1 = 0 . 1 ;
10 o2 = 0 . 2 ;
11 o3 = 0 . 3 ;
12 % Vary t h e v a l u e s
13 %w e i g h t s o f drug
14 %aa = 100 ;
15 A1 = 0 . 0 3 ;
16 % A1 = 0 . 1 ;
17 % A2 = 0 . 1 ;
18 % A3 = 0 . 1 ;
19 % i n i t i a c o n d i t i o n s
20 x10 = 500 ; x20 = 100 ; x30 = 0 ; x40 = 100 ; x50 = 0 ; x60 =
100 ; x70 = 1 0 ;
21 t f =10;
22 y12= p u r i t y a a ( lambdaT , muT , xi , muI , a lpha , muIl , epsV , muV, N1 ,
muVn , lambdaZ , muZ , be t a , muZa , cf , cr , cp , A1 , x10 , x20 , x30 , x40
, x50 , x60 , x70 , t f ) ;
23 o p t i o n s = o d e s e t ( ’ Re lTo l ’ ,1 e−4, ’ AbsTol ’ , [ 1 e−4 1e−4 1e−5 1
e−5 1e−5 1e−5 1e−5 ] ) ;
24 t o =0 ;
25 y0 =[ x10 , x20 , x30 , x40 , x50 , x60 , x70 ] ;
26 [ t ,Y]= ode45 ( @fuctionCC , [ t o t f ] , y0 , o p t i o n s ) ;
27 d i s p ( ’ ’ )
28 f i g u r e ( 1 )
29 p l o t ( t ,Y ( : , 1 ) , ’ r ’ , y1 ( 1 , : ) , y1 ( 2 , : ) , ’−−b ’ , ’ LineWidth ’ , 2 . 0 )
30 x l a b e l ( ’ Time ( Months ) ’ )
31 y l a b e l ( ’ P o p u l a t i o n s o f t h e CD4+ T−c e l l s ’ )
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32 l e g e n d ( ’ Wi thou t Opt imal c o n t r o l ’ , ’ With Opt imal C o n t r o l ’
)
33 f i g u r e ( 2 )
34 p l o t ( t ,Y ( : , 2 ) , ’−r ’ , y1 ( 1 , : ) , y1 ( 3 , : ) , ’−−b ’ , ’ LineWidth ’ , 2 . 0 )
35 x l a b e l ( ’ Time ( Months ) ’ )
36 y l a b e l ( ’ I n f e c t e d CD4+T−c e l l s ’ )
37 l e g e n d ( ’ Wi thou t Opt imal c o n t r o l ’ , ’ With Opt imal C o n t r o l ’
)
38
39 f i g u r e ( 3 )
40 p l o t ( t ,Y ( : , 3 ) , ’−r ’ , y1 ( 1 , : ) , y1 ( 4 , : ) , ’−−b ’ , ’ LineWidth ’ , 2 . 0 )
41 x l a b e l ( ’ Time ( Months ) ’ )
42 y l a b e l ( ’ L a t e n t l y i n f e c t e d CD4+ T−c e l l s ’ )
43 l e g e n d ( ’ Wi thou t Opt imal c o n t r o l ’ , ’ With Opt imal C o n t r o l ’
)
44
45 f i g u r e ( 4 )
46 p l o t ( t ,Y ( : , 4 ) , ’−r ’ , y1 ( 1 , : ) , y1 ( 5 , : ) , ’−−b ’ , ’ LineWidth ’ , 2 . 0 )
47 x l a b e l ( ’ Time ( Months ) ’ )
48 y l a b e l ( ’ I n f e c t i o u s HIV v i r i o n s ’ )
49 l e g e n d ( ’ Wi thou t Opt imal c o n t r o l ’ , ’ With Opt imal C o n t r o l ’
)
50
51 f i g u r e ( 5 )
52 p l o t ( t ,Y ( : , 5 ) , ’−r ’ , y1 ( 1 , : ) , y1 ( 6 , : ) , ’−−b ’ , ’ LineWidth ’ , 2 . 0 )
53 x l a b e l ( ’ Time ( Months ) ’ )
54 y l a b e l ( ’Non− i n f e c t i o u s HIV v i r i o n s ’ )
55 l e g e n d ( ’ Wi thou t Opt imal c o n t r o l ’ , ’ With Opt imal C o n t r o l ’
)
56
57 f i g u r e ( 6 )
58 p l o t ( t ,Y ( : , 6 ) , ’−r ’ , y1 ( 1 , : ) , y1 ( 7 , : ) , ’−−b ’ , ’ LineWidth ’ , 2 . 0 )
160
59 x l a b e l ( ’ Time ( Months ) ’ )
60 y l a b e l ( ’CD8+T−c e l l s ’ )
61 l e g e n d ( ’ Wi thou t Opt imal c o n t r o l ’ , ’ With Opt imal C o n t r o l ’
)
62 f i g u r e ( 7 )
63 p l o t ( t ,Y ( : , 7 ) , ’−r ’ , y1 ( 1 , : ) , y1 ( 8 , : ) , ’−−b ’ , ’ LineWidth ’ , 2 . 0 )
64 x l a b e l ( ’ Time ( Months ) ’ )
65 y l a b e l ( ’ A c t i v a t e d CD8+ T−c e l l s ’ )
66 l e g e n d ( ’ Wi thou t Opt imal c o n t r o l ’ , ’ With Opt imal C o n t r o l ’
)
67 f i g u r e ( 1 0 )
68 p l o t ( y1 ( 1 , : ) , y1 ( 9 , : ) , ’−b ’ , ’ LineWidth ’ , 2 . 0 )
69 x l a b e l ( ’ Time ( Months ) ’ )
70 y l a b e l ( ’ C o n t r o l P r o f i l e s , u 1 ’ )
71 % l e g e n d ( ’ u 1 ’ , ’ u 2 ’ )
72 f i g u r e ( 1 1 )
73 p l o t ( y1 ( 1 , : ) , y1 ( 9 , : ) , ’−b ’ , y1 ( 1 , : ) , y1 ( 1 1 , : ) , ’ g ’ , ’ LineWidth
’ , 2 . 0 )
74 x l a b e l ( ’ Time ( Months ) ’ )
75 y l a b e l ( ’ C o n t r o l P r o f i l e s ’ )
76 l e g e n d ( ’ u 1 ’ , ’ u 3 ’ )
77 % a x i s ( [ 0 t f 0 1 ] )
78 f i g u r e ( 1 2 )
79 p l o t ( y1 ( 1 , : ) , y1 ( 9 , : ) , ’ b ’ , y1 ( 1 , : ) , y1 ( 1 0 , : ) , ’ r ’ , y1 ( 1 , : ) ,
y1 ( 1 1 , : ) , ’ g ’ , ’ LineWidth ’ , 2 . 0 )
80 x l a b e l ( ’ Time ( Months ) ’ )
81 y l a b e l ( ’ C o n t r o l P r o f i l e s ’ )
82 l e g e n d ( ’ u 1 ’ , ’ u 2 ’ , ’ u 3 ’ )
83 % % a x i s ( [ 0 t f i n a l 0 1 ] )
84 f i g u r e ( 1 3 )
85 p l o t ( y1 ( 1 , : ) , y1 ( 1 1 , : ) , ’−g ’ , ’ LineWidth ’ , 2 . 0 )
86 x l a b e l ( ’ Time ( Months ) ’ )
161
87 y l a b e l ( ’ C o n t r o l P r o f i l e s , u 3 ’ )
88 % l e g e n d ( ’ u1 ’ , ’ u2 ’ )
89 %a x i s ( [ 0 t f i n a l 0 1 ] )
90
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There have been many mathematical models aimed at analysing the in-vivo 
dynamics of HIV. However, in most cases the attention has been on the inte-
raction between the HIV virions and the CD4+ T-cells. This paper brings in 
the intervention of the CD8+ T-cells in seeking, destroying, and killing the in-
fected CD4+ T-cells during early stages of infection. The paper presents and 
analyses a five-component in-vivo model and applies the results in investigat-
ing the in-vivo dynamics of HIV in presence of the CD8+ T-cells. We prove 
the positivity and the boundedness of the model solutions. In addition, we 
show that the solutions are biologically meaningful. Both the endemic and vi-
rions-free equilibria are determined and their stability investigated. In addi-
tion, the basic reproductive number is derived by the next generation matrix 
method. We prove that the virions-free equilibrium state is locally asymptoti-
cally stable if and only if 0 1R <  and unstable otherwise. The results show 
that at acute infection the CD8+ T-cells play a paramount role in reducing 
HIV viral replication. We also observe that the model exhibits backward and 
trans-critical bifurcation for some set of parameters for 0 1R < . This is a clear 
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1. Introduction 
One of the most threatening retrovirus in the world is the Human Immunodeficiency 
Virus (HIV) that leads to Acquired Immunodeficiency Syndrome (AIDS). 
Unlike other viruses, HIV is encoded in ribonucleic acid (RNA) rather than 
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deoxyribonucleic acid (DNA). HIV attacks the immune system, weakening it 
and eventually if not treated it makes the infected people highly vulnerable to 
various opportunistic infections. In absence of any HIV-management mechanism, 
infected people progresses to AIDS stage after 10 - 15 years [1]. HIV can be 
transmitted through various modes such as: Sharing sharp objects with infected 
people, having unprotected sex, transfusion using HIV-contaminated blood and 
mother to child transmission during either breast-feeding or via delivery. 
Since the first case of HIV was reported in the early 1980’s, HIV/AIDS has 
been associated to the deaths of more than 35 million people while over 36.9 
million are living with the virus worldwide, making it one of the worst menace 
in the recorded history [2] [3] [4]. However, HIV remains a major cause of 
mortality in the world, having severe consequences mainly in sub-Saharan 
Africa, with a prevalence range of between 12% to 42% [3]. The greatest burden 
of HIV/AIDS lies with the poor communities, who also have the least access to 
antiretroviral therapy (ARTs) and interventions against HIV. Management, 
control and prevention of HIV require an integrated approach, which include, 
awareness/education and treatment with the best ARTs combinations. Lack of 
awareness/education, in access to early diagnosis and effective treatment has 
delayed the success of the global HIV programme in reducing new infection and 
severe HIV/AIDS related deaths. Therefore, there is need for new and more 
advanced interventions for HIV prevention, management and care.  
According to [5], Kenya is among the six HIV high burden countries in the 
world having over 1.6 million individual living with the virus. Although Kenya 
had over 79,000 cases of new infection by 2015, she has however, made notable 
and outstanding strides in controlling and preventing HIV. For instance, the country 
has one of the world’s highest HIV testing rates with about 72% of the total 
population having been tested at least once and 900,000 of the infected persons 
are on ARTs. However, not all efforts are reaching those who need these services. 
Consequently, concentrated epidemics are emerging among vulnerable groups 
such as youths, women, truck drivers, sex workers, prisoners, injecting-drug 
users, men who have sex with men, persons living with disabilities, discordant 
couples, orphan and vulnerable children. Therefore, control and prevention 
approaches should be tailored towards the aforementioned HIV special 
populations as part of wider efforts to control and curb the HIV/AIDS in Kenya. 
In addition, even with all the interventions, there are still a big number of 
Kenyans who do not know their HIV status. Therefore, it is important to 
increase HIV testing in order for people to be aware of their HIV status and be 
referred onto the best treatment, support and care according to the test 
outcomes. Kenyans economy and development has been affected severely by this 
menace. The Kenyan Government therefore, need to come up with sustainable 
methods of funding to improve existing HIV management efforts and to reduce 
the country’s dependence on funding from donors and development partners. 
In-vivo study for HIV dynamics have been done over the years, aimed at 
understanding the interaction mechanism of the body cells and the HIV virus. 
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Such information has proved so valuable especially in the development of ARTs 
and in HIV management. In the recent years, mathematical models of various 
complexity level have been used to simulate and analyse such interactions unlike 
in the past where researches relied on clinical trials [6]. Consequently, many 
researchers [7] [8] [9] [10] in the field of epidiemiological modelling have 
embarked on the process of developing new models that could be used in the 
analysis of HIV dynamics. Many of the developed models describe and give 
insight on the various aspects that result from the interaction of HIV with healthy 
immune cells. The earliest mathematical models were based on the interaction 
between the CD4+ T-cells and the HIV virions. These basic non-linear models 
were developed and used in the analysis of HIV dynamics and consequently, in 
estimating fundamental parameters that brought in new concepts of the disease 
processes and its progression [11]. With the aim of providing the most 
fundamental information on controlling the viral progression, most of these basic 
models include atleast three state variables, which include: the susceptible CD4+ 
T-cells, free HIV virions and the already infected CD4+ T-cells. For instance, 
[12], formulated and analyzed an HIV model with three state variables, that is, 
the susceptible CD4+ T-cells, the already infected CD4+ T-cells and the free HIV 
virions. The model for instance, predicts adequately the disease progression 
from the early infection stage, asymptomatic stage, to full blown-AIDs and the 
viral load at the asymptomatic stage. However, great improvement on the model 
has been done and many other advanced models developed. [13] formulated a 
mathematical model representing a complete dynamic of HIV infection. The 
model aimed at analyzing the interaction between the CD4+ T-cells, macrophage 
cells and the viral load. The results indicate that the CD4+ T-cells play a very 
vital role as far as HIV virions replication is concerned. Similarly [6] analyzed a 
three component model for HIV. The model was aimed at analyzing the HIV 
dynamics during the initial stages of infection. The results showed that viral 
persistence was very high during initial stage of HIV infection. 
Other researches have sought to study the role played by the killer T-cells in 
preventing virions replication in the body. In particular, [14] acknowledged the 
importance of the immune system in HIV infection dynamics by incorporating the 
CD8+ T-cells in HIV dynamic model. The study developed a three-dimensional 
ordinary differential equations of the untreated model. The model showed the 
interaction between the non-infected CD4+ T-cells, infected CD4+ T-cells and 
the immune response. The model had a major shortcoming for its failure to 
incorporate the HIV virions. On other hand, [9], used a five-dimensional 
nonlinear ordinary differential equations (ODEs) model in showing the 
relationship between CD4+ T-cells, virions, defense cells and ARTs. The results 
emphasized the importance of the CD8+ T-cells in fighting the HIV virions 
during acute infection. It has been established that the disease become more 
endemic due to exponential virions replication and the failure of the ARTs to 
reach all the cells. Therefore, the focus on how to reduce virions replication by 
targeting the defense cell is inevitable and it will play a big role in ensuring that 
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the endemicity of the infection is reduced.  
In this paper, we shall mainly focus on HIV dynamics at acute HIV infection 
stage without any focus on the disease progression to AIDS stage which may 
come as a result of not using ARTs. The motivation behind this simple initial 
infection model is the fact that most of the new strategies for HIV management in 
Kenya such as the pre-exposure antiviral treatment and post-exposure antiviral 
treatment targets the HIV virions at the early stages of HIV-infection. For this 
study to be successful we develop a non-linear, five-dimensional deterministic 
model for in-vivo dynamics of HIV with inclusion of the CD8+ T-cells. 
HIV Life Cycle 
HIV, like most viruses lacks the ability to replicate on its own and therefore, 
relies on a host for replication. Although, unlike all other viruses HIV is a 
retrovirus and hence carries the copies of its own RNA [2]. Once the virus gets 
in the body it mainly targets the CD4+ T cells by attaching itself on the 
membrane of the cell. After the infection of the cells by the virus, it is important 
to note that the symptoms do not show immediately until their level reduces to 
about 200 cells per mm3, and the viral load increases to 500 copies per ml [12]. 
The process of HIV replication is outlined in the following steps: First HIV 
virion joins the membrane of the CD4+ T-cell. Then it fuses with the harbour cell 
and releases an enzyme known as reverse transcriptase. Reverse transcriptase 
enzyme transform the genome of the HIV virus to a double-stranded HIV DNA 
from a single-stranded HIV RNA. The transcription process ensures that 
integration of the HIV virion into the host DNA. Once HIV is integrated in the 
cells DNA, it starts to manufacture long chains of HIV protein using their DNA. 
The HIV proteins are the support system for more HIV virions. These long 
chains of HIV proteins (immature and non-infectious) assembles closer the 
membrane of the CD4+ cells and bud out. The immature virions then release an 
enzyme called the protease, which cut the long HIV proteins RNA into smaller 
individual proteins. As the smaller HIV proteins come together with copies of 
HIV’s RNA genetic material, they form a new mature virus particle. Other cells 
can now be infected by the new HIV copies. This clearly shows that a single 
virion lead to the production of many other virions [15]. 
After infection the CD4+ T-cells sends a signal to the CD8+ T-cells. The CD8+ 
T-cells are aimed at destroying and killing the virions [9]. Unfortunately, despite 
immense effort from the mathematician in the field of mathematical modeling 
on HIV/AIDS analysis, the intervention of CD8+ T-cells need to be analyzed 
further. Although researchers suggest that CD8+ T-cells play a paramount role in 
host defense against the HIV virions nothing much has been done to show it 
especially during AIDS stage. One of the objectives of this paper is to present a 
realistic model that will analyze the importance of the CD8+ T-cells in destroying 
the HIV virions. The CD4+ T-cells play critical roles in controlling viral 
infections by prompting CD8+ T-cells to eliminate the free HIV virions. The 
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Source: HIV Basics Course for Nurses. 
Figure 1. HIV Life Cycle. 
 
HIV virus life cycle is presented in Figure 1. 
2. Mathematical Model for HIV Dynamics in-Vivo 
2.1. Introduction 
An in-host HIV dynamics model with the inclusion of the immune cells is 
formulated. We show the model is positively invariant. The basic reproduction 
number expression is derived using the next generation matrix method. We also 
do the analyses on the stability of the steady points of the model.  
2.1.1. HIV Model Formulation 
We shall put into consideration a mathematical model for the in-vivo interaction 
of the HIV virions and the immune system cells. The model is classified into five 
compartments. The following are the variables used in the model (1) the healthy 
CD4+ T-cells ( T ), the infectious HIV virions (V ), the already infected CD4+ 
T-cells ( I ), the immune cells ( Z ), that is, CD8+ T-cells and the activated 
immune cells ( aZ ).  
The healthy CD4+ T-cells are recruited at a constant rate Tλ  from the bone 
marrow and die naturally at a constant rate Tµ . The healthy CD4
+ T-cells are as 
a result of the interaction between the uninfected CD4+ T-cells and the virus at a 
rate χ . They die naturally at a rate Iµ , they are also eliminated by the activated 
CD4+ T-cells at the rate α . In addition, the infected healthy CD4+ T-cells 
produces an average of V  viral particles. The new mature virions produced 
will infect other CD4+ T-cells. The HIV virions population increases due to the 
budding of the infected CD4+ T-cells at a rate V  and die at the rate Vµ . The 
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CD8+ T-cells, are generated from the thymus at a constant rate Zλ , and die 
naturally at a constant rate Zµ . Due to the presence of the HIV virions the 
CD8+ T-cells become activated at the rate β . The activated CD8+ T-cells are 
produced from the CD8+ T-cells the in the presence of the HIV virions, at rate β  
and die naturally at rate 
aZ
µ . The interaction description can be summarized in 
Table 1 and Table 2 which represent the Variables and parameters respectively. 
We present the model diagram in Figure 2. The diagram represent visually a 
mechanisms which govern the system of differential equations for system (1).  
From Figure 2, we derive the following system of initial value non-linear 
































= − − 










                    
(1) 
 
Table 1. Variables for HIV in-vivo model. 
Variable Description 
( )T t  The concentration of the susceptible CD4+ T cells at any time t 
( )I t  The concentration of the infected CD4+ T cells at any time t 
( )V t  The concentration of infectious HIV virions at any time t 
( )Z t  The concentration of the CD8+ T-cells at any time t 
( )aZ t  The population of the activated CD8+ T-cells at any time t 
 
Table 2. Parameters for HIV in-vivo model.  
Parameter Description 
Tλ  The recruitment rate of the susceptible CD4+ T-cells per unit time. 
Tµ  The decay rate of the susceptible CD4+ T-cells. 
χ  The infection rate of the CD4+ T-cells by the virus. 
Iµ  The natural death rate of the infected CD4+ T-cells. 
V  The HIV virions generation rate from the infected CD4+ T-cells. 
Vµ  The death rate of the infectious virus. 
α  The rate at which the infected cells are eliminated by the activated CD8+ T-cells. 
Zλ  The recruitment rate of the CD8+ T-cells per unit time. 
Zµ  The death rate of the CD8+ T-cells. 
β  The activation rate of the CD8+ T-cells due to the presence the infected CD4+ T-cells. 
aZ
µ  The decay rate at of the activated defence cells decay per unit time. 
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Figure 2. A compartmental representation of the in-vivo HIV Dynamics. 
3. Basic Properties of the Model 
Before commencing the steady-states analysis of the model (1), it is important to 
look at some properties to ensure existence of biologically meaningful solutions. 
3.1. Boundedness and the Positivity of the Model Solutions 
Before we analyze the model (1) it is paramount to prove that the key variables 
are non-negative implying that the model solutions will be positive for all 0t >  
and must be bounded for all 0t >  in an invariant region. Invariant region is the 
area in which the model is well posed mathematically and has biological meaning. 
Theorem 1. Let the initial values of the state variables be ( )0 0T ≥ , ( )0 0V ≥ , 
( )0 0I ≥ , ( )0 0Z ≥ , ( )0 0aZ ≥ . Then show that, for every 0t >  the solution 
set ( ) ( ) ( ) ( ) ( ){ }, , , ,T t V t I t Z t Za tΓ =  of the model (1) is non-negative and Γ  
is the invariant region.  
Proof. Taking the first part of Equation (1) we have,  
( )













≥                      
(2) 
Hence T is non-negative for all 0t > . 
Similarly for the infected CD4+ T-cells we have,  
( )d
d I a I a
I TV I IZ Z I
t
χ µ α µ α= − − ≥ − −
              
(3) 
By integration and separation of variables Equation (3) gives,  
( ) ( )d0 e I aZ tI I µ α− +∫≥                        (4) 
Hence I is non-negative for all 0t > . 
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Similarly for the HIV virions we have,  
d
d V I V V
V I V
t
µ µ µ= − ≥ −
                    
(5) 
By integration and separation variables Equation (3) gives,  
( ) ( )d0 e V tV V µ−∫≥  
Hence V is non-negative for all 0t > . 













λ µ β µ β
µ β
= − − ≥ − +
≥ − +
               
(6) 
We separate variables and integrate both sides with respect to the 
corresponding variables as follow,  
( ) ( )d0 e Z I tZ Z µ β− +∫≥                        (7) 
Hence Z is non-negative for all 0t > . 



















= − ≥ −
≥ −
                  
(8) 
By integration and separation of variables we get;  
( ) ( )d0 e za ta aZ Z µ−∫≥                        (9) 
Hence aZ  is non-negative for all 0t > .                             
3.2. Invariant Region 
Notably, all the state variables of system (1) have been proved to be non-negative. 
In addition, parameters of model (1) monitors cell population, hence they are 
also non-negative for all, 0t > . Consequently the model (1) analysis is done in 
the region Γ  that is biologically meaningful.  
Theorem 2. Let ( ) 0T t ≥ , ( ) 0V t ≥ , ( ) 0I t ≥ , ( ) 0Z t ≥ , ( ) 0aZ t ≥ . Then 
the solutions of ( )T t , ( )V t , ( )I t , ( )Z t , ( )aZ t  are bounded and the region 
Γ  is positively invariant for all 0t ≥ .  
( ) ( ) ( ) ( ) ( )( ) 5 0, , , , , , , V I TT Za a
T Z T V
T t I t V t Z t Z t T I Z Z V Vε µ λλ λ
µ µ µ µ
 
Γ = ∈ + ≤ + ≤ ≤ + 
 
 (10) 
Proof. The total population of the CD4+ T-cells, ( )4T I N t+ = , is clearly 
non-constant value. Hence the evolution equation representing the change in the 
population of the CD4+ T-cells is;  
( )

















λ µ µ α
λ µ
= − − −
≤ −
                
(11) 
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By separation of variables method for solving differential inequality, Equation 
























                 
(12) 









                  
(13) 
But  
0T TC Nλ µ= −                        (14) 
Therefore, Equation (12) becomes;  









                 
(15) 
Thus at any time 0t >  we have;  
( )4 0max , T
T




                      
(16) 
Hence, all feasible solutions set for the CD4+ T-cells of the model (1) enters 
the region:  
( ) ( )( ) 2 4 0, , max , TT
T
T t I t N N λ
µ
   Γ = ∈ ≤  
   

           
(17) 
Similarly the total number of the CD8+ T-cells, ( )8aZ Z N t+ = , at disease 
free equilibrium are given by;  







                    
(18) 
By separation of variables method for solving differential inequality Equation 












−                       
(19) 
Integrating Equation (19) we have  









                
(20) 
Thus at any time 0t >  we have;  
( )8 0max , Z
Z




                      
(21) 
Hence, all feasible solutions set for the CD8+ T-cells of the model (1) enters 
the region;  
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( ) ( )( ) ( )2 8 0, , max , ZZ a
Z
Z t Z t N t N c λ
µ
   Γ = ∈ ≤  
   

         
(22) 
Considering the V  population of the model (1) we have’  












              
(23) 



















                     
(24) 
Hence V  is bounded. Consequently the feasible solution for the model (1) is;  
( ) ( ) ( ) ( ) ( )( ) 5 0, , , , , , , V I TT Za a
T Z T V
T t V t I t Z t Z t T I Z Z V Vε µ λλ λ
µ µ µ µ
 
Γ = ∈ + ≤ + ≤ ≤ + 
 
 (25) 
All the state variables are positive and bounded. Consequently, from Equation 
(25), Γ  is positively invariant of model (1). Hence, it is possible to study the 
dynamics of the HIV model (1) in Γ .                                 
With theorem 2 we conclude that the model is valid and will remain so during 
the whole course of study if and only if the initial data are biologically meaningful. 
In addition it is evident that with time the number of virions will reduce to non- 
detectable level.  
Remark 1. Suppose ( ) ( ) ( ) ( ) ( )0 , 0 , 0 , 0 , 0 0aT I V Z Z >  be given. Then there 
exist a differentiable continuous function , , , , : 0,a fT I V Z Z T    R  such that 
( ), , , , aT I V Z Z  is bounded and  
( )( ) ( ) ( ) ( ) ( ) ( )( ), , , , 0 0 , 0 , 0 , 0 , 0a aT I V Z Z T I V Z Z= .  
Therefore, the model solutions will always be positive if the initial values for 
the state variables are non-negative for all 0t >  in the closed interval 0, fT   . 
4. Equilibria and Reproductive Number 
For us to fully understand the dynamics of the five component HIV model we 
study its stability. In this model there exist two critical points. The critical points 
represent the case before the virions get to the body, that is virions-free 
equilibrium point that is, 0aV I Z= = = , and when the virus persist in the body, 
that is, 0, 0V I≠ ≠  and 0aZ ≠ . 
Before infection by HIV virions, the model as represented by Equation (1), has a 
unique feasible HIV-free steady state solution to be referred to as the virions-free 
equilibrium (VFE). The virions-free equilibrium of the model (1) is given by:  
( )0 , , , , ,0,0, ,0T Za
T Z




                 
(26) 
4.1. Basic Reproductive Number 
Researchers in the field of in-vivo HIV modelling aims at finding the optimal 
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conditions that determine the spread of the HIV virions in the susceptible CD4+ 
T-cells. In order to do this, researchers consider the basic reproductive number 
( 0R ). According to [16], the basic reproductive number represent the number of 
secondary infection that result from single infected T-cell. 0R  measures the 
potential of HIV spread in the host and probably attacking a large number of the 
T-cells. The 0R  obtained for the virions-free equilibrium by the next 
generation matrix guarantee local stability of the model (1). 0R  is used in 
stability analysis of the critical points. If 0 1R <  the virions-free equilibrium is 
locally asymptotically stable and if 0 1R >  it is said to be unstable. Notably, a 
large value of 0R  indicates disease epidemic. Consequently, in order to control 
viral replication it is important to ensure that 00 1R< < .  
Computation of R0 
In this paper we shall adopt the next generation matrix method for the 
derivation of 0R  [16]. Mathematically, 0R  is given by ( )10R FVρ −=  where 
ρ  is the spectral radius of the next generation matrix [17] and F  is the 
matrix of the infections while V  is the transfer of individuals out of 
compartment [18]. The expression of 0R  is the dominant eigenvalue of the 
next generation matrix. In model (1) we have two infection classes, therefore, the 








 =  
                           
(27) 
The matrix that represent the transfer between compartments at the 







=  −                        
(28) 

















                        
(29) 




V T T VFV
χε λ χλ
µ µ µ µ−
 
 =  
                      
(30) 




 and 0, therefore, the 







                        
(31) 
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Figure 3. Basic Reproductive number increases with the infection rate. 
 
Figure 3 illustrates how 0R  is affected by the change of χ .  
Increasing the infection rate would lead to a rise in the number of secondary 
infection this is clearly depicted from the reproductive number given in 
Equation (31). The only way of reducing this is by introducing ARTs that target 
the HIV lifecycle at the entry level of the HIV virions to the CD4+ T-cells, that is, 
during fusion stage and hence the recommended drugs are the Fusion Inhibitors. 
Similarly, increasing the rate at which free HIV virions are generated from the 
infected cells would lead to an increase in the reproductive number. This means 
that it is paramount to bring in treatment at the budding level or to introduce 
ARTs drugs that would help in ensuring that the HIV virions generated from the 
infected CD4+ T-cells are defective and non-infectious. The ARTs that can play 
that role are the protease inhibitors. The protease inhibitors (PIs) inhibits the 
release of the viral protease enzyme that ensures the maturity of HIV virions 
upon budding from the host membrane. Consequently, the virions produced by 
the infected cells after the introduction of PIs are defective and non-infectious 
[19]. Conversely, if the rate at which the virus dies increases the rate of 
secondary infection would be at the minimum level. The HIV virions can die 
naturally or triggered by the CD8+ T-cells. According to [9], the CD8+ T-cells 
seek, destroy, and kill the cells infected by the HIV virions. This means that if 
the CD8+ T-cells are able to fight the virions by killing the infected CD+ T-cells 
the number of secondary infection would reduce and eventually the virions 
maybe eliminated from the body. This shows that during the initial HIV 
infection stage CD8+ T-cells are very important as far as fighting and reducing 
HIV virions replication is concerned. The most fundamental thing would for 
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researcher to establish what happens to CD8+ T-cells at the chronic level. Do 
they still fight the virus? Or probably are the CD4+ T-cells so worn out that they 
are not able to alert the CD8+ T-cells? 
4.2. Local Stability of the Virions-Free Equilibrium (VFE) 
Theorem 3. The virions-free equilibrium 0E  of the model (1) is locally 
asymptotically stable if 0 1R <  and unstable if 0 1R >   
Proof. In this study we have a non-linear differential equations model hence 
we shall use linearization method by [20] to study and prove the local stability of 
the virions-free equilibrium. The Jacobian matrix of the DFE for the model (1) is 

























−                
(32) 







































           
(33) 
The characteristic equation in Λ  for Equation (33) is given by  
5 4 3 2
4 3 2 1 0 0b b b b bΛ − Λ − Λ − Λ − Λ + =               (34) 
where, 
4 Za Z V I Tb µ µ µ µ µ= − − + − +  
3
T
V I T Za T Z T I T V Za Z
T
Za I Za V Z I Z V I V
b λχ ε µ λ µ λ µ λ µ λ µ µ µ
µ
µ µ µ µ µ µ µ µ µ µ
= − − − − −




T V I Za V I Z V I T Za Z
T T T
T Za I T Za V T Z I T Z V T I V
Za Z I Za Z V Za I V Z I V
b λ λ λλ χ ε µ χ µ ε µ µ ε µ χ λ µ µ
µ µ µ
λ µ µ λ µ µ λ µ µ λ µ µ λ µ µ
µ µ µ µ µ µ µ µ µ µ µ µ
= + + −
− − − − −




T Za V I T Z V I Za Z V I T Za Z I
T T T
T Za Z V T Za I V T Z I V Za Z I V
b Tλ λ λλ µ ε µ χ λ µ ε µ χ µ µ ε µ χ λ µ µ µ
µ µ µ
λ µ µ µ λ µ µ µ λ µ µ µ µ µ µ µ
= + + +
− − − −
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The eigenvalues for the Jacobian matrix are given by; 1 TµΛ = − , 2 ZµΛ = − , 
3 ZaµΛ = − , 




I T V T T I T V I T I T V T V
T
µ µ µ µ χλ µ µ ε µ µ µ µ µ µ µ
µ
− − + + − +
Λ = , 




I T V T T I T V I T I T V T V
T
µ µ µ µ χλ µ µ ε µ µ µ µ µ µ µ
µ
+ + + − +
Λ = −  
It is evident that 1Λ , 2Λ , 3Λ  and 5Λ . However we need to determine the 
conditions that would guarantee that 4Λ  is also negative, since for local 
stability all the eigenvalues must be negative. 
Suppose 4 0Λ < , we have:  
( )
2 2 2 2 2





I T V T T I T V I T I T V T V
T
I T V T T I T V I T I T V T V
V T T V
µ µ µ µ χλ µ µ ε µ µ µ µ µ µ µ
µ
µ µ µ µ χλ µ µ ε µ µ µ µ µ µ µ
µ µ χλ ε
− − + + − +
<
+ > + − +
>     
(35) 






                         
(36) 





= < . Thus, the virions-free equilibrium 
is locally asymptotically stable.                                        
4.3. The Endemic Equilibrium 
To analyze the endemic equilibrium, this study adopt the assumption made by 
[14] that the free virus spread of infection and there is no cell-to-cell transfer of 
the HIV virions. The endemic equilibrium 1E  exist when, ( ) 0T t > , ( ) 0I t > , 
( ) 0V t > , ( ) 0Z t > , ( ) 0aZ t > . An endemic equilibrium ( )* * * * *1 , , , , aE T I V Z Z= , 
satisfies;  
* * * *


























− − = 
− = 
− − = 
− = 

                  
(37) 
Hence, the endemic equilibria of the model (1) correspond to the non-negative 
solutions of the Equation (37). Therefore, we solve the system (37) in terms of 
*
aZ  and obtain the endemic equilibrium as;  
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(38) 
We then obtain the following cubic polynomial that describes the existence of 
the possible equilibria.  
( ) ( )* * *2 *2 1 0 0,a a a ap Z Z Z Z= Φ +Φ +Φ =                (39) 
where,  
( )









Za Z Za I Z
Za Z T I Za I Z T T I Za Z
Za Z T V
R
R R
βµ µ µ µ αλ
µ µ µ µ µ µ µ βλ λ β µ µ αλ
µ µ µ µ
Φ = − +
 Φ = − − − +  

Φ = −      
(40) 
We re-write Equation (40) to ensure that 2 0Φ >  as;  
( )









Za Z Za I Z
Za Z T I Za I Z T T I Za Z
Za Z T V
R
R R
βµ µ µ µ αλ
µ µ µ µ µ µ µ βλ λ β µ µ αλ
µ µ µ µ
Φ = +
 Φ = − − + +  

Φ = −      
(41) 
From Equation (39), if * 0aZ = , then we have disease-free equilibrium treated 
earlier in Equation (26). The solution to the following equation defines the 
existence of the possible endemic equilibrium.  
*2 *
2 1 0 0,a aZ ZΦ +Φ +Φ =                     (42) 
The two roots of the quadratic Equation (42) is given by;  
2





−Φ ± Φ − Φ Φ
=
Φ                    
(43) 
Consequently, depending on the signs of 2 1,Φ Φ  and 0Φ  the model (1) 
may have unique, two or no positive roots. We now analyze the three scenarios 
as follows. 
Case 1: 























Φ                       
(45) 
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 represent a unique 
positive equilibrium point. This is the critical equilibrium point.  
Case 2: 
If 0 1R >  then 0 1 20, 0, 0Φ > Φ < Φ >  and using the signs rule Descartes, the 
sign of the coefficients of the quadratic Equation (39) changes once. So there is a 
unique positive equilibrium point, *1 0aZ > . Consequently, there exist at least 
one endemic equilibrium point. 
Case 3: 
If 0 1R <  then 0 10, 0Φ > Φ <  and using the signs rule by Descartes, the sign 
of the coefficients of the quadratic Equation (31) changes twice. So there are two 
unique positive equilibria point. Consequently, aZ
∗  has two positive endemic 
turning points, implying that at 0 1R <  there is a possibility for the model to 
exhibit backward bifurcation. So the existence of the threshold cR  is assumed 
in the result. 
4.4. Bifurcation Analysis of the Endemic Equilibria 
Backward bifurcation plays a fundamental role in controlling and eradicating 
diseases. Backward bifurcation occurs in models that have multiple equilibria 
when 0 1R < . Consequently, having 0 1R <  is important but not a sufficient 
indicator for the control and elimination of the infection [21]. Therefore, there is 
need to reduce the basic reproductive to avoid endemic states and in turn 
guarantee viral elimination [22]. Various researchers [23], [24] have established 
that HIV dynamics models exhibit backward bifurcation phenomenon where the 
stable virions-free equilibrium co-exist with an endemic equilibrium, for 0 1R < . 
This section focuses on bifurcations of the model in order to analyze the stability 
of the endemic equilibrium point. In many epidemic models, the virions-free 
equilibrium loses the stability when 0 1R > , which results in a bifurcation. From 
the model (1) we have critical 0R  denoted by cR  as;  
( )
( )
T Za I Z
c
Za I Z I T
R
βλ µ µ αλ
µ µ µ µ βλ
+
=
−                    
(46) 
If 1cR >  in Equation (46) then we have a forward bifurcation and if 1cR <  
then the model exhibit backward bifurcation. It is important to note that 
existence of a backward bifurcation with endemic equilibrium when 1cR <  is 
very important in epidemiological applications. Notably, it has very important 
consequences in the strategies and control policies designed for HIV viral 
eradication. From the epidemiological point of view reducing 0R  below unity is 
no longer a guarantee that the HIV virions will be eliminated completely or 
reduced to non-detectable level. In addition, this affects HIV virus control since 
the disease progresses even when 0 1R < . Furthermore, existence of backward 
bifurcation may result to a model that is globally unstable. From Equation (46) 
backward bifurcation is only possible if the rate Iµ  at which the infected CD4
+ 
T-cells dies increases. From model (1) the infected cells may either die naturally 
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or they can be destroyed and killed by the activated CD8+ T-cells. Another 
parameter of interest as far as backward bifurcation is concerned is the β , the 
rate at which the CD8+ T-cells are activated. Reducing β  would lead to 
backward bifurcation. Biologically, bi-stability may lead to unexpected adverse 
consequences for ARTs and backward bifurcation may provide an explanation 
for several phenomena observed clinically among HIV patients.  
Epidemiological Implication of Backward Bifurcation 
It is paramount to carry out a deep discussion under epidemiological point of 
view. From the results it is evident that the bifurcation depends mainly on 
immunity of the infected person and Treatment, that is, efficacy of the ARTs. 
Use of ARTs as a way of managing an HIV persons may help in reducing the 
transmission rate. However, this may only be possible if the person adhere to the 
drugs. In the model the transmission rate is presented by χ . For the immunity 
of the infected person it is important to analyze the role played by the CD8+ 
T-cells. From (46) it can be seen clearly the immune cells plays a very vital role. 
Therefore, it is fundamental, for HIV eradication, to find ways in which the 
immunity of the infected person may be boosted. This may be done through 
proper diet or through use of prescribed medication. Thus it is very important to 
education people living with HIV/AIDS (PLWHAs) on proper nutrition and the 
availability on the drugs to boost the immunity. 
From the point of HIV virions eradication public policy makers must work to 
ensure information education material (IEC) are available in all public places. 
They must also ensure that the drugs are accessible and available. This may play 
a major role in ensuring that the backward bifurcation scenario are avoided. 
In summary if the backward bifurcation cannot be avoided, public policy 
makers have to particularly be careful since having 0 1R <  does not guarantee 
that the viral load may get to non-detectable level, the disease might eventually 
progress to AIDS. However, from the numerical values used in model (1) 
results to a forward bifurcation as shown in the Figure 4 From an 
epidemiological point of view, forward bifurcations means that when 0 1R <  
small perturbations from 0E  are unable to generate an endemic disease.in 
addition, when 0 1R > , such small perturbations move the system (1) away 
from VFE the epidemic outbreak takes place and the disease might stabilize in 
an endemic state.  
Remark 2. The existence of a backward bifurcation shows that even if 0 1R <  
by some control measures, HIV may still persist. The control of HIV becomes 
more difficult. 
4.5. Global Stability of the Virions-Free Equilibrium 
Using the approach of [25] we investigate the global stability of the virions-free 
equilibrium for the model (1). Using this approach we list two conditions that if 
met will guarantee the global asymptotic stability of the virions-free equilibrium.  
Theorem 4. Suppose we can express model (1) as;  
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(47) 
such that,  
( ),0 0G X =                          (48) 
where the column vector components of MX R∈  denote the uninfected 
population and the components of nW R∈  denote the infected population. Let 
( )*0 ,0E X=  be the virions-free equilibrium for the system. 
Then ( )*0 ,0E X=  is globally asymptotically stable if and only if: 
1) The 0 1R < , that is, locally asymptotically stable. 




= , *X  is globally asymptotically stable. 
3) ( ) ( ) ( )ˆ ˆ, , , , 0G X W PG G X W G X W= − ≥  for ( ), HX Z ∈Ω . 
where ( )*,0WP D G X=  represents an M-matrix (the off diagonal elements of P 
are non negative) and HΩ  is the feasible reqion for the model.  
If model (1) satisfies the conditions mentioned above then the fixed point 
( )*0 ,0E X=  is a globally asymptotic stable equilibrium of model system (1) 
provided that 0 cR R< . For model (1) the result is stated and proved in Theorem 
5. 
Theorem 5. The virions-free equilibrium point ( )*0 ,0E X=  is a globally 
asymptotically stable equilibrium of system (1) provided that 0 cR R<  and the 
conditions (2) and (3) of Theorem 4 are satisfied.  
Proof. From the system (1) we let ( ), , aX T Z Z=  and ( ),W I V= , then we 
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(52) 
Since 0aZ Iα ≥  then, ( )ˆ , 0G X W ≥ . In addition, the matrix P  is an 
M-Matrix since all its off-diagonal elements are non-negative. This therefore, 
proves the global stability of the virions-free Equilibrium ( )0E . That is,  












= . Consequently, by Theorem 5, the disease free equilibrium of the 
model (1) is globally asymptomatically stable.                            
Theorem 5 implies that when 0 cR R<  a small influx of free HIV virions into 
the body cells, will not lead to AIDS. The subsequent numbers of those infected 
cells will be less than that of their predecessors and eventually the disease maybe 
reduced to non-detectable level. 
5. Numerical Analysis 
In order to observe the variables on the HIV model given in Equation (1) over a 
period of time, the study applied Matlab programming language. The initial 
values of the model were set as; 0 1000T = , 0 10I = , 0 1V = , 0 500Z = , 
0 10aZ = . This section is aimed at investigating numerically the behaviour of 
each compartment on the onset of infection without any medical treatment. The 
values for the parameter are described in Table 3.  
Discussion 
Figure 5 shows that at initial infection stage the level of the susceptible CD4+ 
T-cells reduces for the first three months and later the body immunity stabilizes 
and the number of the susceptible CD4+ T-cells increases. However, it fails to go 
back to the pre-infection stage. Clinicians have established that the depletion of 
CD4+ T-cells is a indication of HIV infection. Clinicians have established that 
the first few weeks after infection the virus is characterized by inflammatory 
response including extreme flu like symptoms such as swollen nodes, fever, sore  
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Table 3. Parameters for in-vivo HIV model. 
Parameters Description Value Source 
Tλ  The recruitment rate of non-infected CD4+ T-cells produced per unit time 10 cell/mm3/day [26] 
Tµ  The rate at which the non-infected CD4+ T-cells decay 0.01 day−1 [27] 




Iµ  The death rate of the infected CD4+T-cells 0.5 day−1 [28] 
Vε  The rate in which HIV virions are generated from the infected CD4+T-cells 100 vir. cell−1 day−1 [2] 
Vµ  The death rate of the infectious virus 3 day−1 [2]. 
α  The rate at which the infected cells are eliminated by the activated CD8+T-cells 0.02 day−1 [9] 
Zλ  The rate at which the CD8+ T-cells are produced per unit time 20 cell/mm3/day [9] 
Zµ  The death rate of the CD8+ T-cells 0.06 day−1 [9] 
β  The rate at which the CD8+ T-cells are activated by the presence of the virus and the infected CD4+ T-cells 0.004 day−1 [9] 
aZ
µ  The rate at which the activated defence cells decay 0.004 day−1 [9] 
 
 
Figure 5. A Figure showing the number of the susceptible CD4+ T-cells with change. 
 
throat, rashes, muscles and joint pains and headache. This takes place up to the 
forth week. In this phase the natural immune response changes to “allergy-like” 
immune response replica of a mild anaphylactic reaction. Due to these changes 
the viral replication is high, infection of the CD4+ T-cells is high and the 
activation of the CD8+ T-cells and B-lymphocytes rises. As a result, the amount 
of CD4+ T-cells falls very drastically. Later, due to the immune response, new 
CD4+ T-cells are generated rapidly by the thymus to replace the already infected 
P. M. Ngina et al. 
 
 
DOI: 10.4236/am.2017.88087 1173 Applied Mathematics 
 
ones and hence their level rise again as depicted by the Figure 5. 
In Figure 6, the person has just been infected with HIV virions, the acute 
infection takes place two to four weeks later. At this time, when the HIV virions 
infect a few number of the susceptible CD4+ T-cells, replications take place and 
new HIV virions are produced. The high number of infectious virions attaches 
themselves to the membrane of the CD4+ T-cells infecting them. The cycle 
continues and more virions are produced hence more CD4+ T-cells are infected. 
This explains why the number of the infected CD4+ T-cells increases rapidly for 
the first 2 months as depicted by the Figure 6. Meanwhile at this stage the body 
is relaying on the natural immune response while waiting for the CD4+ T-cells 
Adaptive Immune response. Consequently, the adaptive immune response sets 
in and kill most of the infected CD4+ T-cells causing a drastic fall on the number 
of infected CD4+ T-cells to almost nil as depicted in the Figure 6. Unfortunately, 
a few mutants develop. The new mutants start infecting the uninfected CD4+ 
T-cells. As a result to this the infected CD4+ T-cells count rises but at a slower 
rate. After 300 days the level start to rise again. 
Figure 7 shows that at early HIV infection stage the level of the HIV virions 
reduces to almost zero during. This is the phase in which the virions attaches 
themselves to the membrane of the CD4+ T-cells. However, after about three 
days the infected CD4+ T-cells burst releasing infectious HIV virus. This explain 
why at acute stage of infection, large number of HIV virions are produced in the  
 
 
Figure 6. A Figure showing the population of the infected CD4+T-cells with respect to 
time. 
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Figure 7. A Figure showing the number of the HIV virions with respect to time. 
 
patients body. With time the HIV virions continue to replicate and infecting 
more CD4+ T-cells. This explains the decline on the level of the susceptible CD4+ 
T-cells as depicted in Figure 5. However, after the immune response sets in it 
destroys the infected cells, suppresses viral replication and inhibits more 
production of the infectious virus since the cells available for infection are 
decimated. Furthermore, comparing Figure 5 and Figure 7 the number of HIV 
virions reduces as the number of the susceptible CD4+ T-cells this is contrarily to 
the work done by [29]. Their study, which has been criticized by many 
researches, established that the fall of the viral load was due to a decline in the 
target cells (CD4+ T-cells), a process called target cell limitation. Consequently, 
due to the incerase on the number of the infected CD4+ T-cells, a signal is sent to 
the CD8+ T-cell and consequently the cells are activated to kill the infected cells. 
This helps in reducing the level of the viral load in the body. The number of the 
CD4+ T-cells count begins to increase during this point, though it may never 
return to the pre-infection levels. It may be paramount for the patient to begin 
ARTs during this stage. The virus level cannot reduce to non-detectable level 
since it is very difficult to control the HIV virions free in circulation when not 
attached to the CD4+ T-cells. 
In Figure 8 we monitor the change in the number of CD8+ T-cells during 
initial infection stage. From Figure 8 the level of CD8+ T-cells reduces during for 
the first three months. This may be due to the fact that a big number of the CD8+ 
T-cells die within few weeks, leaving a reservoir of CD8+ memory T-cells which  
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Figure 8. A Figure showing the number of CD8+ T-cells with respect to time. 
 
are HIV-specific which persist, irrespective of the presence of antigen or CD4+ 
T-cells. In addition, many of the cells get activated to fight the virus. However, 
after three months the number increases gradually, this is because of the 
reduction of the viral load and the infected CD4+ T-cells.  
In Figure 9, we monitor the number of the activated CD8+ T-cells. The 
number of the activated cells rises after the first 3 days. This correspond to the 
time in which the infected CD4+ T-cells start to increase. Most of the cells are 
activated to kill the infected T-cells and consequently control the viral replication. 
According to [30] CD4+ T-cells plays an important role in the initiation and 
persistence of CD8+ T-cells responses. The CD8+ T-cell activation can lead to a 
number of immune responses such as antibody production, activation of 
phagocytic cells and direct cell killing. Therefore, the best immune response for 
different types of diseases is implemented by natural mechanism. CD8+ T-cells 
have been shown to express CD4+ T-cells receptors on their surface after 
activation through the T-cell receptor, allowing infection by HIV. Some 
researchers such as [28] suggest this is a mechanism through which CD8+ T-cells 
get destroyed late in infection. From Figure 9 it is evident that during infection 
most of the CD8+T-cells get activated to fight the virus. This explain the 
exponential rise. 
6. Conclusion 
In this paper, we have presented an in-vivo HIV dynamics model with inclusion  
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Figure 9. A Figure showing the number of the activated CD8+ T-cells with respect to 
time. 
 
of the CD8+ T-cells. We first showed that the key variables of the model were 
non-negative and bounded to ensure that it is biologically relevant. We have 
computed the expression for the basic reproductive number 0R  and the 
equilibria of the model. It is evident that the rate of infection greatly influences 
the basic reproductive number. The mathematical analysis of the model showed 
the existence of virions-free equilibrium. In addition, the system exhibits 
backward and trans-critical bifurcation under some restriction on parameters. 
This shows that having 0 1R <  is not enough to eradicate the HIV-virions to 
non-detectable level. Numerical analysis were done to give more insight 
regarding the model. The results clearly show the introduction of HIV virions in 
the body without the use of ARTs does not mean that the disease is likely to 
persist in the body. The body have a way of reducing the HIV virions to very low 
level after three months of infection. This is in agreement with the biological 
mechanism of the HIV-cells interaction. However, as much as it is so in this 
study, the parameters were not varied; this means that the behavior might 
slightly be different between individuals. Furthermore, the simulations for the 
model have showed the importannce of the CD8+ T-cells in fighting the HIV 
virions. At the primary phase of HIV infection, there is an increase in the level 
viral load and a reduction in the population of the CD4+ T-cells, which reduces 
after three months due to the presence of the killer cells. However, as much as 
this study has only established the role played by the immune cells at the acute 
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infection other researches such as [31] has shown that patients who fail to 
develop HIV/AIDS after 15 years or longer have significantly higher levels of 
immune cells compared to a normal HIV-infected patients. Therefore, it is 
fundamental to maintain a high population of the immune cells which in turn 
will lead to low level of the viral load. In addition, due to the high increase of the 
virions during the first three months it is important to introduce ARTs to 
prevent HIV transmission. This will help in the reduction of new infection.  
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The in vivo dynamics of HIV infection, the infection mechanism, the cell types infected, and the role played by the cytotoxic cells
are poorly understood. This paper uses mathematical modelling as a tool to investigate and analyze the immune system dynamics
in the presence of HIV infection. We formulate a six-dimensional model of nonlinear ordinary differential equations derived from
known biological interaction mechanisms between the immune cells and the HIV virions. The existence and uniqueness as well
as positivity and boundedness of the solutions to the differential equations are proved. Furthermore, the disease-free reproduction
number is derived and the local asymptotic stability of the model investigated. In addition, numerical analysis is carried out to
illustrate the importance of having 𝑅0 < 1. Lastly, the biological dynamics of HIV in vivo infection are graphically represented.The
results indicate that, at acute infection, the cytotoxic T-cells play a paramount role in reducingHIV viral replication. In addition, the
results emphasize the importance of developing controls, interventions, and management policies that when implemented would
lead to viral suppression during acute infection.
1. Introduction
For the last three decades Human Immunodeficiency Virus
(HIV) has been a big challenge in the whole world though
its impact is mostly felt in Sub-Saharan Africa. Over 36
million people have been infected since early 1980s and over
25 million of died [1]. Due to the high mortality associated
with the virus, HIV has become a major problem for human
Health. Many researchers [2–5] have sought to analyze the
infectionmechanism of the virus. It has been found that HIV
targets and infects CD4+ T-cells. This is because CD4+ T-
cells have a protein on its surface that can bind to foreign
substances such as HIV, that is, through exploitation of the
CCR5 and CXCR4 coreceptors expressed on their surfaces.
Once inside the CD4+ T-cells, the HIV, which is a retrovirus,
is converted toDNA.The virus thenmultiplies inside the cells
that burst releasingmoremature virions.This in turn triggers
the thymus to produce more CD4+ T-cells. Consequently,
more HIV virions are produced. Hence, the major hallmarks
of HIV infection include the destruction of helper CD4+ T
lymphocytes and subsequent loss of immune competence.
HIV virions in particular weakens the cell function by
damaging the helper cells necessary in building a robust
immune response. Depletion of the CD4+ T-cells results in
a weakened immune system [6].
During the initial infection stage, high level of viral
replication takes place lasting for about three to six weeks
upon infection [3]. This period is followed by the asymp-
tomatic stage which is characterized by high level of immune
response; this helps in stabilizing the viral load in the infected
person. This stage lasts for several years and varies from
patient to patient. It is important to note that during this
period the infected person shows no sign of the infection.
However, if not treated the virus may progress to disease/
symptomatic/AIDS stage. This is when the body is prone
to many opportunistic infections. It is characterized by a
decrease in the number of CD4+ T-cells and an increase in
the viral load. In addition, within-host virus genetic diversity
decreases [7, 8].
Mathematicians in the field of epidemiological mod-
elling have developed models to analyze the HIV infection
mechanism in vivo. These models have provided important
insights into diseases behaviors and how best it could be
controlled. To date, mathematical modelling has become
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a paramount tool, in understanding the dynamics of HIV
and in decision making processes regarding intervention
programmes for controlling and managing the virus in
many countries. Arruda et al. [9] proposed and analyzed a
five-dimensional model for HIV infection in vivo with the
inclusion of the CD8+ T-cells. As much as the study included
the activation process in the in vivo model the argument
that the CD8+ T-cells kills the virus directly is clinically
wrong. Hattaf and Yousfi [10] analyzed an in vivoHIVmodel.
However, the model only included the CD4+ T-cells and
the virus and omitted the infected CD4+ T-cells. Ogunlaran
and Oukouomi Noutchie [11] analyzed a three-dimensional
model, which included the CD4+ T-cells, the infected CD4+
T-cells, and the HIV virions. This study was more interested
in establishing how to maximize the number of the infected
cells after introduction of ARTs. Nonetheless, the study failed
to put in account the role played by the CD8+ T-cells in
fighting the virions. Omission of such important variables in
the model paints the wrong picture of the disease dynamics.
The question of the role played by one’s immune system could
not be answered by such a model.
Zarei et al. [12] developed a five-dimensional in vivo
HIV model. The study included concentration of healthy
CD4+ T-cells, concentration of infected CD4+ T-cells, and
cytotoxic T-cells which were divided into precursors CTLp
and effectors and the free virus particles. This study assumed
that cytotoxic T lymphocyte (CTL) response depends on
CD4+ T-cell help and that HIV virions impairs T-helper
cell function. Consequently, the proliferation of the CTLp
population is proportional to both infected cells in the body
and the number of uninfected T-helper cells. The simulated
results indicated the importance of the CTL cells in the HIV
model.The study had some few shortcomings since it failed to
account for the resistant and the wild type CD4+ T-cells. The
rate inwhich the two types of the CD4+ T-cells are infected by
the HIV virions is quite different, hence the need to include
them in the model.
Zhuang and Zhu [13] analyzed a three-dimensional in-
host HIV model. As much as this model was so basic since
it had only three compartments it brought out important
insight as far as HIV dynamics are concerned. The time lag
from infection of the CD4+ T-cells to the cells becoming
actively infected was included in the model. The considera-
tion of such a parameter is very important in HIV research.
The study established the global existence of bifurcating peri-
odic solutions with the assistance of global Hopf bifurcation
theory. The numerical results in the study indicated that the
latent period plays an important role in the disease spread and
the disease may be controlled by shortening it.
Ngina et al. [3] analyzed a five-dimensional in-host
model.The results from the study established the importance
of the CD8+ T-cells in controlling HIV viral progression.
The stability analysis of the model indicated the presence of
backward bifurcation implying that having 𝑅0 < 1 does not
guarantee eradication of the virus in the body.
This study wishes to improve the research by Ngina et al.
[3] by introducing the wild type and and the resistant CD4+
T-cells. The study will also be aimed at addressing the gaps
noted from the cited literature.
2. Model Description
We shall put into consideration a mathematical model for
the in vivo interaction of the HIV virions and the immune
system cells. The model is classified into six compartments.
The following are the variables used in the model: the wild
type healthy CD4+ T-cells (𝑇𝑤); resistant type healthy CD4+
T-cells (𝑇𝑟); the infectiousHIV virus particles (𝑉); the already
infected CD4+ T-cells (𝐼); and the cytotoxic T-cells (CTL),
that is, CD8+ T-cells (𝑍) and the activated cytotoxic T-cells
(𝑍𝑎).
The wild type healthy CD4+ T-cells are recruited at a
constant rate 𝜆𝑇𝑤 from the thymus and die naturally at a
constant rate 𝜇𝑇𝑤 . These cells are infected by the virus at
the rate 𝜒𝑤𝑇𝑤𝑉. The resistant type healthy CD4+ T-cells are
recruited from the thymus at a constant rate 𝜆𝑇𝑟 and die
naturally at a constant rate 𝜇𝑇𝑟 . These cells are infected by
the virus at the rate 𝜒𝑟𝑇𝑟𝑉. The infected CD4+ T-cells result
from the infection of both the wild and resistant type
healthy CD4+ T-cells and die at a rate 𝜇𝐼𝐼, and are killed by
activated cytotoxic T-cells at the rate 𝛼𝐼𝑍𝑎. They could also
be recruited directly from the thymus at a constant rate 𝜆𝑍.
Clinical finding indicates that CTL response depends on
infected CD4+ T-cells. Consequently, the recruitment into
the population of the CTL cells is given by 𝑐𝑍𝐼. This results
from the stimulation by the viral antigen of the infected cells.
CTLs are activated at the rate 𝛽𝑍𝐼. Due to the absence of the
viral antigen the CTL T-cells die at the rate 𝜇𝑍𝑍 while the
activated CTL cells die at the rate 𝜇𝑍𝑎𝑍𝑎.The freeHIV virions
are produced by the infected CD4+ T-cells at the rate 𝜖𝑉𝜇𝐼𝐼
and they die at the rate 𝜇𝑉𝑉.
𝑑𝑇𝑤𝑑𝑡 = 𝜆𝑇𝑤 − 𝜇𝑇𝑤𝑇𝑤 − 𝜒𝑤𝑇𝑤𝑉,
𝑑𝑇𝑟𝑑𝑡 = 𝜆𝑇𝑟 − 𝜇𝑇𝑟𝑇𝑤 − 𝜒𝑟𝑇𝑟𝑉,
𝑑𝐼𝑑𝑡 = 𝑉 (𝜒𝑤𝑇𝑤 + 𝜒𝑟𝑇𝑟) − 𝜇𝐼𝐼 − 𝛼𝐼𝑍𝑎,
𝑑𝑉𝑑𝑡 = 𝜖𝑉𝜇𝐼𝐼 − 𝜇𝑉𝑉,
𝑑𝑍𝑑𝑡 = 𝜆𝑍 + 𝑐𝑍𝐼 − 𝜇𝑍𝑍 − 𝛽𝑍𝐼,
𝑑𝑍𝑎𝑑𝑡 = 𝛽𝑍𝐼 − 𝜇𝑍𝑎𝑍𝑎.
(1)
The parameters used in model (1) are described in Table 1
3. Properties of the HIV Model
3.1. Positivity of Solutions. The in vivo HIV model monitors
cell population. Hence, there is a need to prove that the state
variables for model (1) remain nonnegative. In particular we
show that, with nonnegative initial conditions, the solutions
of model (1) will remain nonnegative for all time values 𝑡 ≥ 0.
We thus have the following theorem.
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Table 1: Parameters for in vivoHIV dynamics with therapy model.
Parameter Description
𝜆𝑇𝑤 The rate at which the wild type non-infected CD4+ T-cells are produced.𝜆𝑇𝑟 The production rate of the resistant type non-infected CD4+ T-cells per unit time.𝜒𝑤 The rate at which the wild type CD4+ T-cells are infected by the HIV virions.𝜒𝑟 The rate at which the resistant CD4+ T-cells are infected by the HIV virions.𝜇𝑇𝑤 The death rate of the wild type CD4+ T-cells.𝜇𝑇𝑟 The death rate of the resistant type CD4+ T-cells.𝜇𝐼 The death rate of the infected CD4+ T-cells.𝜖𝑉 The number of virions releases per bursting infected cells.𝜇𝑉 The death rate of the infectious virus.𝛼 The rate at which the infected cells are eliminated by the activated CTL T-cells.
𝑐 Proliferation rate of CTL T-cells.
𝜆𝑍 The rate at which the cytotoxic T-cells are produced.𝜇𝑍 The death rate of the CTL T-cells.𝛽 The rate at which the CTL T-cells are activated due to the presence infected CD4+ T-cells.
𝜇𝑍𝑎 The rate at which the activated defense cells decay.
Theorem 1. Let the parameters for model (1) be nonneg-
ative constants. A nonnegative solution (𝑇𝑤(𝑡), 𝑇𝑟(𝑡), 𝐼(𝑡), 𝑉(𝑡),𝑍(𝑡), 𝑍𝑎(𝑡)) for model (1) exists for all state variable with
nonnegative initial conditions (𝑇𝑤(0) ≥ 0, 𝑇𝑟 ≥ 0, 𝐼(0) ≥0, 𝑉(0) ≥ 0, 𝑍(0) ≥ 0, 𝑍𝑎 ≥ 0) for all 𝑡 ≥ 0.
Proof. From the first equation of model (1) we have
𝑑𝑇𝑤𝑑𝑡 = 𝜆𝑇𝑤 − 𝜇𝑇𝑤𝑇𝑤 − 𝜒𝑤𝑇𝑤𝑉
= 𝜆𝑇𝑤 − (𝜇𝑇𝑤 + 𝜒𝑤𝑉)𝑇𝑤 > − (𝜇𝑇𝑤 + 𝜒𝑤𝑉)𝑇𝑤.
(2)
By separation of variable method we have
𝑑𝑇𝑤𝑇𝑤 > − (𝜇𝑇𝑤 + 𝜒𝑤𝑉)𝑑𝑡. (3)
Integrating (3) we have
𝑇𝑤 > 𝐶𝑒−∫𝑡0 (𝜇𝑇𝑤+𝜒𝑤𝑉(𝑠))𝑑𝑠. (4)
Taking the initial conditions at 𝑡 = 0 and 𝑇𝑤(0) = 𝑇𝑤0 then
from (4) we have
𝐶 = 𝑇𝑤0 . (5)
Therefore, (4) can be written as
𝑇𝑤 > 𝑇𝑤0𝑒−∫𝑡0 (𝜇𝑇𝑤+𝜒𝑤𝑉(𝑠))𝑑𝑠. (6)
Thus,
𝑇𝑤 (𝑡) > 0 ∀𝑡 ≥ 0. (7)
Similarly, using the same argument, it can be shown that the
state variables 𝑇𝑟(𝑡) > 0, 𝐼(𝑡) > 0, 𝑉(𝑡) > 0, 𝑍(𝑡) > 0, 𝑍𝑎(𝑡) >0 are nonnegative for all 𝑡 > 0. Therefore, the solutions of
system (1) remain positive for all 𝑡 ≥ 0. This completes the
proof.
3.2. Boundedness of Solutions
Theorem 2. All solutions (𝑇𝑤(𝑡), 𝑇𝑟(𝑡), 𝐼(𝑡), 𝑍(𝑡), 𝑍𝑎(𝑡)) ∈ R6
of model (1) are bounded and there exists a biological feasible
region Γ for model (1) given as
Γ = {(𝑇𝑤 (𝑡) , 𝑇𝑟, 𝐼 (𝑡) , 𝑉 (𝑡) , 𝑍 (𝑡) , 𝑍𝑎 (𝑡))
∈ R6 | 𝑇𝑤 (𝑡) > 0, 𝑇𝑟 (𝑡) > 0, 𝐼 (𝑡) > 0, 𝑉 (𝑡)
> 0, 𝑍 (𝑡) > 0, 𝑍𝑎 (𝑡) > 0} .
(8)
Proof. The total population of the CD4+ T-cells, 𝑇𝑤 + 𝑇𝑟 +𝐼 = 𝑁4(𝑡), is a nonconstant value. Hence, according to (1), the
evolution equation representing the change in the population
of the CD4+ T-cells is given by
𝑑𝑁4 (𝑡)𝑑𝑡 = 𝜆𝑇𝑤 + 𝜆𝑇𝑟 − 𝜇𝑇𝑤𝑇𝑤 − 𝜇𝑇𝑟𝑇𝑟 − (𝜇𝐼 + 𝛼𝑍𝑎) 𝐼,
𝑑𝑁4 (𝑡)𝑑𝑡 ≤ 𝜆𝑇𝑤 + 𝜆𝑇𝑟 − 𝜇𝑇𝑤𝑇𝑤 − 𝜇𝑇𝑟𝑇𝑟 − 𝜇𝐼𝐼,
𝑑𝑁4 (𝑡)𝑑𝑡 ≤ 𝜆𝑇𝑤 + 𝜆𝑇𝑟 − (𝜇𝑇𝑤 + 𝜇𝑇𝑟 + 𝜇𝐼)𝑁4 (𝑡) .
(9)
We solve (9) using the separation of variable method for
solving differential inequality.
𝑑𝑁4 (𝑡)𝑑𝑡 + (𝜇𝑇𝑤 + 𝜇𝑇𝑟 + 𝜇𝐼)𝑁4 (𝑡) ≤ 𝜆𝑇𝑤 + 𝜆𝑇𝑟 . (10)
Integrating factor for (10) is given by
I.F = 𝑒(𝜇𝑇𝑤+𝜇𝑇𝑟+𝜇𝐼)𝑡. (11)
Multiplying (10) by the integrating factor given in (11) we
have,
𝑁4 (𝑡) 𝑒(𝜇𝑇𝑤+𝜇𝑇𝑟+𝜇𝐼)𝑡 ≤ 𝜆𝑇𝑤 + 𝜆𝑇𝑟𝜇𝑇𝑤 + 𝜇𝑇𝑟 + 𝜇𝐼 𝑒
(𝜇𝑇𝑤+𝜇𝑇𝑟+𝜇𝐼)𝑡 + 𝐶. (12)
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Applying the initial condition in (12), at 𝑡 = 0, and letting𝑁(0) = 𝑁40 , we obtain
𝑁40 = 𝜆𝑇𝑤 + 𝜆𝑇𝑟𝜇𝑇𝑤 + 𝜇𝑇𝑟 + 𝜇𝐼 + 𝐶. (13)
Hence,
𝐶 = 𝑁40 − 𝜆𝑇𝑤 + 𝜆𝑇𝑟𝜇𝑇𝑤 + 𝜇𝑇𝑟 + 𝜇𝐼 (14)
Substituting (14) into (12) we have
𝑁4 (𝑡) ≤ 𝑒−(𝜇𝑇𝑤+𝜇𝑇𝑟+𝜇𝐼)𝑡 [ 𝜆𝑇𝑤 + 𝜆𝑇𝑟𝜇𝑇𝑤 + 𝜇𝑇𝑟 + 𝜇𝐼 𝑒
(𝜇𝑇𝑤+𝜇𝑇𝑟+𝜇𝐼)𝑡
+ 𝑁40 − 𝜆𝑇𝑤 + 𝜆𝑇𝑟𝜇𝑇𝑤 + 𝜇𝑇𝑟 + 𝜇𝐼] ,
𝑁4 (𝑡) ≤ 𝜆𝑇𝑤 + 𝜆𝑇𝑟𝜇𝑇𝑤 + 𝜇𝑇𝑟 + 𝜇𝐼 + (𝑁40 −
𝜆𝑇𝑤 + 𝜆𝑇𝑟𝜇𝑇𝑤 + 𝜇𝑇𝑟 + 𝜇𝐼)
⋅ 𝑒−(𝜇𝑇𝑤+𝜇𝑇𝑟+𝜇𝐼)𝑡
(15)
As 𝑡 → ∞ (15) becomes
lim
𝑡→∞
𝑁4 (𝑡) ≤ 𝜆𝑇𝑤 + 𝜆𝑇𝑟𝜇𝑇𝑤 + 𝜇𝑇𝑟 + 𝜇𝐼 . (16)
Similarly as 𝑡 → 0 (15) becomes
lim
𝑡→0
𝑁4 (𝑡) ≤ 𝑁40 . (17)
From (16) and (17) we conclude that𝑁4(𝑡) is bounded above
by
𝑁4 (𝑡) ≤ max {𝑁40 , 𝑄} , (18)
where 𝑄 = (𝜆𝑇𝑤 + 𝜆𝑇𝑟)/(𝜇𝑇𝑤 + 𝜇𝑇𝑟 + 𝜇𝐼).
From (18) the state variables describing the evolution of
the total population of the CD4+ T-cells are less than or equal
to the ratio of the recruitment rate and the decay rate.
The same procedure can be used to show that all the state
variables are bounded. Since all state variables are positive
and bounded in R6, then the region Γ is positively invariant.
Remark 3. The biologically feasible region Γ for model (1)
defined by the compact set
Γ = {(𝑇𝑤 (𝑡) , 𝑇𝑟, 𝐼 (𝑡) , 𝑉 (𝑡) , 𝑍 (𝑡) , 𝑍𝑎 (𝑡)) ∈ R6, 𝑇𝑤
+ 𝑇𝑟 + 𝐼 ≤ 𝜆𝑇𝑤 + 𝜆𝑇𝑟𝜇𝑇𝑤 + 𝜇𝑇𝑟 , 𝑍 + 𝑍𝑎 ≤




with initial conditions 𝑇𝑤(0), 𝑇𝑟(0), 𝐼(0), 𝑉(0), 𝑍(0), 𝑍𝑎(0) >0 is positively invariant and attracting for all 𝑡 > 0. The
domain Γ is positively invariant under the flow induced by the
system (1). Therefore, system (1) is biologically meaningful
and it is feasible to analyse the model in the domain Γ.
4. Disease-Free Equilibrium and Its Stability
The disease-free equilibrium point occurs when there is no
infection in the body and hence it is obtained by setting
infectious classes in (1) to zero; that is, 𝑉 = 𝐼 = 𝑍𝑎 = 0,
𝐸0 = (𝑇𝑤0, 𝑇𝑟0, 0, 0, 𝑍0, 0)
= (𝜆𝑇𝑤𝜇𝑇𝑤 ,
𝜆𝑇𝑟𝜇𝑇𝑟 , 0, 0,
𝜆𝑍𝜇𝑍 , 0) .
(20)
4.1. Basic Reproductive Number. We apply the next genera-
tionmatrixmethod for the derivation of𝑅0 [16].𝑅0 is given by𝑅0 = 𝜌(𝐹𝑉−1), where 𝜌 is defined as the spectral radius of the
next generation matrix [17] and 𝐹 represents the appearance
of new infections while 𝑉 is the rate of transfer of the
infections [18]. Using the Van den Driessche and Watmough
[18] method we have three infection classes, that is, 𝐼(𝑡), 𝑉(𝑡),










The matrix that represents the transfer of the infections





































The eigenvalues for the matrix given by (24) are 0, 0 and((𝜆𝑤𝜇𝑇𝑟𝜒𝑇𝑤 + 𝜆𝑇𝑟𝜇𝑇𝑤𝜒𝑇𝑟)/𝜇𝑇𝑟𝜇𝑇𝑤𝜇𝑉)𝜖𝑉.
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Thus the reproductive number 𝑅0, which is given by the
greatest eigenvalue, is





𝑅0 as given by (25) represents the number of secondary
infection that results from a single infected cell over its
average life time 1/𝜇𝑉. In addition, it is important to note that
the infection will die out if 𝑅0 < 1 while the HIV infection
may become endemic if 𝑅0 > 1.
4.2. Sensitivity Analysis of 𝑅0 with respect to the Model
Parameters. The aim of researchers especially in the field of
HIVmodelling is to understand the dynamics of HIV so as to
control it. This is mainly done by targeting some parameters
to which 𝑅0 is sensitive.
We apply the normalized forward index method in the
analysis. The normalized forward sensitivity index of 𝑅0 with
respect to the parameter 𝑃 is given by
𝜕𝑅0𝜕𝑃 ∗ 𝑃𝑅0 , (26)
where 𝑃 represents the parameters on the basic reproductive




𝜒𝑇𝑤𝜆𝑇𝑤𝜇𝑇𝑟𝜆𝑇𝑤𝜒𝑇𝑊𝜇𝑇𝑟 + 𝜆𝑇𝑟𝜒𝑇𝑟𝜇𝑇𝑤 ,
𝜕𝑅0𝜕𝜆𝑇𝑟
𝜆𝑇𝑟𝑅0 =
𝜒𝑇𝑟𝜆𝑇𝑟𝜇𝑇𝑤𝜆𝑇𝑤𝜒𝑇𝑊𝜇𝑇𝑟 + 𝜆𝑇𝑟𝜒𝑇𝑟𝜇𝑇𝑤 ,
𝜕𝑅0𝜕𝜒𝑇𝑤
𝜒𝑇𝑤𝑅0 =
𝜒𝑇𝑤𝜆𝑇𝑤𝜇𝑇𝑟𝜆𝑇𝑤𝜒𝑇𝑊𝜇𝑇𝑟 + 𝜆𝑇𝑟𝜒𝑇𝑟𝜇𝑇𝑤 ,
𝜕𝑅0𝜕𝜒𝑇𝑟
𝜒𝑇𝑟𝑅0 =
𝜒𝑇𝑟𝜆𝑇𝑟𝜇𝑇𝑤𝜆𝑇𝑤𝜒𝑇𝑊𝜇𝑇𝑟 + 𝜆𝑇𝑟𝜒𝑇𝑟𝜇𝑇𝑤 ,
𝜕𝑅0𝜕𝜇𝑇𝑤
𝜇𝑇𝑤𝑅0 = −
𝜒𝑇𝑤𝜆𝑇𝑤𝜇𝑇𝑟𝜆𝑇𝑤𝜒𝑇𝑊𝜇𝑇𝑟 + 𝜆𝑇𝑟𝜒𝑇𝑟𝜇𝑇𝑤 ,
𝜕𝑅0𝜕𝜇𝑇𝑟
𝜇𝑇𝑟𝑅0 = −






From the sensitivity index represented as in Table 2 it is
evident that 𝜖𝑉 is themost positively sensitive parameter.This
means that to maintain a small number on 𝑅0 we have to
reduce this parameter whereas increasing these parameters
Table 2: Sensitivity indices of𝑅0 evaluated at the baseline parameter.
Parameters Parameter value sensitivity index
𝜆𝑇𝑤 10 0.428724544𝜆𝑇𝑟 0.03198 0.571275455𝜒𝑇𝑤 0.000024 0.428724544𝜒𝑇𝑟 0.01 0.571275455𝜇𝑇𝑤 0.01 −0.428724544𝜇𝑇𝑟 0.01 −0.571275455𝜖𝑉 100 1𝜇𝑉 3 −1
Table 3: Parameters for in vivoHIV model.
Parameters Value Source
𝜆𝑇𝑤 10 cell/mm3/day Attarian and Tran [2]𝜆𝑇𝑟 0.03198 cell/mm3/day Attarian and Tran [2]𝜇𝑇𝑤 0.01 day−1 Srivastava et al. [14]𝜇𝑇𝑟 0.01 day−1 Attarian and Tran [2]𝜒𝑤 0.000024mm3 vir−1 day−1 Attarian and Tran [2]𝜒𝑟 0.01mm3 vir−1 day−1 Attarian and Tran [2]𝜇𝐼 0.5 day−1 Wodarz and Nowak [7]𝜀𝑉 100 vir. cell−1 day−1 Mbogo et al. [15]𝜇𝑉 3 day−1 Mbogo et al. [15].𝛼 0.02 day−1 Arruda et al. [9]
𝜆𝑍 20 cell/mm3/day Arruda et al. [9].𝜇𝑍 0.06 day−1 Arruda et al. [9]𝑐 0.000005 L2 cells2 day1 Zarei et al. [12]
𝛽 0.004 day−1 Arruda et al. [9]
𝜇𝑍𝑎 0.004 day−1 Arruda et al. [9]
will lead to an increase in the 𝑅0 whereas 𝜇𝑉 is the most
negatively sensitive parameter. This means that increasing
this parameter will decrease the value of 𝑅0.
Using the parameters values in Table 3we present the Tor-
nado plots of partial rank correlation coefficients (PRCCs) of
the parameters that influence 𝑅0 in Figure 1.
From Figure 1 it is evident that a decrease in the rate
of HIV virions production (𝜖𝑉) would lead to a decrease
in the value of 𝑅0. This can be done by introducing HIV
drugs such as the reverse transcriptase inhibitors (RTI) or the
protease inhibitor (PI). RTI prevents the production of more
HIV virions since it inhibits the reverse transcription process.
If the HIV RNA is not reverse transcribed to HIV DNA,
then the virus inside the cells cannot multiply. In addition,
use of PIs inhibits the production of protease enzyme that
is necessary for the maturation of the HIV virions; conse-
quently, the virus produced after its introduction would be
noninfectious and immature. Furthermore, a strong immune
response would lead to a reduction in the number of the HIV
virions. Activated cytotoxic T-cells fight and kill/remove the
infected cells. This in turn reduces the number of the HIV
virions produced.
Increase in the death rate of free HIV virions would also
lead to a decrease in 𝑅0. This could be done by introducing
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Figure 1: Tornado plot showing the sensitivity of 𝑅0 to some of the
parameters values.
the ARTs drugs aforementioned. However, it is important
for researchers to establish the most optimal HIV drugs that
would lead to immune reconstruction with minimal side
effects.
4.3. Effect of 𝑅0 on the In Vivo Dynamics of HIV. In this
subsection we establish the effects of 𝑅0 on the dynamics of
infected cells and the HIV virions. We apply the parameter
values described in Table 3.
From Figure 2 it is evident that change in 𝑅0 has a big
impact on the magnitude of infected cells and the HIV viral
load. It is evident from the graphs in Figure 2 that an increase
in𝑅0; that is, having𝑅0 > 1 leads to an increase in the number
of the HIV virions and the infected cells. This implies that
the body immunity is threatened and the infected personmay
progress to AIDS stage if not treated with the ARTs. However,
when 𝑅0 < 1 the number of the HIV virions in the blood
reduces significantly; therefore the infection may die out. For
medical practitioners to reduce the effect of the infection it is
important to ensure that𝑅0 < 1.This is by developing control,
interventions, and management policies that if implemented
would ensure that 𝑅0 < 1. In the next section we analyze the
stability of the disease-free equilibrium point.
4.4. Local Stability of the Disease-Free Equilibrium (DFE)
Theorem 4. The disease-free equilibrium 𝐸0 of system (1) is
locally asymptotically stable if 𝑅0 < 1 and unstable if 𝑅0 > 1.
Proof. Van den Driessche and Watmough [18] indicated
that the stability of the disease-free equilibrium point of a
dynamical system is determined by the stability of the matrix𝐹 − 𝑉 given by








We solve the following to obtain the eigenvalues of (28):
|𝐹 − 𝑉 − Λ𝐼|
=
󵄨󵄨󵄨󵄨󵄨󵄨󵄨󵄨󵄨󵄨󵄨󵄨󵄨󵄨󵄨󵄨󵄨󵄨󵄨󵄨󵄨󵄨󵄨
−𝜇𝐼 − Λ 𝜒𝑤𝜆𝑇𝑤𝜇𝑇𝑤 +
𝜒𝑟𝜆𝑇𝑟𝜇𝑇𝑟 0𝜖𝑉𝜇𝐼 −𝜇𝑉 − Λ 0𝜆𝑍𝜇𝑍 (𝑐 − 𝛽) 0 −𝜇𝑍 − Λ
󵄨󵄨󵄨󵄨󵄨󵄨󵄨󵄨󵄨󵄨󵄨󵄨󵄨󵄨󵄨󵄨󵄨󵄨󵄨󵄨󵄨󵄨󵄨
= 0. (29)
The characteristic equation of (28) is given by
Λ3 + 𝑏2Λ2 + 𝑏1Λ + 𝑏0 = 0, (30)
where
𝑏2 = 𝜇𝑍 + 𝜇𝑉 + 𝜇𝐼,
𝑏1 = 𝜇𝑉𝜇𝑍𝜇𝑇𝑟𝜇𝑇𝑤 + 𝜇𝑉𝜇𝑇𝑟𝜇𝑇𝑤𝜇𝐼 + 𝜇𝑍𝜇𝑇𝑟𝜇𝑇𝑤𝜇𝐼 − 𝜇𝑇𝑟𝜒𝑤𝜇𝑇𝑤𝜆𝑇𝑤𝜖𝑉 − 𝜇𝑇𝑤𝜒𝑟𝜇𝑇𝑤𝜆𝑇𝑟𝜖𝑉𝜇𝑇𝑤𝜇𝑇𝑟 ,
𝑏0 = 𝜇𝑍𝜇1 (𝜇𝑉𝜇𝑇𝑟𝜇𝑇𝑤 − 𝜇𝑇𝑟𝜒𝑤𝜆𝑇𝑤𝜖𝑉 − 𝜇𝑇𝑤𝜒𝑟𝜆𝑇𝑟𝜖𝑉)𝜇𝑇𝑤𝜇𝑇𝑟 .
(31)
Using the Routh-Hurwitz criterion [19], to determine the
conditions for the real part of the roots of the characteristic




𝑏2𝑏1 − 𝑏0 > 0.
(32)
We can clearly observe from (31) that all the Routh-Hurwitz
conditions are satisfied. Thus all the eigenvalues according
to the characteristic equation are negative and real. This
implies that the virions-free equilibrium point is locally
asymptotically stable when 𝑅0 < 1 and unstable when 𝑅0 >1. The epidemiological implication of Theorem 4 is that the
HIV virions could be cleared from the body if and only if𝑅0 < 1.























(a) Population of the infected CD4+ T-cells
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(b) Population of the HIV virions
Figure 2: The HIV dynamics with varying 𝑅0.
5. Numerical Simulation
This section is aimed at investigating numerically the behav-
ior of each compartment on the onset of infection without
any medical treatment. We use Maple software to analyze the
HIV dynamics in vivo without any interventions apart from
the body immunity. The initial values of the model were set
as 𝑇𝑤0 = 1000, 𝑇𝑟0 = 10, 𝐼0 = 10, 𝑉0 = 10, 𝑍0 = 500, and𝑍𝑎0 = 30. The values for the parameter are adopted from
Table 3.
Figure 3 shows the dynamics of the wild type CD4+ T-
cells. The hallmark of HIV/AIDS pathogenesis is the deple-
tion of CD4+ T-cell populations. It is evident from Figure 3
that as the disease progresses the number of the CD4+ T-cells
decreases. However, due to the immune system mechanism
the reduction of the CD4+ T-cells is followed by an increase
in the number of the CD4𝑇 which coincides with immune
system reconstruction. This can be explained by the fact that
the body mechanism will always try to be at an equilibrium.
However, as the immune system weakens the body is unable
to reconstruct itself, and that is why we get a straight line
after the second year. The results in this study agrees with
clinical observation [20–22]. It has been indicated that initial
destruction of the cells is counteracted by CD4+ memory T-
cell regeneration that preserves CD4+ T-cell numbers. The
number, however, does not go back to preinfection stage.This
process is not maintained for a longer period and that is why
we see a drastic drop in the level of the CD4+ T-cells. In HIV
as the number of the cells decreases the body immunity lacks
the ability to fight other infections. That is why HIV infected
people are prone to many opportunistic deceases as the CD+























Figure 3: Population of the wild type CD4+ T-cells.
Figure 4 shows the dynamic of the resistant CD4+ T-cells.
The dynamics of these cells are similar to that of the wild type
cells. Nonetheless since the cells resist infection they remain
at a low level after the third month, which is not the case with
the wild type CD4+ T-cells.
Figure 5 shows the dynamics of the infected CD4+ T-
cells. It is evident that at acute infection the number of the
infected cells increases at a very sharp rate and then decreases




















































Figure 5: Population of the infected CD4+ T-cells.
exponentially. However, after the 100 days the level increases,
but since the body has a way of balancing the cells, we see an
increase is followed by a decrease. The harmonic oscillations
is maintained up to 500 days. Due to the weak immune
system the number of infected cells remains at a constant rate
from 600 days which might remain so for several years. HIV
has proved to have no cure so far. However, as researchers we
need to find a way of killing all the infected cells before they
bud out and produce mature HIV virions. So far clinicians
have indicated that HIV-induced cell death actually increases



















Figure 6: Population of the HIV virus particles.
Figure 6 represents the dynamics of the HIV virions for
the first 1000 days after infection. It is evident that the number
of HIV virions increases in the first few days after infection.
Afterwards the number of virions decreases. This is because
of the recruitment of the cytotoxic cells to fight the free virus.
After about three months the level increases exponentially;
this is because many infected cells burst releasing a higher
number of the virions. Since the cytotoxic cells kill the
infected cells then indirectly they reduce the number of HIV
virions produced. A sharp increase after three months is,
therefore, followed by a decrease in the number of HIV
virions. After 500 days, the number of HIV virions remains at
a constant rate. It is important to note that new HIV virions
are emitted from an infected CD4+ T-cell, via bursting of the
cell. This implies that a single burst produces a big number of
new HIV particles.
Figure 7 represents the dynamics of the of the cytotoxic
cells in the first 1000 days after infection.These are specialized
cells of the adaptive immune system capable of finding and
eliminating pathogen-infected cells. They are responsible for
destroying and killing the infected cells and in turn help to
restore the immune system.They arise from the bonemarrow
and later relocate to the thymus for maturation. During this
process they are able to express a unique antigen-binding
molecule known as the T-cell receptor. The receptor enables
them to monitor all cells of the body, ready to destroy any
cell posing a threat to the organism. Nonetheless, for the
cytotoxic cells to fight and destroy any infected cell they
must be activated and the dynamics of the activated cells is
shown in Figure 8. The activation takes place at the surface
of accessory cells, which mature during the innate immune
responses triggered by an infection.
From Figure 8 it is evident that the number of the
activated CD8+ T-cells increases exponentially for the first
month. The cells are activated in preparation to kill the





































Figure 8: Population of the activated cytotoxic T-cells.
already infected CD4+ T-cells. The number then reduces to a
minimum after 5months (150 days) though not to the level of
the preinfection period. This coincides with the reduction in
the number of the free HIV virions. Onward a nonharmonic
curve is seen for the dynamics of the activated cytotoxic cells.
6. Conclusion
This paper presented a six-dimensional in vivoHIVdynamics
model. The model analyzes HIV virus dynamics focusing
on the highly dynamic interaction between HIV virions,
uninfected wild and resistant type CD4+ T-cells, infected
CD4+ T-cells, and CTLs. The inclusion of the immune
response to viral infection was a key feature in examining the
course of HIV infection. The model was aimed at analyzing
the mechanism of the HIV virus during the entry time up
to the maturation time and the role played by the activated
CD8+ T-cells in fighting and killing the HIV virions. We
started by proving that the model was epidemiologically
well posed. We later derived the expression of the basic
reproductive number, 𝑅0. It was evident that the model
was locally stable and the simulated results from the model
emphasized the importance of maintaining 𝑅0 below one.
The cytotoxic cells play a very crucial role in our system as
far as infection control is concerned. It is evident from the
numerical results that high level of the virus and infected cells
in the body result in an increase in the level of the activated
defense cells. The activated cells fight the infected cells and
indirectly reduce the viral load. In addition, due to the high
increase of the virions during the first three months it is
important to introduce ARTs to prevent HIV transmission.
This will help in the reduction of new infection. From this
study we note that there is production of high number of
HIV virions during the early stages of infection; it is therefore
paramount to initiate ARTs to prevent HIV transmission.
In addition, the medical practitioners and the government
should initiate HIV programs and management polices that
will lead to having 𝑅0 < 1.
In conclusion, lessons learnt by the various researchers,
governmental and nongovernmental organizations, and clin-
icians in addressing the HIV for the last three decades must
be collaboratively collected and the findings implemented.
In future it is important to carryout the optimal control
to establish the role played by the HIV drugs and also the
optimal drug combinations.
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HIV is one of the major causes of deaths, especially in Sub-Saharan Africa. In this paper, an in vivo deterministic model of
differential equations is presented and analyzed for HIV dynamics. Optimal control theory is applied to investigate the key roles
played by the various HIV treatment strategies. In particular, we establish the optimal strategies for controlling the infection using
three treatment regimes as the system control variables. We have applied Pontryagin’s Maximum Principle in characterizing the
optimality control, which then has been solved numerically by applying the Runge-Kutta forth-order scheme.The numerical results
indicate that an optimal controlled treatment strategywould ensure significant reduction in viral load and also inHIV transmission.
It is also evident from the results that protease inhibitor plays a key role in virus suppression; this is not to underscore the benefits
accrued when all the three drug regimes are used in combination.
1. Introduction
There is an ever-changing need for new and useful treatment
regimes that will provide assistance and relief in all aspects
of the human condition. Subsequently, many researchers
have embarked on the journey of analyzing the dynamics of
various diseases affectingmankindwith the aim of improving
control and effect and finally eradicating the diseases from
the population. Modelling and numerical simulations of the
infectious diseases have been used as tools to optimize disease
control. This is due to the fact that medical community
has insufficient animal models for testing efficacy of drug
regimes used in controlling infections. Human immunod-
eficiency virus (HIV) is one of the major problems that
researchers have been working on for over three decades.
According to the Joint United Nations Programme on HIV
and AIDS (UNAIDS), there were 36.7 million people living
with HIV/AIDS in 2016, 1.6 million of which live in Kenya
[1]. Nonetheless, many treatment regimes for HIV have been
approved by the US Food and Drug Administration. Among
them, is the Highly Active Antiretroviral Therapy (HAART)
which is the latest combinations in use, in most countries.
HAART has been proven to be highly effective in viral
suppression, prolongs life of the infected person, and also
reduces the rate of HIV transmission. However, even over
three decades since the first HIV cases were reported, the
virus had no cure and hence various control methods for
HIV/AIDS have been recommended. These controls range
from preventive measures to treatment regimes. Preventive
measures aim at reducing the number of newHIV infections,
while treatment regimes target the already infected persons
to increase their life expectancy and reduce the rate of
HIV transmission. Various treatment strategies are still the
subject of many ongoing clinical trials that are investigating
their benefits versus risks aimed at determining the most
optimal treatment for HIV. Unfortunately, various host-
pathogen interaction mechanisms during HIV infection and
progression to AIDS are still unknown. Consequently, many
questions like which is the best combination, when is the
best time to start treatment, and how the treatment should
be administered are yet to be answered fully.
Mathematical modelling is one of the many important
tools used in understanding the dynamics of disease trans-
mission. It is also used in developing guidelines important in
disease control. In HIV, mathematical models have provided
a framework for understanding the viral dynamics and have








































Figure 1: A compartmental representation of the in vivo HIV dynamics with therapy.
been used in the optimal allocation of the various interven-
tions against the HIV virions [2–4]. A fundamental goal of
developing and applying the aforementioned mathematical
models of HIV is to influence treatment decisions and
construct better treatment protocols for infected patients.
Most of the modern mathematical models that have been
developed apply the optimal control theory. Optimal control
theory is a branch of mathematics developed to find optimal
ways of controlling a dynamical system [5]. It has been
applied by mathematicians to assist in the analysis of how
to control the spread of infectious diseases. The results are
used in making key decisions that involve complex biological
mechanism. In particular, it is used to determine the best
dosage for various available vaccines or treatment in use
for controlling infection. For instance, Gaff and Schaefer
[6] applied optimal theory in evaluating mitigation strategy
that would be highly effective in minimizing the number of
people who get infected by an infection. The study applied
both vaccinations and treatment as control variables for
their various model. The results indicated that as much as
treatment is paramount in controlling any infection, the
most optimal method would be the combination of the
two interventions. Furthermore, Bakare et al. [7] applied
optimal control in an SIR model. The study illustrated the
use of optimal control theory in establishing the optimal
educational campaign and treatment strategies that would
minimize the population of the infected persons as well as
cutting the cost of controlling the various diseases.The results
indicated that, for controlling infection, it is important to
target the uninfected populations and apply measures that
will prevent them from getting the infection.
In the literature, optimal control theory has also been
applied both in-host and population HIV dynamics model.
For instance, Yusuf and Benyah [14] applied optimal theory
on HIV population model. The study aimed at determining
the best method of controlling the spread of HIV/AIDS
within a specified time frame. The study considered three
control variables, that is, safe sex, education, and ARTs. The
numerical results of the objective function for the model
indicated that safe sex practice and early initiation ofARTs are
themost optimal ways ofmitigating the spread of HIV/AIDS.
The study established that if the aforementioned strategies are
well implemented, this would lead to anHIV-free nation in 10
years. In addition, for in-host model, optimal control theory
has been applied in the search for optimal therapies for HIV
infection.
Drugs such as fusion inhibitors (FIs), reverse transcrip-
tase inhibitors (RTIs), and protease inhibitors (PIs) have
been developed and applied in the various optimal control
problems. Srivastava et al. [15] analyzed an initial infection
model with reverse transcriptase inhibitors (RTIs).The study
argued that the use of RTIs reverts back an infected cell to
susceptible. However, this is unlikely since once a CD4+ T-
cell is infected it cannot go back to susceptible. The only
possible way is for it to remain latently infected but fail
to produce infectious virus, since RTIs inhibit the reverse
transcription process. Hattaf and Yousfi [16] analyzed two
optimal treatments of HIV infection model. The study aimed
at measuring the efficiency of RTIs and PIs. This was done
by maximizing objective function aimed at increasing the
number of the uninfected cells, decreasing the viral load, and
minimizing the treatment cost. The results indicated that use
of therapy is important in HIV control. It is also important to
note that the study included two types of viruses, that is, the
infectious virus and the noninfectious virus. Noninfectious
virus is due to the use of PIs as a treatment regime.
Karrakchou et al. [17] applied optimal control theory on
HIV. Like Hattaf and Yousfi [16], the study applied the two
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Figure 2: Simulated control strategies.
Table 1: Variables for HIV in vivo model with therapy.
Variable Description
𝑇(𝑡) The concentration of the noninfected CD4+ T-cells per cubic millimetre at any time 𝑡
𝐼(𝑡) The concentration of the infected CD4+ T-cells per cubic millimetre at any time 𝑡
𝐼𝑙 The concentration of latently infected CD4+ T-cells per cubic millimetre at any time 𝑡𝑉(𝑡) The concentration of HIV virions, copies/mL, at any time 𝑡
𝑉𝑛(𝑡) The concentration of the immature noninfectious virions, copies/mL, at any time 𝑡𝑍(𝑡) The concentration of the CD8+ T-cells per cubic millimetre at any time 𝑡
𝑍𝑎(𝑡) The concentration of the activated CD8+ T-cells per cubic millimetre at any time 𝑡
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Table 2: Parameters for HIV in vivo model with therapy.
Parameter Description
𝜆𝑇 The rate at which the noninfected CD4+ T-cells are produced per unit time.𝜇𝑇 The rate at which the noninfected CD4+ T-cells decay.𝜒 The rate at which the CD4+ T-cells are infected by the virus.
𝜇𝐼 The death rate of the infected CD4+ T-cells.𝜇𝐼𝑙 The death rate of the latently infected CD4+ T-cells.𝜀𝑉 The rate in which HIV virions are generated from the infected CD4+ T-cells.𝜇𝑉 The death rate of the infectious virus.𝜇𝑉𝑛 The death rate of the noninfectious virions.𝛼 The rate at which the infected cells are eliminated by the activated CD8+ T-cells.
𝜆𝑍 The rate at which the CD8+ T-cells are produced per unit time.𝜇𝑍 The death rate of the CD8+ T-cells.𝛽 The rate at which the CD8+ T-cells are activated by the presence of the virus and the infected CD4+ T-cells.
𝜇𝑍𝑎 The rate at which the activated defense cells decay.
Table 3: Control variables for HIV in vivo model.
Control variable Description Purpose
0 ≤ 𝑢1 ≤ 1 Fusion inhibitors Are a class of antiretroviral drugs that work on the outside of the host CD4+ T-cellto prevent HIV from fusing with and infecting it.
0 ≤ 𝑢2 ≤ 1 Reverse transcriptase inhibitors Are a class of antiretroviral drugs used to treat HIV infection by inhibiting thereverse transcription process.
0 ≤ 𝑢3 ≤ 1 Protease inhibitors
Are a class of antiviral drugs that are widely used to treat HIV/AIDS by inhibiting
the production of protease enzyme necessary for the production of infectious viral
particles.
control strategies, that is, RTIs and the PIs. However, the
study failed to put into account both the latently infected
cells and the noninfectious virus that results due to the
use of RTIs and PIs, respectively. Failure to include such
important variables in themodel underscores the adequacy of
themodel in representing the actualHIV in-hostmechanism.
In addition, Arruda et al. [12] applied optimal control theory
in HIV immunology.The study used two control variables in
fightingHIVwith the inclusion of theCD8+ T-cells.However,
the study has some shortcomings; for instance, the study
suggested that activated CD8+ T-cells kill the HIV virions
and also the infected cells. This is not the scenario, since the
activated CD8+ T-cells are only able to kill infected CD4+ T-
cells which in turn reduce the population of the HIV virions.
Unfortunately, even with the aforementioned work done on
HIV, the implementation of some of the recommendations
has been proven to be inefficient and in most cases not
economically viable, especially to the developing countries.
As per the literature cited, it is clear that as much as
ARTs have been used for viral suppression, the optimal
treatment schedule necessary to maintain low viral load is
always an approximation. Until the time when HIV cure
is found, physicians will try as much as possible to apply
the control strategy that will inhibit viral progression while
simultaneously holding the side effects of treatment to a
minimum. Most of the treatment regimes have many side
effects that must be maintained at a low level. For example,
long-term use of protease inhibitors is associated with insulin
intolerance, cholesterol elevation, and the redistribution of
body fat. Therefore, there is a need to establish the optimal
treatment strategy, that is, the one which both maximizes the
patient’s uninfected CD4+ T-cells andminimizes the harmful
side effects due to the drugs.
This study has addressed some of the shortcomings noted
from the in-host HIV dynamics models by applying three
control variables representing the three drug regimes on the
market, that is, the fusion inhibitor, reverse transcriptase
inhibitors, and the protease inhibitors, in the in vivo HIV
model. In addition, the study has incorporated the CD8+
T-cells in the model. For the analysis, the study will apply
optimal control theory together with Pontryagin’s Maximum
Principle in solving the objective function with the aim of
establishing the optimal treatment strategy.
2. Model Formulation
2.1. Model Description. In order for us to carry out optimal
control processes, it is paramount to formulate a model that
describes the basic interaction between the HIV virions and
the body immune system.We develop a mathematical model
for HIV in-host infection with three combinations of drugs.
We define eight variables for themodel as follows: susceptible
CD4+ T-cells (𝑇), latently infected CD4+ T-cells (𝐼𝑙), infected
CD4+ T-cells (𝐼), HIV infectious virions (𝑉), noninfectious
HIV virions (𝑉𝑛), CD8+ T-cells (𝑍), and the activated CD8+
T-cells (𝑍𝑎).
The parameters for the model are as follows. The sus-
ceptible CD4+ T-cells are produced from the thymus at a
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Table 4: Parameters and controls for HIV in vivo model with therapy.
Parameters Value Source
𝜆𝑇 10 cell/mm3/day Nowak et al. [8]𝜇𝑇 0.01 day−1 Srivastava and Chandra [9]𝜒 0.000024mm3 vir−1 day−1 Alizon and Magnus [10]
𝜇𝐼 0.5 day−1 Wodarz and Nowak [11]𝜇𝐼𝑙 0.5 day−1 Wodarz and Nowak [11].𝜀𝑉 100 vir. cell−1 day−1 Estimate𝜇𝑉 3 day−1 Mbogo et al. [2].𝜇𝑉𝑛 0.06 day−1 Estimate𝛼 0.02 day−1 Arruda et al. [12]
𝜆𝑍 20 cell/mm3/day Arruda et al. [12]𝜇𝑍 0.06 day−1 Arruda et al. [12]𝛽 0.004 day−1 Arruda et al. [12]
𝜇𝑍𝑎 0.004 day−1 Arruda et al. [12]𝑢1 0-1 variable Estimate𝑢2 0-1 variable Estimate𝑢3 0-1 variable Estimate
Table 5: The initial values for the variables for HIV in vivo model.
Variable Values
𝑇(𝑡) 𝑇(0) = 500 cell/mm3
𝐼(𝑡) 𝐼(0) = 100 cell/mm3
𝐼𝑙 𝐼𝑙(0) = 0 cell/mm3𝑉(𝑡) 𝑉(0) = 100 virion/mm3
𝑉𝑛(𝑡) 𝑉𝑛(0) = 0 virion/mm3𝑍(𝑡) 𝑍(0) = 100 cell/mm3
𝑍𝑎(𝑡) 𝑍𝑎(0) = 10 cell/mm3
constant rate 𝜆𝑇, die at a constant per capita rate 𝜇𝑇, and
become infected by theHIVvirions at the rate𝜒𝑇𝑉. However,
due to the use of fusion inhibitor (𝑢1) which prevents the
entry of the HIV virions into the CD4+ T-cells, a fraction𝑢1𝜒𝑉𝑇 reverts back to susceptible class. In addition, when
the infected CD4+ T-cells are exposed to the HIV virions
in presence of reverse transcriptase inhibitor (𝑢2), the HIV
virions RNA may not be reverse-transcribed. This results in
a proportion 𝑢2𝜒𝑉𝑇 of the infected cells becoming latently
infected. The infected cells are killed by the CD8+ T-cells at
the rate𝛼 and they die naturally at the rate𝜇𝐼, whereas latently
infected cells die at the rate 𝜇𝐼𝑙 . This study assumes that the
latently infected cells will die naturally and have no possibility
of producing infectious virions nor becoming activated to
become infectious. However, if the protease inhibitor (𝑢3)
is used as a treatment strategy, it inhibits the production of
protease enzyme,which is necessary for production ofmature
HIV virions. This therefore means that we have two kinds of
HIV virions produced from infected CD4+ T-cells, that is,
the infectious HIV virions and the immature noninfectious
virions. The infectious HIV virions are produced at the rate(1−𝑢3)𝜖𝑉 and die at the rate 𝜇𝑉, while the noninfectious HIV
virions are produced at the rate 𝑢3𝜖𝑉 and die at the rate 𝜇𝑉𝑛 .
Furthermore, the CD8+ T-cells are produced naturally from
the thymus at the rate 𝜆𝑍, they die naturally at the rate𝜇𝑍, and
they can also be activated to kill the infected cells at the rate𝛽. The activated CD8+ T-cells die naturally at the rate 𝜇𝑍𝑎 .
It is very important to point out that the CD8+ T-cells are
activated to kill the infected CD4+ T-cells and not the virus
as suggested by Arruda et al. [12].
The summary for the model description is given as
follows. The variables, parameters, and the control variables
for the in-host model are described in Tables 1, 2, and 3,
respectively.
From Figure 1 and the description above, we derive
the following system of ordinary differential equations to
describe the in vivo dynamics of HIV:
𝑑𝑇
𝑑𝑡 = 𝜆𝑇 − 𝜇𝑇𝑇 − (1 − 𝑢1 (𝑡)) 𝜒𝑇𝑉,
𝑑𝐼
𝑑𝑡 = (1 − 𝑢2 (𝑡)) 𝜒𝑇𝑉 − 𝜇𝐼𝐼 − 𝛼𝐼𝑍𝑎,
𝑑𝐼𝑙𝑑𝑡 = 𝑢2 (𝑡) 𝜒𝑇𝑉 − 𝜇𝐼𝑙𝐼𝑙,
𝑑𝑉
𝑑𝑡 = (1 − 𝑢3 (𝑡)) 𝜖𝑉𝜇𝐼𝐼 − 𝜇𝑉𝑉,
𝑑𝑉𝑛𝑑𝑡 = 𝑢3 (𝑡) 𝜖𝑉𝜇𝐼𝐼 − 𝜇𝑉𝑛𝑉𝑛,
𝑑𝑍
𝑑𝑡 = 𝜆𝑍 − 𝜇𝑍𝑍 − 𝛽𝑍𝐼,
𝑑𝑍𝑎𝑑𝑡 = 𝛽𝑍𝐼 − 𝜇𝑍𝑎𝑍𝑎.
(1)
3. Optimization Process
Control efforts are carried out to limit the spread of the
disease and, in some cases, to prevent the emergence of drug
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Figure 3: The population of the CD4+ T-cells in various control strategies.
resistance. Optimal control theory is a method that has been
widely used to solve for an extremum value of an objective
functional involving dynamic variables. In this section, we
consider optimal control methods to derive optimal drug
treatments as functions of time.The control variables as used
in (1) are described as follows. The control 𝑢1 represents the
effect of fusion inhibitors, which are the drugs that protect
the uninfected CD4+ T-cells by preventing the entry of the
virus into the CD4+ T-cells membrane. The control variable𝑢2 simulates the effect of reverse transcriptase inhibitors.
These drugs hinder the reverse transcription process. The
third control variable 𝑢3 simulates the effect of protease
inhibitors, which prevent the already infected cells from
producing mature infectious virions. The aforementioned
controls represent effective chemotherapy dosage bounded
between 0 and 1. The situation 𝑢1(𝑡) = 𝑢2(𝑡) = 𝑢3(𝑡) =1 represents total efficacy of the fusion inhibitors, reverse
transcriptase inhibitors, and protease inhibitors, respectively,
and 𝑢1(𝑡) = 𝑢2(𝑡) = 𝑢3(𝑡) = 0 represents no treatment. It is
worth noting that the aforementioned control variables are
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Figure 4: The population of the latently infected CD4+ T-cells in various control strategies.
bounded Lebesgue-integrable functions. The study aims at
maximizing the levels of the healthy CD4+ T-cells, as well as
the levels of the CD8+ T-cells (𝑍), while minimizing the viral
load (𝑉) and at the same time keeping cost and side effects
of treatment at a minimum. With the above description, the
following objective function (2) needs to be maximized:
𝐽 (𝑢1 (𝑡) , 𝑢2 (𝑡) , 𝑢3 (𝑡)) = 12 ∫
𝑇𝑓
0
(𝑤1𝑇 (𝑡) + 𝑤2𝑍 (𝑡)
− 𝑤3𝑉 (𝑡) − 𝐴1𝑢21 − 𝐴2𝑢22 − 𝐴3𝑢23) 𝑑𝑡
(2)
subject to the ordinary differential equations given in model
(1). 𝑇(𝑡), 𝑍(𝑡), and 𝑉(𝑡) are the solutions of the ODEs (1).
The quantities 𝑤1 and 𝑤2 represent the cost associated with
maximizing the number of CD4+ T-cells and the CD8+ T-
cells, respectively, while 𝑤3 represents the cost associated
with minimizing the viral load. In addition, 𝐴1, 𝐴2, and 𝐴3
are nonnegative constants representing the relative weights
attached to the current cost of each treatment regime and𝑇𝑓 is a fixed terminal time of the treatment program subject
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Figure 5: The population of the infected CD4+ T-cells in various control strategies.
to the ordinary differential equations described in model (1).
This study assumes that the cost of controls is of quadratic
form. Furthermore, it is also based on the fact that there is no
linear relationship between the effect of treatment on CD4+
T-cells and CD8+ T-cells and the HIV virions. Consequently,𝑢1, 𝑢2, and 𝑢3 are Lebesgue-integrable; that is, they are piece-
wise continuous and integrable. The fundamental aim of this
therapeutic strategy is to maximize the objective functional
defined in (2) by increasing the number of the uninfected
CD4+ T-cells and the CD8+ T-cells, decreasing the viral load
(𝑉), and minimizing the harmful side effects and cost of
treatment over the given time interval [0, 𝑇𝑓]. Therefore, we
aim at determining the optimal controls 𝑢∗1 , 𝑢∗2 , and 𝑢∗3 such
that
𝐽 (𝑢∗1 (𝑡) , 𝑢∗2 (𝑡) , 𝑢∗3 (𝑡))
= max {𝐽 (𝑢1 (𝑡) , 𝑢2 (𝑡) , 𝑢3 (𝑡)) : (𝑢1, 𝑢2, 𝑢3) ∈ 𝑈} , (3)


















Figure 6: HIV entry mechanism [13].
where 𝑈 is a set of all measurable controls defined by
𝑈 = {𝑢 = (𝑢1, 𝑢2, 𝑢3) : 𝑢𝑖 measurable, 0 ≤ 𝑢𝑖 (𝑡) ≤ 1, 𝑡
∈ [0, 𝑇𝑓]} .
(4)
In the next section, we show the existence of an optimal
control for system (1) and later derive the optimality system.
This study will employ Pontryagin’s Maximum Principle.
4. Characterization of the Optimal Control
Thenecessary conditions that an optimal control must satisfy
come from Pontryagin’s Maximum Principle [5].
Theorem 1. Suppose that the objective function
𝐽 (𝑢1 (𝑡) , 𝑢2 (𝑡) , 𝑢3 (𝑡)) = 12 ∫
𝑇𝑓
0
(𝑤1𝑇 (𝑡) + 𝑤2𝑍 (𝑡)
− 𝑤3𝑉 (𝑡) − 𝐴1𝑢21 − 𝐴2𝑢22 − 𝐴3𝑢23) 𝑑𝑡
(5)
is maximized subject to the controls and state variables given
in model (1) with
𝑇 (0) = 𝑇0,
𝐼 (0) = 𝐼0,
𝐼𝑙 (0) = 𝐼𝑙0,
𝑉 (0) = 𝑉0,
𝑉𝑛 (0) = 𝑉𝑛0,
𝑍 (0) = 𝑍0,
𝑍𝑎 (0) = 𝑍𝑎0.
(6)
Then there exist optimal controls (𝑢∗1 , 𝑢∗2 , 𝑢∗3 ∈ 𝑈) such that
𝐽 (𝑢∗1 (𝑡) , 𝑢∗2 (𝑡) , 𝑢∗3 (𝑡))
= max {𝐽 (𝑢1 (𝑡) , 𝑢2 (𝑡) , 𝑢3 (𝑡)) : (𝑢1, 𝑢2, 𝑢3) ∈ 𝑈} . (7)
Proof. The existence of the solution can be shown using the
results obtained in Fleming and Rishel [18], since
(1) the class of all initial conditions with controls 𝑢1, 𝑢2,
and 𝑢3 in the control set𝑈 are nonnegative values and
are nonempty, where 𝑢𝑖, 𝑖 = 1, 2, 3, is a Lebesgue-
integrable function on [0, 𝑇𝑓],
(2) the right-hand side of system (1) is bounded by a
linear function of the state and control variables,
by definition, each right-hand side of system (1) is
continuous and can be written as a linear func-
tion of 𝑈 with coefficients depending on time and
state. Furthermore, all the state and control variables𝑇, 𝐼, 𝐼𝑙, 𝑉, 𝑉𝑛, 𝑍, 𝑍𝑎, 𝑢1, 𝑢2, and 𝑢3 are bounded
on [0, 𝑇𝑓],
(3) by definition, the control set𝑈 is convex and closed.A
set 𝐾 ∈ R⋉ is said to be a convex set if and only if
𝜆𝑥 + (1 − 𝜆) 𝑦 ∈ 𝐾 (8)
for all 𝑥, 𝑦 ∈ 𝐾 and all 𝜆 ∈ [0, 1],
this condition is satisfied by the control set 𝑈,
(4) the integrand which is (1/2)(𝐴1𝑢21 +𝐴2𝑢22 +𝐴3𝑢23) of
the objective functional is concave on 𝑈,
(5) there exist constants 𝑏1 > 0, 𝑏2 > 0, and 𝛽 > 1 such
that the integrand of the objective function 𝐽(𝑈, 𝑡) is
bounded by 𝐿(𝑡, 𝑇, 𝑉, 𝑉𝑛, 𝐼, 𝐼𝑙, 𝑍, 𝑍𝑎, 𝑢1, 𝑢2, 𝑢3) ≤ 𝑏2 −𝑏1(|𝑢1|2 + |𝑢2|2 + |𝑢3|2)𝛽/2,
this implies that
𝑤1𝑇 (𝑡) + 𝑤2𝑍 (𝑡) − 𝑤3𝑉 (𝑡) − 𝐴1𝑢21 − 𝐴2𝑢22 − 𝐴3𝑢23
≤ 𝑏2 − 𝑏1 (󵄨󵄨󵄨󵄨𝑢1󵄨󵄨󵄨󵄨2 + 󵄨󵄨󵄨󵄨𝑢2󵄨󵄨󵄨󵄨2 + 󵄨󵄨󵄨󵄨𝑢3󵄨󵄨󵄨󵄨2) ,
(9)
where 𝑏1 depends on the upper bound on 𝑇, 𝑍, 𝑉
while 𝑏1 > 0 since 𝐴1, 𝐴2, 𝐴3 > 0 according to the
definition.
Since all the above conditions are satisfied, we conclude that
there exist optimal controls 𝑢1∗, 𝑢2∗, and 𝑢3∗.
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5. Necessary Conditions of the Control
We now proceed by applying Pontryagin’s Maximum Prin-
ciple [5]. We begin by defining Lagrangian (Hamiltonian
augmented):
𝐿 (𝑇, 𝐼, 𝐼𝑙, 𝑉, 𝑉𝑛, 𝑍, 𝑍𝑎, 𝜆1, 𝜆2, 𝜆3, 𝜆4, 𝜆5, 𝜆6, 𝜆7, 𝑢1, 𝑢2, 𝑢3)
= 𝑤1𝑇 + 𝑤2𝑍 − 𝑤3𝑉 − 𝐴1𝑢21 − 𝐴2𝑢22 − 𝐴3𝑢23
+ 𝜆1 (𝜆𝑇 − 𝜇𝑇𝑇 − (1 − 𝑢1 (𝑡)) 𝜒𝑇𝑉)
+ 𝜆2 ((1 − 𝑢2 (𝑡)) 𝜒𝑇𝑉 − 𝜇𝐼𝐼 − 𝛼𝐼𝑍𝑎) + 𝜆3 (𝑢2 (𝑡)
⋅ 𝜒𝑇𝑉 − 𝜇𝐼𝑙𝐼𝑙) + 𝜆4 ((1 − 𝑢3 (𝑡)) 𝜖𝑉𝜇𝐼𝐼 − 𝜇𝑉𝑉)
+ 𝜆5 (𝑢3 (𝑡) 𝜖𝑉𝜇𝐼𝐼 − 𝜇𝑉𝑛𝑉𝑛) + 𝜆6 (𝜆𝑍 − 𝜇𝑍𝑍
− 𝛽𝑍𝐼) + 𝜆7 (𝛽𝑍𝐼 − 𝜇𝑍𝑎𝑍𝑎) + 𝑤11𝑢1 + 𝑤12 (1
− 𝑢1) + 𝑤21𝑢2 + 𝑤22 (1 − 𝑢2) + 𝑤31𝑢3 + 𝑤32 (1
− 𝑢3) ,
(10)
where 𝑤𝑖𝑗(𝑡) ≤ 0 are the penalty multipliers that ensure the
boundedness of the control variables 𝑢1(𝑡), 𝑢2(𝑡), and 𝑢3(𝑡)
and satisfy the following conditions:
𝑤11𝑢1 = 𝑤12 (1 − 𝑢1) = 0 at 𝑢∗1
𝑤21𝑢2 = 𝑤22 (1 − 𝑢2) = 0 at 𝑢∗2
𝑤31𝑢3 = 𝑤32 (1 − 𝑢3) = 0 at 𝑢∗3 ,
(11)
where 𝑢∗1 , 𝑢∗2 , and 𝑢∗3 represent the optimal controls.
Therefore, Pontryagin’s Maximum Principle gives the
existence of adjoint variables that are obtained by differen-
tiating the Lagrangian given by (10) with respect to the state
variables 𝑇, 𝑉, 𝐼, 𝐼𝑙, 𝑍, and 𝑍𝑎.
The adjoint variables are given by
?̇?1 = − 𝜕𝐿𝜕𝑇
= −𝑤1 + 𝜆1 (𝜇𝑇 + (1 − 𝑢1) 𝜒𝑉) − 𝜆2𝜒𝑉 (1 − 𝑢2)
− 𝜆3𝑢2𝜒𝑉,
?̇?2 = −𝜕𝐿𝜕𝐼
= 𝜆2 (𝜇𝐼 + 𝛼𝑍𝑎) − 𝜆4𝜀𝑉𝜇𝐼 (1 − 𝑢3) − 𝜆5𝑢3𝜖𝑉𝜇𝐼
+ 𝜆6𝛽𝑍 − 𝜆7𝛽𝑍,
?̇?3 = −𝜕𝐿𝜕𝐼𝑙 = 𝜆3𝜇𝐼𝑙 ,
?̇?4 = − 𝜕𝐿𝜕𝑉
= 𝑤3 + 𝜆1𝜒𝑇 (1 − 𝑢1) − 𝜆2𝜒𝑇 (1 − 𝑢2) − 𝜆3𝜒𝑇𝑢2
+ 𝜆4𝜇𝑉,
?̇?5 = − 𝜕𝐿𝜕𝑉𝑛 = 𝜆5𝜇𝑉𝑛 ,
?̇?6 = − 𝜕𝐿𝜕𝑍 = −𝑤2 + 𝜆6 (𝜇𝑍 + 𝛽𝐼) − 𝜆7𝛽𝐼,
?̇?7 = − 𝜕𝐿𝜕𝑍𝑎 = 𝜆2𝛼𝐼 + 𝜆7𝜇𝑍𝑎 ,
(12)
where
𝜆𝑖 (𝑇𝑓) = 0, 𝑖 = 1, . . . , 7, (13)
are the transversality conditions.
By maximization of the Lagrangian with respect to








Therefore, differentiating the Lagrangian 𝐿 given in (10) with
respect to 𝑢1 on the set 𝑈 : 𝑡 | 0 ≤ 𝑢1(𝑡) ≤ 1, we get the
following optimality equation:
𝜕𝐿
𝜕𝑢1 = −2𝐴1𝑢𝐼 + 𝜒𝑇𝑉𝜆1 + 𝑤11 − 𝑤12 = 0. (15)
Let 𝑢1 = 𝑢∗1 in (15). Then, solving (15), we obtain the optimal
control 𝑢∗1 as
𝑢∗1 = 𝜒𝑇𝑉𝜆1 + 𝑤11 − 𝑤122𝐴1 . (16)
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To determine an explicit expression for an optimal control 𝑢∗1
without 𝑤11 and 𝑤12, we consider the following three cases:
(1) On the set (𝑡 | 0 < 𝑢∗1 < 1), suppose we set 𝑤11 =𝑤12 = 0 in (16). Then the optimal 𝑢∗1 control is given
by
𝑢∗1 = 𝜒𝑇𝑉𝜆12𝐴1 . (17)
(2) Similarly, on the set (𝑡 | 𝑢∗1 = 1), we have 𝑤11 = 0 and𝑤12 ≥ 0; then from (16), we have
𝑢∗1 = 1 = 𝜒𝑇𝑉𝜆1 − 𝑤122𝐴1 . (18)
Equation (18) can be reduced to
𝜒𝑇𝑉𝜆12𝐴1 ≥ 1 = 𝑢
∗
1 . (19)
Therefore, for this set, we have
𝑢∗1 = min(1, 𝜒𝑇𝑉𝜆12𝐴1 ) . (20)
(3) Finally, on the set (𝑡 | 𝑢∗1 = 0), we have 𝑤12 = 0 and𝑤11 ≥ 0; then from (16), we have
𝑢∗1 = 0 = 𝜒𝑇𝑉𝜆1 + 𝑤112𝐴1 , (21)
which implies that
𝜒𝑇𝑉𝜆12𝐴1 ≤ 0. (22)
Consequently, combining all the three cases given by (17),
(20), and (22), we obtain the optimal control, 𝑢∗1 , as follows:
𝑢∗1 (𝑡) =
{{{{{{{{{{{{{{{
𝜒𝑇𝑉𝜆12𝐴1 if 0 <
𝜒𝑇𝑉𝜆12𝐴1 < 1
0 if 𝜒𝑇𝑉𝜆12𝐴1 ≤ 0
1 if 𝜒𝑇𝑉𝜆12𝐴1 ≥ 1.
(23)
This implies that the control 𝑢∗1 (𝑡) is formulated as follows:
𝑢∗1 = max(0,min(1, 𝜒𝑇𝑉𝜆12𝐴1 )) . (24)
We use the same argument to obtain an explicit expression for
an optimal control 𝑢∗2 without 𝑤21 and 𝑤22. We differentiate
the Lagrangian 𝐿 given in (10) with respect to 𝑢2 on the set𝑈 : 𝑡 | 0 ≤ 𝑢2(𝑡) ≤ 1. We therefore obtain the optimality
equation as
𝜕𝐿
𝜕𝑢2 = −2𝐴2𝑢2 + 𝜒𝑇𝑉 (𝜆3 − 𝜆2) + 𝑤21 − 𝑤22 = 0
at 𝑢2 = 𝑢∗2 .
(25)
Therefore, solving (25), we obtain the optimal control 𝑢∗2 as
follows:
𝑢∗2 = 𝜒𝑇𝑉 (𝜆3 − 𝜆2) + 𝑤21 − 𝑤222𝐴2 . (26)
According to the conditions given by (11), we derive the
following distinct three cases:
(1) On the set (𝑡 | 0 < 𝑢∗2 < 1), we have 𝑤21 = 𝑤22 = 0 in
(26). Then the optimal 𝑢∗2 control is given by
𝑢∗2 = 𝜒𝑇𝑉 (𝜆3 − 𝜆2)2𝐴2 . (27)
(2) On the set (𝑡 | 𝑢∗2 = 1), we have 𝑤21 = 0 and 𝑤22 ≥ 0;
then from (26), we have
𝑢∗2 = 1 = 𝜒𝑇𝑉 (𝜆3 − 𝜆2) + 𝑤222𝐴2 . (28)
Rearranging (28) we have
𝜒𝑇𝑉 (𝜆3 − 𝜆2)2𝐴2 ≥ 1 = 𝑢
∗
2 . (29)
Thus, for the this set, we have
𝑢∗2 = min(1, 𝜒𝑇𝑉 (𝜆3 − 𝜆2)2𝐴2 ) . (30)
(3) Finally, on the set (𝑡 | 𝑢∗2 = 0), we have 𝑤22 = 0 and𝑤21 ≥ 0; then from (26), we have
𝑢∗2 = 0 = 𝜒𝑇𝑉 (𝜆3 − 𝜆2)2𝐴2 , (31)
which implies that
𝜒𝑇𝑉 (𝜆3 − 𝜆2)2𝐴2 ≤ 0. (32)
Consequently, combining all the three cases given by (27),




𝜒𝑇𝑉 (𝜆3 − 𝜆2)2𝐴2 if 0 <
𝜒𝑇𝑉 (𝜆3 − 𝜆2)2𝐴2 < 1
0 if 𝜒𝑇𝑉 (𝜆3 − 𝜆2)2𝐴2 ≤ 0
1 if 𝜒𝑇𝑉 (𝜆3 − 𝜆2)2𝐴2 ≥ 1.
(33)
Hence, the optimal control 𝑢∗2 (𝑡) is formulated as follows:
𝑢∗2 = max(0,min(1, 𝜒𝑇𝑉 (𝜆3 − 𝜆2)2𝐴2 )) . (34)
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To obtain the expression for optimal control 𝑢∗3 , we differen-
tiate (10) with respect to 𝑢3 on the set 𝑈 : 𝑡 | 0 ≤ 𝑢3(𝑡) ≤ 1 to
get the following optimality equation:
𝜕𝐿
𝜕𝑢3 = −2𝐴3𝑢3 − 𝜀𝑉𝜇𝐼𝐼𝜆4 + 𝑤31 − 𝑤32 = 0. (35)
Let 𝑢3 = 𝑢∗3 in (35); then we obtain the optimal control 𝑢∗3 :
𝑢∗3 = −𝜀𝑉𝜇𝐼𝐼𝜆4 + 𝑤31 − 𝑤322𝐴3 . (36)
(1) On the set (𝑡 | 0 < 𝑢∗3 < 1), we have 𝑤31 = 𝑤32 = 0 in
(36). Then the optimal control 𝑢∗3 is given by
𝑢∗3 = −𝜀𝑉𝜇𝐼𝐼𝜆42𝐴3 . (37)
(2) On the set (𝑡 | 𝑢∗3 = 1), we have 𝑤31 = 0 and 𝑤32 ≥ 0;
then from (36), we have
𝑢∗3 = 1 = −𝜀𝑉𝜇𝐼𝐼𝜆4 + 𝑤322𝐴3 . (38)
Equation (38) can be reduced to
−𝜀𝑉𝜇𝐼𝐼𝜆42𝐴3 ≥ 1 = 𝑢
∗
3 . (39)
Hence, for this set, we have
𝑢∗3 = min(1, −𝜀𝑉𝜇𝐼𝐼𝜆42𝐴3 ) . (40)
(3) Finally, on the set (𝑡 | 𝑢∗3 = 0), we have 𝑤32 = 0 and𝑤31 ≥ 0; then from (36), we have
𝑢∗3 = 0 = −𝜀𝑉𝜇𝐼𝐼𝜆4 + 𝑤312𝐴3 , (41)
which implies that
−𝜀𝑉𝜇𝐼𝐼𝜆42𝐴3 ≤ 0. (42)
Consequently, combining all the three cases given by (37),
(40), and (42), the optimal control, 𝑢∗3 , is characterized as
𝑢∗3 (𝑡) =
{{{{{{{{{{{{{{{
−𝜀𝑉𝜇𝐼𝐼𝜆42𝐴3 if 0 <
−𝜀𝑉𝜇𝐼𝐼𝜆42𝐴3 < 1
0 if −𝜀𝑉𝜇𝐼𝐼𝜆42𝐴3 ≤ 0
1 if −𝜀𝑉𝜇𝐼𝐼𝜆42𝐴3 ≥ 1.
(43)
Therefore, the optimal control, 𝑢∗3 (𝑡), is formulated as
𝑢∗3 = max(0,min(1, −𝜀𝑉𝜇𝐼𝐼𝜆42𝐴3 )) . (44)
It is worth noting that the optimal controls depend on
the adjoint variables 𝜆1, 𝜆2, 𝜆3, and 𝜆4, since the adjoint
variables correspond to the state variables, 𝑇, 𝐼, 𝐼𝑙, 𝑉, and
the first four equations in (1) contain the control terms.
6. Numerical Simulation
In this section, we investigate the effect of optimal strategy
on HIV by applying Runge-Kutta forth-order scheme on
the optimality system. The optimality system is obtained by
taking the state system together with the adjoint system,
the optimal control, and the transversality conditions. The
dynamical behaviour of the models in relation to various
control is also studied. The optimal strategy is achieved by
obtaining a solution for the state system (1) and costate
system (12). An iterative scheme is explored and used
to determine the solution for the optimality system. The
numerical method utilized is the forward-backward sweep
method that incorporates iterative Runge-Kutta fourth-order
progressive-regressive schemes. The progressive scheme is
used in obtaining the solutions of the state ODEs given in
(1) with the initial conditions, while the regressive scheme
is applied in obtaining the solutions of the adjoint system
given by (12) with transversality conditions given in (13). The
controls are updated at the end of each iteration using the
formula for optimal controls. We continue with the iterations
until convergence is achieved. This is a two-point boundary-
value problem, with separated boundary conditions at times𝑡0 = 0 and 𝑡 = 𝑇𝑓. This explains our choice in using
the fourth-order Runge-Kutta scheme. For the numerical
simulation, we take 𝑇 = 310 days or 10 months. This
value represents the time in which treatment is stopped.
Furthermore, the values of the weight function are taken as𝐴1 = 𝐴2 = 𝐴3 = 0.01. Table 4 consists of the parameter
values that are used in the numerical simulations of the in
vivo model, while Table 5 consists of the proposed initial
values of the state variables.
The initial values given in Table 5 are chosen in such a
way that they reflect a patient during acute infection. This is
in line with the WHO recommendations that stipulate that
all people living with the HIV be put on ARTs irrespective of
their CD4+ counts unlike in the past where the CD4+ count
had to be less than 500 cells/mm3 [19].
6.1. Results and Discussion. Figure 2 represents the various
control strategies. It is evident that the control 𝑢1 remains
at the maximum for the first two months and drops to zero
onward, while control 𝑢2 remains at maximum for the first
four and a half months and then drops to 30% the sixth
and the ninth months and drops to the minimum after the
10th month. In addition, the control strategy 𝑢3 remains at
a maximum for the first ninth months, only dropping to a
minimum at the tenth month. From these results, we can
see that protease inhibitor can be administered for a longer
period of time.
Figure 3 shows the population of the CD4+ T-cells in
different treatment strategy. In all the cases, it is evident that
the introduction of the ARTs plays a significant role as far
as controlling HIV is concerned. Nonetheless, it is clear that
when fusion inhibitor (𝑢1) is used without other controls, the
number of CD4+ T-cells reduces significantly and a longer
time is taken before the number increases. In particular, the
drug effectiveness seems to be felt after the first two months.
We interpret the results to mean that it is difficult to control















































































































































































0 1 2 3 4 5 6 7 8 9 10
With control u1 With control u2
With control u3 With controls u1 and u2
With controls u1 and u3 With controls u2 and u3 With all the three controls
Figure 7: The population of the HIV virions in various control strategies.
the HIV virions by targeting its cell-entry mechanism. The
use of protease inhibitor, however, leads to an increase in the
number of the CD4+ T-cells. In addition, it is evident that a
combination of the three drugs evokes a more pronounced
CD4+ T-cells increase than in monotherapy or combination
of two drugs.
It is important to point out that CD4+ T-cell responses in
number of cells gained were similar for patients treated with
combination of two drugs therapies and patients treated with
combination of three drugs therapies.
Figure 4 presents the dynamics of the latently infected
cells after the introduction of the various control strategies.
It is evident that the latently infected cells are produced
after the introduction of reverse transcriptase inhibitor to
an HIV infected cell. Since the latently infected cells do not
produce infectious virions, it is important to administer RTIs
to an infected person. This will reduce the number of virions
producing cells.
Figure 5 shows the change in the population of the
infectedCD4+ T-cells with time in different control strategies.
From the simulated results, we see that use of ARTs plays a
















































































































































































































0 1 2 3 4 5 6 7 8 9 10
With control u1 With control u2
With control u3 With controls u1 and u2
With controls u1 and u3 With controls u2 and u3 With all the three controls
Figure 8: The population of the noninfectious HIV virions in various control strategies.
fundamental role, especially in controlling the rate of infec-
tion. Nonetheless, when the fusion inhibitors are introduced
in the body, the number of the infected cells still increases for
the first few months.This clearly shows that it is very difficult
to control theHIV virions at the entry level.The reasonwould
probably be based on the fact that HIV uses a complex series
of steps to deliver its genome into the host cell cytoplasm
while simultaneously evading the host immune response as
shown in Figure 6.
Figure 7 shows the change in the population of the
HIV virions in different drug combination(s). It is evident
that controls 𝑢1 and 𝑢2 are not as very effective as PIs
in controlling viral progression. In particular, there is no
significant difference when the control 𝑢1 is used and when
no control is used at all. Researches such as [20] suggest
that viruses blocked by entry inhibitors such as the fusion
inhibitors are likely redistributed to plasma, where they
artificially increase the number of HIV virions. This may
probably be the reason why there is an indication of having

















































































































































0 1 2 3 4 5 6 7 8 9 10
With control u1 With control u2
With control u3 With controls u1 and u2
With controls u1 and u3 With controls u2 and u3 With all the three controls
Figure 9: The population of the CD8+ T-cells in various control strategies.
high number of viral loads even when control 𝑢1 is applied.
In addition, the fusion inhibitor prevents the entry of the
virions unlike the other two drugs that allow the entry of
the HIV virions into the cells, confirming the absorption
effect. Simulated results shows that protease inhibitor plays
a significant role in reducing viral progression and it is
the best single drug in use for viral suppression. This is in
agreement with some of the works done in the field of in vivo
HIV dynamics which have concluded that protease inhibitors
are more effective than reverse transcriptase inhibitors and
fusion inhibitors in terms of viral load reduction in HIV
infected patient [21–23].The simulated results also emphasize
the importance of using a combination of the various ARTs
when treating HIV.
From Figure 8, it is evident that noninfectious viruses are
produced after the introduction of the protease inhibitor in
the body. Introduction of PIs to HIV infected cells generates
a pool of immature HIV virions; this leads to the transfer
of noninfectious virus across the virological synapse. This
































































































































































































0 1 2 3 4 5 6 7 8 9 10
With control u1 With control u2
With control u3 With controls u1 and u2
With controls u1 and u3 With controls u2 and u3 With all the three controls
Figure 10: The population of the activated CD8+ T-cells in various control strategies.
therefore implies that the virus produced will not infect more
susceptible CD4+ T-cells.
Figure 9 shows the population of the CD8+ T-cells in
different treatment strategy. Both the RTIs and PIs cause a
substantial increase in the population of the CD8+ T-cells in
HIV infected patients. However, it is evident that as much
as these two drugs plays a major role, the combination of
all the three controls produces a higher immune system
reconstitutionwith sustained increases in circulating number
of CD8+ T-cells.
Figure 10 shows the population of the activated CD8+ T-
cells. The activation process plays a major role in controlling
the HIV virus particles.This is because the cells fight, destroy,
and kill the infected CD4+ T-cells. This in turn reduces the
number ofHIV virions produced. From the simulated results,
it is evident that, after the introduction of the ARTs, the
number of activated CD8+ T-cells reduced significantly. The
reduction may be attributed to the reconstituted immune
system or due to the reduction of the retroviral activity on the
cells [24]. However, the question we need to ask ourselves is
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whether this reduction has any clinical benefit. In the future,
it is important to analyze the clinical benefit accrued from the
reduction of the CD8+ T-cells activation process.
7. Conclusion
In this paper, we have analyzed a seven-dimension in vivo
HIV model with inclusion of three drug combinations, that
is, FIs, RTIs, and PIs. Optimal control theory is applied to
determine the optimal treatment regime. The study applied
Pontryagin’s Maximum Principle in deriving the conditions
for optimal control, which maximizes the objective function.
The systems of ODEs, the state system, and the adjoint system
were solved numerically by both forward and backward
Runge-Kutta forth-order scheme. Results from the numerical
simulations show that FIs and RTIs should be used within
the four months and later the doctors should change the
drugs and introduce another type, whereas the PIs can be
used for a longer period of time without necessarily leading
to major side effect. However, the inferiority of monotherapy
compared with combination of therapies has been observed
in the simulated result, especially in suppression of viral
replication, CD4+ and CD8+ T-cells reconstitution, and
controlling disease progression.
ARTs have been seen to play a significant role as far
as viral suppression is concerned. Therefore, they should
be recommended for all patients immediately after one is
diagnosed asHIV-positive regardless of the CD4+ count.This
supports the guidelines by WHO. However, the simulated
results suggest that PI is possibly the best single drug and
fusion inhibitor is the worst drug in terms of viral load and
infected cells reduction. From the results, we recommend
that RTIs be used as initial therapy for HIV. FI should be
introduced to the patient after the RTIs but should never be
used alone.
In the future, it is important to develop the model in such
a way that it brings out the relationship between the number
of the CD8+ T-cells and the CD4+ T-cells produced in the
thymus.
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